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Stellingen 
1. Cafestol grijpt sterker aan op de cholesterolhuishouding van de mens dan 
kahweol (ditproefschrift). 
2. Artsen dienen patiënten met een hoog risico op hart- en vaatziekten het 
drinken van ongefilterde koffie te ontraden {dit proefschrift). 
3. In epidemiologisch onderzoek naar het verband tussen koffiedrinken en hart-
en vaatziekten is navraag naar het type koffie noodzakelijk {ditproefschrift). 
4. Cafestol is de krachtigste cholesterolverhogende verbinding die van nature 
in de voeding voorkomt. 
5. Er is onvoldoende reden om aan te nemen dat de oorzaak van de French 
paradox ligt in het drinken van rode wijn. 
6. In observationeel onderzoek zal de overtuiging dat er een verband bestaat 
de kans op het vinden van dat verband aanzienlijk vergroten. 
7. Wetenschappelijke tijdschriften zouden onderzoekers moeten toestaan om 
manuscripten anoniem voor publikatie aan te bieden. 
8. Brede toepassing van de techniek om voedselgewassen genetisch te 
wijzigen zal de verschillen in welvaart tussen Noord en Zuid verder doen 
toenemen. 
9. De houding tegen rokers neemt steeds minder de vorm aan van een houding, 
en steeds meer die van een hysterie. 
10. Veel misverstanden tussen wetenschappers en journalisten zouden 
voorkomen worden als de eersten zich meer in journalistiek en de laatsten 
zich meer in wetenschap zouden interesseren. 
1 1 . De inburgering van vreemde woorden en uitdrukkingen verrijkt de 
Nederlandse taal. 
12. De in de horeca gebruikte slagzin De koffie staat klaar! garandeert geen 
verse koffie. 
13. Vroeger was alleen de toekomst beter. 
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Abstract 
Health effects of unfiltered coffee: diterpenes in coffee 
and their effects on blood lipids and liver enzymes in man 
PhD thesis by Rob Urgert, Department of Human Nutrition, Wageningen 
Agricultural University, Wageningen, the Netherlands, April 4, 1997 
Boiled coffee raises blood levels of cholesterol and triglycerides in man. 
Cafestol and kahweol are responsible. These diterpenes also raise blood levels of 
alanine aminotransferase (ALT). The objective of the present studies was to further 
specify the health effects of cafestol and kahweol. 
Unfiltered coffee contains up to 5 g of grounds per liter. Intake of 8 g/day 
of such grounds for 3 weeks raised cholesterol by 0.65 mmol/L and ALT by 18 U/L 
in healthy volunteers. Diterpenes in floating grounds thus contribute to the 
hyperlipidaemic and ALT-elevating effects of unfiltered coffee. Chemical analyses 
showed that boiled, cafetière (also called French press), and Turkish coffee are rich 
in diterpenes. Levels are moderate in espresso and mocha coffee, and negligible in 
percolated, instant, and filtered coffee. 
We studied the separate activities of cafestol and kahweol in a randomised, 
double-blind cross-over study with 10 male volunteers. Intake of 63 mg/day of 
cafestol for 4 weeks raised cholesterol by 17%, triglycerides by 86%, and ALT by 
78%. Additional intake of 51 mg/d of kahweol only marginally raised the lipid 
responses, but more than doubled the ALT responses. Cafestol therefore is more 
hyperlipidaemic than kahweol, but both affect liver cells. 
To study long term effects, we gave 46 volunteers 0.9 liter/day of either 
filtered or cafetière coffee for 6 months in a randomised experiment. ALT levels 
were still raised by 45%, and LDL by 9%, after 6 months of intake of cafetière 
coffee, but most of the initial rise in triglycerides had disappeared. 
Lipoprotein(a) is an atherogenic particle made by the liver. We found that 
lipoprotein(a) levels were 65% higher in chronic drinkers of boiled coffee than in 
peers drinking filtered coffee. However, supplements rich in diterpenes lowered 
lipoprotein(a) in four experiments. 
In conclusion, the strong and persistent effects on total and LDL cholesterol 
levels are a good reason to advise patients with a high coronary risk to limit the 
intake of brews rich in cafestol. Effects of unfiltered coffee on triglycerides and 
lipoprotein(a) may be insignificant for atherogenic risk. The effects of cafestol and 
kahweol on liver cells may be innocuous, but coffee drinkers with raised levels of 
alanine aminotransferase might also do well in abstaining from unfiltered coffee. 
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CHAPTER 1 
ABSTRACT 
In 1963, the theory arose that coffee drinking could increase the risk of coronary 
heart disease. The majority of people in Western society drink coffee daily, and coronary 
heart disease is a common cause of death. As a result, the presumed link between coffee 
and heart disease has produced a myriad of reports in scientific journals and in the lay 
media. 
Coronary heart disease involves a reduction in blood flow to the heart muscle. 
Accumulation of fatty deposits in the artery wall - or atherosclerosis -- is the main cause 
of reduced blood flow. The risk of atherosclerosis, and thus of coronary heart disease, is 
increased by many factors. The most notable are cigarette smoking, a high blood pressure, 
diabetes, and a high concentration of cholesterol in the blood. 
Coffee beans contain the diterpenes cafestol and kahweol. They are released by hot 
water from ground coffee, and are present in brews that are not prepared with a paper 
filter. Cafestol and kahweol strongly affect lipid metabolism in humans. They also seem 
to affect liver cells, as they modify the blood level of various enzymes from the liver. This 
thesis focuses on the health consequences of drinking unfiltered coffee by further 
specifying the effects of preparations rich in coffee diterpenes on blood levels of lipids and 
liver enzymes in humans. 
This chapter summarizes the history of coffee and the line of research which has 
resulted in the identification of coffee diterpenes as the cholesterol-raising factors in 
coffee. An outline of the thesis is given at the end of this chapter. 
THE HISTORY OF COFFEE 
The first wr i t ten words about coffee originate f rom the ninth century when 
a Persian doctor reported on the digestive properties of coffee. It is believed that 
coffee was f irst cult ivated in the sixth century. Arab traders and pilgrims took 
coffee f rom Ethiopia to Mocha in Yemen, f rom where it spread throughout the 
Arabian peninsula. Originally, the coffee beans and cherries were chewed as a 
st imulant against fat igue, and it was only in the middle of the f i f teenth century that 
coffee became common as a beverage [1] . The habit of drinking coffee rapidly 
grew throughout the Ottoman empire in the sixteenth century, and in the 
seventeenth century, coffee crossed the Mediterranean Sea, spread through 
Europe, and reached the British settlements in North America [2] . 
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The Dutch smuggled a coffee plant out of the port of Mocha in 1690 and 
succeeded in cult ivating coffee on a commercial basis in Java. Halfway through the 
eighteenth century, the yearly import of coffee in Amsterdam amounted to 1,400 
kg of beans. The Dutch supremacy in coffee trading ended when they donated a 
seedling f rom a coffee plant to Louis XIV. He planted it in the Jardin des Plantes 
in Paris and, on royal bequest, made it the ancestor of most of the coffee trees 
planted during the 18th century in the Western hemisphere [2] . 
Nowadays, coffee plantations all over the world yield 6 x 109 kilograms of 
beans each year. About three-quarters of the world coffee production consist of 
Coffea arabica (arabica) beans, the remainder being Coffea canephora (robusta) 
beans. Most coffee is consumed in Europe, w i th an average per capita 
consumption of 4 .6 kg of coffee beans per year [3] . Within Europe, coffee is most 
popular in Scandinavian countries, Austr ia, and the Netherlands (figure 1). 
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Consumption of green coffee (kg/year) 
FIGURE 1. Per capita consumption of green coffee in selected countries in kilograms per 
year. Consumption is estimated from data on imports minus exports of all forms of coffee 
beans adjusted for changes in inventories [3]. Each two kg of green beans per year roughly 
correspond to one cup of coffee per day. 
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COFFEE AND CORONARY HEART DISEASE 
In 1963, Paul and coworkers suggested that coffee drinking could increase 
the risk of developing heart disease [4]. Many studies that followed could not 
confirm this, although some found a link [5,6]. The evidence was insufficient to 
incriminate caffeine, as controlled studies showed no profound effect of caffeine, 
either on blood pressure [7,8] or on blood lipid levels [9-12]. Paul's original finding 
[4] later appeared to be due to confounding by smoking habits [13]. Nevertheless, 
the incoherent messages brought by scientists kept stirring up people's feelings 
about an unfavourable effect of coffee on the heart. 
In 1983, findings from a cohort of 14,000 Norwegians put things into a new 
perspective; Thelle and colleagues reported a strong positive relation between 
coffee drinking and the blood level of cholesterol [14]. Again, such a link was not 
observed in other Europeans or Americans [15]. A series of both epidemiological 
surveys [16-20] and experimental studies [21-26] then unravelled the mystery: 
coffee brewed by boiling grounds with water and consumed unfiltered — as was 
common practice in Norway -- strongly raised cholesterol levels, but filtered coffee 
as consumed in Western European countries and in America did not. 
THE CHOLESTEROL-RAISING FACTORS IN COFFEE BEANS 
The next question was which particular compound or characteristic of boiled 
coffee was responsible for its cholesterol-raising effect. A major step in answering 
this question was the discovery that boiled coffee contains some lipids which are 
absent in filtered coffee [23,24]. The cholesterol-raising factor was obviously 
among these lipids; consumption of a lipid-rich fraction from boiled coffee [27] or 
intake of oils pressed from coffee beans [20,28,29] strongly raised cholesterol and 
triglyceride levels in volunteers. Two groups of investigators [20,30] then 
simultaneously reported that the responsible factor(s) belonged to the class of 
lipids called diterpenes. 
The two major coffee diterpenes are cafestol and kahweol (figure 2). They 
are natural constituents of coffee beans [2], and are released from roast and 
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ground coffee beans by hot water. Cafestol and kahweol do not pass a paper fi lter, 
but, in unfiltered brews, they are present in minuscule oil droplets and in f loating 
grounds. Coffee diterpenes are powerful modulators of lipid metabolism in humans; 
each twen ty milligrams of diterpenes ingested per day for four weeks raises blood 
levels of total cholesterol by three percent, and triglycerides by ten or more percent 
[20 ,30 ] . Intake of cafestol and kahweol for short periods also modifies the blood 
levels of various liver enzymes [20 ,28 ] , which may point to changes in the 
homeostasis of liver cells [31] . 
Cafestol Kahweol 
FIGURE 2. Structure of the coffee diterpene alcohols cafestol and kahweol. Compared to 
cafestol, kahweol has an additional double bond between the C1 and C2 carbon. 
Diterpenes occur in coffee beans either as free alcohols or esterified to fatty acids at the 
C17-position [2]. 
BLOOD LIPIDS OF INTEREST 
Cholesterol 
The fat-soluble compound cholesterol is transported through the blood in 
specialised carrier proteins called lipoproteins. Lipoproteins are characterised by 
their relative density. About 70 percent of total serum cholesterol is carried by low-
density l ipoproteins (LDL) which play a central role in the delivery of cholesterol 
f rom the liver to peripheral tissues [32] . Most of the remainder is carried by high-
density l ipoproteins (HDL) which are essential in the 'reverse' cholesterol transport, 
f rom peripheral tissues back to the liver [33 ] . Consumption of dietary fat ty acids 
and cholesterol [34 ] , alcohol intake [35] , and obesity [36] are important 
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determinants of the blood level of cholesterol, or of its distribution over different 
particles. 
A high blood level of cholesterol increases the risk of atherosclerotic 
diseases. Prospective studies have shown that a 10 percent increase in total 
cholesterol implies a 20 to 50 percent increase in the risk of heart disease [37]. 
Clinical, epidemiological, and genetic studies convincingly demonstrate that this 
risk increase is mainly due to the level of LDL cholesterol [32]. In contrast, there 
is abundant evidence that a high blood level of HDL cholesterol lowers the risk of 
coronary heart disease [33,38]. As yet, no trials have specifically studied whether 
a change in HDL cholesterol will result in a change in coronary risk; the benefit of 
raising HDL cholesterol must still be definitively proven. 
Triglycerides 
Triglycerides consist of three fatty acids bound to one glycerol molecule. 
Triglycerides obtained from dietary intake are carried from the intestines to the liver 
by 'chylomicrons', and are subsequently transported to peripheral tissues by very-
low-density lipoproteins (VLDL) [39]. High triglyceride levels are also associated 
with increased coronary risk [40-42], but it is controversial whether triglyceride 
level is an independent risk factor for coronary heart disease. For instance, 
adjustment for HDL cholesterol tends to eliminate the relationship between 
triglyceride levels and coronary risk [41]. It is also unclear whether levels in the 
fasting state (when most of the triglycerides are in VLDL) are similarly atherogenic 
to those in the postprandial state (when most are in chylomicrons) [42]. Therefore, 
more studies are needed to fully clarify the role of triglycerides in the development 
of atherosclerosis. 
Lipoprotein(a) 
Lipoprotein(a) [Lp(a)] is distinguished from LDL only by the presence of a 
large apolipoprotein [apo(a)] [43]. Despite the structural likeness of Lp(a) and LDL, 
Lp(a) levels in serum are unaffected by many interventions known to affect levels 
of LDL cholesterol [44]. Dietary influences on Lp(a) levels are also minimal, except 
for dietary trans fatty acids which cause a modest rise [45-47]. The claims that 
16 
GENERAL INTRODUCTION 
fish oils [48,49] and high doses of ascorbic acid [50] lower Lp(a) levels could not 
be verified [51-55]. 
An extensive body of laboratory evidence indicates that Lp(a) could be 
critical in the development of atherothrombotic diseases [56]. Many prospective 
studies have also shown a higher risk of atherothrombotic disease in individuals 
with high Lp(a) levels [57-64], but some prospective studies were negative 
[65-68]. The latter do not necessarily refute an effect of Lp(a) on cardiovascular 
health, but call for more studies to define the strength of the relationship and its 
consistency among different populations. 
BLOOD LIVER ENZYMES OF INTEREST 
Alanine and aspartate aminotransferase 
Levels of aminotransferases in blood are employed in clinical practice as 
indicators of hepatocellular damage. In liver cells, alanine aminotransferase (ALT, 
SGPT) is solely found in the cytoplasm, whereas aspartate aminotransferase (AST, 
SGOT) is predominantly found in the mitochondria. The aminotransferases are 
released from hepatic cells as a consequence of increased membrane permeability 
as well as membrane breakage. Alanine aminotransferase is the more sensitive and 
specific test of acute hepatocellular damage, whereas rises in aspartate 
aminotransferase are more marked in chronic damage [31]. Rises of 50 to 100 
times the upper limit of the laboratory reference range are observed with liver 
diseases or use of hepatotoxic drugs [69]. Smaller increases, often without clinical 
symptoms, are found in alcoholics and obese people [70,71]. 
Healthy volunteers who consumed coffee diterpenes for four to six weeks 
showed raised blood levels of alanine aminotransferase, and, to a lesser extent, of 
aspartate aminotransferase [20,28]. Blood levels did not exceed the upper limit of 
normal in most volunteers, and normalised when intake of diterpenes was stopped. 
These alterations most likely indicate small-scale injury to liver cells [31]. However, 
chronic consumers of coffee rich in diterpenes did not have elevated levels of 
aminotransferases [20,72], which suggests that the hepatocellular effect of 
cafestol and kahweol is transient. 
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K-Glutamyltransferase and alkaline phosphatase 
Although p-glutamyltransferase and alkaline phosphatase are found in many 
organs, their circulating levels are used in clinical practice as indicators of 
cholestatic disease, i.e. impaired bile f low. Blood levels of ^-glutamyltransferase are 
also used to monitor alcohol abuse [31] . 
Levels of /-glutamyltransferase and alkaline phosphatase in serum were 
slightly reduced upon intake of coffee diterpenes, whereas a rebound rise in 
K-glutamyltransferase was observed upon cessation of t reatment [20 ] . Chronic 
boiled-coffee drinkers had lower /-glutamyltransferase levels than filter coffee 
drinkers [73 ] , which suggests that this effect persists wi th chronic intake. 
OBJECTIVE AND OUTLINE OF THE THESIS 
The objective of our research was to further specify the health effects of 
drinking unfi ltered coffee in humans. This objective was subdivided into five prime 
questions: 
Are cafestol and kahweol available from grounds? 
Intake of coffee diterpenes dissolved in oils raised cholesterol levels 
[20 ,28-30 ] , but their eff icacy from floating grounds was unknown; unfiltered 
coffee brews may contain a fair amount of diterpenes carried by such particles. We 
measured the amount of f loating grounds in coffee brews, and, in t w o experiments 
w i th healthy volunteers, we studied whether consumption of such grounds could 
affect blood levels of lipids and liver enzymes (Chapter 2). 
What are the determinants of the diterpene content of coffee? 
We developed a gas chromatography method to analyse diterpene content 
and applied it to a range of brews collected in countries where a particular type of 
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coffee is popular. We also prepared a range of brews under standard laboratory 
conditions to examine factors that influence diterpene content (Chapter 3). 
Are cafestol and kahweol both effective? 
Kahweol occurs only in the major coffee strain arabica, whereas cafestol 
occurs in both robusta and arabica beans [2]. Oils pressed from robusta beans 
raised serum cholesterol [20,28,29], which suggests that cafestol is active. 
However, the activity of kahweol was unknown. We examined the separate effects 
of cafestol and kahweol on blood lipids and liver enzymes in a randomised cross-
over study with ten healthy male volunteers who received either pure cafestol 
alone or a mixture of cafestol and kahweol for four weeks (Chapter 4). 
Does the hepatocellular effect persist with prolonged intake? 
Most of the evidence of the hepatocellular effect of cafestol and kahweol 
was derived from short-term experiments. As chronic drinkers of boiled coffee did 
not have higher levels of alanine aminotransferase than matched filter coffee 
drinkers [20], we hypothesised that the effect is transient with prolonged intake. 
In addition, the time course of the changes in total and LDL cholesterol as induced 
by coffee diterpenes was remarkable; a steady state was not reached within four 
weeks of treatment [20,30]. We studied the effects of prolonged intake of cafestol 
and kahweol on serum levels of liver enzymes and lipids in a randomised parallel 
trial with 46 healthy volunteers who received either cafetière or filtered coffee for 
six months (Chapter 5). 
Do cafestol and kahweol affect serum lipoprotein(a)? 
The increase in alanine aminotransferase levels with diterpene intake may 
point to slightly disturbed hepatocyte integrity [31], and the impact on lipid 
metabolism could also be due to effects on the liver [74]. Apolipoprotein(a) is 
synthesised in the liver [75], and circulating levels of Lp(a) are largely determined 
by the rate of production [76]. The hypothesis that cafestol and kahweol affect the 
synthesis and secretion of apo(a), thereby reducing the circulating level of Lp(a), 
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was tested in an observational study with Norwegian coffee consumers (Chapter 
6) and in four experiments with Dutch volunteers (Chapter 7). 
Finally, chapter 8 summarizes the knowledge about the cholesterol-raising 
factors from coffee beans, including the information brought in by the present 
studies. It also describes the implications of drinking unfiltered coffee for health. 
Chapter 9 describes the main conclusions of our studies and recommendations for 
further research. 
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ABSTRACT 
The diterpenes cafestol and kahweol are present in unfiltered coffee in oil droplets 
and floating fines. They elevate serum cholesterol and alanine aminotransferase (AL T). We 
measured fines in coffee brews, and examined diterpene availability from spent grounds 
in healthy volunteers. Turkish or Scandinavian boiled coffee contained 2-5 g/L and French 
press coffee 1.5 g/L of fines. Intake of 8 g of fine grounds per day for three weeks 
increased cholesterol by 0.65 mmol/L (95% Confidence Interval, 0.41 to 0.89 mmol/Lj and 
ALT by 18 U/L (95% Confidence Interval, 4 to 32 U/L) relative to controls (n=7 per 
group). In a cross-over study (n= 15), mean serum cholesterol was 4.9 mmol/L after 
consumption of both fine and coarse grounds for 10 days (P=0.43). Serum ALT activities 
were 29 U/L on fine and 21 U/L on coarse grounds (P=0.02). Floating fines could 
contribute substantially to the hyperlipidemic andAL T-elevating effect of unfiltered coffee. 
Diterpene measurements in coffee brews should include the contribution of fines 
(AMERICAN JOURNAL OF CLINICAL NUTRITION 1995; 61: 149-154). 
INTRODUCTION 
Scandinavian boiled coffee - prepared by boiling coarsely ground coffee 
beans w i th water and decanting the fluid wi thout f i l tration - elevates serum 
cholesterol and triglycerides [1-4] . The diterpenoid alcohol cafestol , possibly 
together w i th kahweol , is responsible for this effect [5 ] . Cafestol plus kahweol 
esters also elevate at least transiently the serum activity of alanine 
aminotransferase (ALT) in serum and depress serum levels of creatinine in humans 
not accustomed to drinking boiled coffee [5] . The lower serum values of gamma-
glutamyltransferase ( K - G T ) among habitual consumers of boiled coffee [5-7] are 
also due to consumption of cafestol and kahweol [5] . 
Cafestol and kahweol are largely retained by a paper fi lter [8 ,9 ] . 
Scandinavian-type boiled coffee and other types of turbid coffee brews, such as 
Turkish coffee - brewed by boiling powdery coffee grounds wi th water -, French 
press ("plunger" or "cafetière") coffee and espresso coffee contain diterpenes both 
in oil droplets and in f loating coffee bean particles [8 ,10 ,11 ] . Diterpenes in coffee 
oil affect serum lipids and liver enzymes [5] . Floating coffee fines may add 
considerably to the intake of cafestol and kahweol f rom such brews. However, it 
is unknown to which degree cafestol and kahweol are absorbed f rom grounds. 
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We therefore studied particle contents of turbid coffee brews, and changes 
in serum lipid levels, creatinine, and ALT and y-GT activit ies in volunteers after 
consumption of spent coffee grounds. 
MATERIALS, SUBJECTS AND METHODS 
Particle content of coffee brews 
Brews were prepared w i th coarse (Roodmerk, Douwe Egberts, Utrecht, The 
Netherlands), fine (Café Honesta, Marvelo BV, Zaandam, The Netherlands), very 
fine (Espresso Piazza, Douwe Egberts, Utrecht, The Netherlands) or powdery 
grounds (Misr Cafe, Misr CAFECO, Egypt) [12 ] . 
Scandinavian boiled coffee was brewed wi th 10 min boil ing, and 5 min 
settl ing t ime. French press coffee (also known as "plunger" or "cafet ière" coffee) 
was prepared by pouring boiling water onto grounds in a glass jug of 1 liter (Bodum 
AG, Triengen, Switzerland), and pushing down the metal screen strainer (plunger) 
after 5 min incubation. Percolated coffee was prepared by recirculating boiling 
water for 20 min using a household percolator. Espresso coffee was prepared w i th 
a household espresso machine (Espresso Duo, Philips, Eindhoven, The 
Netherlands), and mocha coffee wi th an aluminum mocha-maker (Marimba, ABC, 
Crusinallo, Italy). Two different Middle Eastern brews were prepared. For "Israeli 
mud" coffee [13 ] , grounds were mixed w i th boiling water in a cup and al lowed to 
settle for 5 minutes. For "Turkish/Greek" coffee [12 ] , grounds were added to 
boiling water in a traditional Turkish brewing device (' ibrik', 100 mL). When a foam 
had formed, the heat was turned off and the brew decanted. Drip fi ltered brews 
were prepared in an electric coffee maker (Philips, Eindhoven, The Netherlands) 
wi th a paper (Melit ta, Gorinchem, The Netherlands), cot ton (Bean Bag, USA), nylon 
(Prestige, France) or gold filter (Swissgold, Elfo Ag Sachsein, Sachsein, 
Switzerland). All brews were prepared in fourfo ld. 
Ten mL of each unfiltered brew, espresso, mocha or French press brew was 
centr i fuged at 3000 rpm for 5 min (Centaur 2, MSE, England) and the lipid-
containing upper layer was washed away w i th 1 mL of hexane. The tube was then 
dried at 105°C , and weighed. For drip fi ltered and percolated brews, samples of 
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200 mL were centrifugea in containers of 250 mL at 19200 x g (Highspeed 18, 
MSE, Crawley, England). The lipid-containing upper layer was washed away with 
25 mL of hexane. The particle precipitate was then collected by filtration over 
paper (Schleicher & Schuell, Dassel, Germany), dried at 105 °C, and weighed. 
Effect of coffee grounds on serum lipids and liver enzymes 
We examined the effect of fine grounds in a randomised controlled parallel 
study (STUDY 1), and studied the influence of particle size by giving either fine or 
coarse grounds in a cross-over study (STUDY 2). 
PREPARATION OF THE GROUNDS. Medium-roasted Mexican Arabica beans of one 
batch (Simon Levelt, Amsterdam) were used for both studies. They were ground 
in a beaker with rotation blade (Krups KM75, Solingen, Germany). For study 1, fine 
grounds were obtained by grinding beans to pass a 0.5 mm metal sieve (Retsch, 
Haan, Germany). For study 2, coarsely ground coffee was obtained by collecting 
grounds passing a 1.4 but not a 1.0 mm sieve, while grounds passing the 1.0 mm 
sieve were ground to pass an 0.5 mm metal sieve to obtain fine grounds. 
Spent coffee grounds were prepared twice a week, by mixing ground coffee 
beans with boiling water (70 g/L), boiling them for 5 min and allowing them to 
settle for 5 min. The spent grounds were collected on a 75 //m metal sieve 
(Retsch, Haan, Germany) and allowed to drain for 30 minutes before being divided 
into daily portions. 
We analysed cafestol and kahweol contents in coffee grounds of every 
brewing session for study 1, and in one portion of study 2. Lipids were saponified 
with ethanolic KOH, 5 mol/L, and 5a-cholestane was added as an internal standard. 
The free diterpene alcohols were extracted with diisopropylether, and analysed as 
trimethylsilylethers on a Hewlett Packard 5890 series II gas Chromatograph 
(Avondale, PA19311, USA). Authenticity and purity of the peaks were verified on 
a Hewlett Packard G1019A mass spectrometer. 
SUBJECTS. Approval for the studies was obtained from the human ethics 
committee of the department. Subjects were recruited by personal approach. The 
study protocol was explained to them before they gave their written informed 
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consent. None suffered from glucosuria or proteinuria, and none reported a history 
of gastro-intestinal, liver or kidney diseases. One woman withdrew from study 2 
in the first week because of gastro-intestinal discomfort. All other participants 
completed study 1 (n = 14) or study 2 (n = 15) successfully. They were mostly 
young, lean, and non-smoking (table 1). They consumed no or only moderate 
amounts of alcohol and coffee. They did not take medications affecting serum 
lipids or liver enzymes, and the levels of these were all within normal limits. 
TABLE 1 . Baseline characteristics of the participants3 
Sex (M/F) 
Age (years) 
Body Mass Index (kg/m2)b 
Oral contraceptive users 
Smokers 
Daily coffee consumption (cups) 
Weekly alcohol consumption (glasses) 
Study 1 
6/8 
24 ± 3 
21.8 ± 
2 
2 
3 ± 2 
7 ± 7 
2.1 
Study 2 
9/6 
26 ± 5 
22.0 ± 2.3 
2 
3 
3 ± 2 
4 ± 3 
Values are numbers, or means ± SD 
Body weights were measured without shoes or heavy clothing. 
Hypotheses and designs 
STUDY 1. The hypothesis to be tested was that daily ingestion of eight g of 
coffee grounds elevates serum cholesterol and ALT activity. Calculations showed 
that we would need 6 subjects per group to detect a difference in serum 
cholesterol of 0.50 mmol/L with a power of 90%, and 7 to detect a difference in 
ALT of 20 U/L (CT = 0 . 0 5 ) . 
During the run-in period of 14 days, subjects consumed 125 mL of 'hopjes-
caramelvla', a commercially available, sweet-flavoured dairy dessert providing 3.8 
g of fat (2.5 g saturated, 1.3 g mono-unsaturated fatty acids) and 12.5 mg of 
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cholesterol per day. Venous blood samples were taken f rom each subject on days 
-3 and 0. 
During the test period of 21 days both groups consumed 125 mL of hopjes-
caramelvla per day. The experimental group mixed fine spent coffee grounds just 
before consumption w i th the hopjes-caramelvla, which masked the bitter taste of 
the grounds fairly wel l . Subjects were provided wi th grounds tw ice a week and 
were requested to store them at 4 ° C . They were free to choose the t ime of 
consumpt ion, but they had to consume them every day at the same t ime. 
Consumption of the grounds was not allowed with in half an hour after subjects 
had taken any food or drink except water. 
Compliance was monitored by asking the subjects to report the t ime of 
consumpt ion of the grounds daily in a special diary. They were instructed to 
maintain their usual dietary and living habits and to report deviations f rom it. 
Subjects were asked to restrict coffee use during the experiment to paper fi ltered 
coffee w i th a daily maximum of 6 cups. Tea was allowed freely. They also kept 
daily records of coffee and alcohol consumpt ion, and medication use. 
Venous blood samples were taken on days 18 and 2 1 , and 59 days after the 
experiment (day 80). 
STUDY 2. We hypothesised that serum cholesterol and serum ALT would be 
higher on fine grounds than on coarse grounds. The study was designed to detect 
a difference between the t w o treatments in serum cholesterol of 0 .20 mmol/L and 
in serum ALT of 10 U/L w i th a power of 9 0 % (a = 0.05). 
Baseline blood samples were drawn on days -4 and 0. Subjects were 
randomised into t w o groups and consumed either fine or coarse grounds for 11 
days. On day 11 blood samples were taken. No grounds were consumed on days 
12, 13 and 14. Then treatments were swi tched. Final blood samples were drawn 
on days 25 and 28. Serum levels were checked in fourteen subjects 99 days after 
the experiment (day 127). Other requirements were similar to study 1. 
Blood assays 
Blood samples were taken after an overnight fast. Sera were obtained by 
centr i fugat ion, stored at -80°C and analysed wi th in one run. Sera obtained post-
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experimentally were analysed separately. Sera were analysed enzymatically for 
total cholesterol [14] and triglycerides [1 5]. Mean bias for control sera provided by 
the Centers for Disease Control (Atlanta, USA) was -2% for total cholesterol and 
4% for triglycerides. The coefficient of variation within runs ranged from 0.7 to 
2 . 1 % . Creatinine was measured with a modified Jaffé method using a Spectrum 
kit (Abbott Laboratories, North Chicago, USA) [16]. Serum activities of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) [17], gamma-
glutamyltransferase (y-GT) [18] and alkaline phosphatase [19] were measured at 
37°C using Abbott Spectrum reagents. The mean bias for 'Monitrol' control sera 
(Baxter Dade, Switzerland) ranged from -0.3% to 1 %. The coefficient of variation 
within runs ranged from 0.8 to 10%. Upper limits of normal were 53.5 U/L for ALT 
activity, 39.7 U/L for AST activity, and 92 U/L for alkaline phosphatase activity, 
and for y-GT activity 63 U/L for men and 35 U/L for women. 
Statistics 
STUDY 1. Effects of grounds consumption were investigated by subtracting 
the mean of the two baseline values (days -3 and 0) from the mean of the values 
on grounds at the end of the trial (days 18 and 21 ). Differences in group means of 
changes were compared using an unpaired, one-tailed f test. 
STUDY 2. Effects of particle size were analysed by comparing values obtained 
on days 11 and 25, i.e. after ten days of consumption of either type of grounds; 
t tests [20] showed period effects for all serum variables (p<0.05) except 
triglycerides. However, f tests for equality of carry-over effects from the first into 
the second period [20] showed similar carry-over between the two groups for all 
variables (p = 0.10). Therefore, values after consumption of coarse grounds were 
subtracted from values after fine grounds irrespective of sequence, and differences 
were tested against zero with a one-tailed f test. 
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RESULTS 
Particle content of coffee brews 
Unfiltered coffee types contained the highest amount of f loating f ines, 
ranging f rom 2 g dry weight per liter of Scandinavian coffee to about 5 g/L for 
Middle Eastern coffee brews (table 2). French press coffee contained 1.5 g/L and 
other unfi ltered coffee types contained less. Use of a paper filter led to negligible 
amounts of coffee fines. 
TABLE 2. Levels of coffee bean particles (mean ± SD) in various coffee brews as 
consumed. 
Coffee type 
Unfiltered 
Scandinavian boiled 
Israeli mud [1 3] 
Turkish/Greek 
Other 
French press 
espresso 
mocha 
percolated 
drip filtered 
paper filter 
nylon filter 
gold filter 
cotton filter 
Brewing 
strength 
q/L water 
80 
80 
80 
50 
150 
100 
50 
50 
50 
50 
50 
Grind 
coarse 
powdery 
powdery 
coarse 
very fine 
very fine 
coarse 
fine 
fine 
fine 
fine 
Particle content 
q dry weiqht/L 
2.1 ± 0.5 
5.0 ± 1.2 
5.3 ± 1.8 
1.5 ± 0.2 
0.8 ± 0.1 
1.2 ± 0.4 
0.4 ± 0.0 
0.1 ± 0.0 
0.4 ± 0.0 
0.6 ± 0.1 
0.3 ± 0.1 
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Effect of coffee grounds on serum lipids and liver enzymes 
The 29 out of 30 subjects who completed either of the studies successfully 
reported only minor complaints. Two subjects reported flatulence during the first 
week of treatment. Hyperactivity was reported by two subjects during the first 
days, even though caffeine was probably largely absent from the grounds [11]. 
STUDY 1. Diaries kept by the subjects showed that all of the 147 daily 
portions of grounds had been consumed. Dry weights of the grounds portions were 
(mean + SD) 7.8 + 0.2 g/d. The grounds provided 39 + 4 mg of cafestol and 49 
+ 5 mg of kahweol per day (n = 5). 
After 21 days of grounds consumption, participants showed a mean rise in 
serum cholesterol of 0.65 mmol/L (95% Confidence Interval, 0.41 to 0.89 mmol/L) 
relative to the control group (table 3, figure 1). An increase in serum cholesterol 
was seen in each of the subjects consuming coffee grounds, ranging from 0.29 to 
1.09 mmol/L. The mean rise in ALT activity relative to controls was 18 U/L (95% 
CI, 4 to 32 U/L), or 0.3 times our upper limit of normal. The treatment group also 
showed higher values of serum triglycerides and serum AST, and lower values of 
K-GT, alkaline phosphatase and creatinine (p<0.10). All serum values returned to 
baseline level after cessation of the treatment. 
STUDY 2. Diaries showed that only one out of the 360 daily portions of 
grounds had not been consumed. Dry weights of the grounds portions of the seven 
brewing sessions were 7.1 ± 0.3 g/d for coarse grounds and 6.6 ± 0.5 g/d for 
fine grounds. The coarse coffee grounds provided 37 mg of cafestol and 54 mg of 
kahweol and the fine grounds 48 mg of cafestol and 56 mg of kahweol per day 
(n = 1). 
Serum cholesterol levels showed a similar response for both treatment 
sequences (figure 2). Mean levels were 4.9 mmol/L both after consumption of fine 
and of coarse grounds (table 4). Mean ALT activity in serum was 29 U/L on fine 
and 21 U/L on coarse grounds (p for difference 0.02). Serum values of triglycerides 
and AST were higher, and those of p-GT lower on fine than on course grounds (p 
< 0.05). 
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TABLE 3 . S T U D Y 1 . Mean changes ( ± SD) in values of serum lipids, liver enzymes, and 
creatinine in healthy volunteers consuming hopjes-caramelvla (control group) or hopjes-
caramelvla with 7.8 g/day of dry weight of fine spent coffee grounds (treatment group) 
for 2 1 days, and differences between changes \ 
Control Treatment Difference between P-value 
group (n = 7) group (n = 7) groups (95% CI) 
Cholesterol (mmol/L) 0.01 ± 0.23 0.66 ± 0.24 
Triglycerides (mmol/L) 0.06 ± 0.27 0.36 ± 0.34 
ALT (U/L) 3 ± 4 21 ± 19 
K-GT (U/L) 0 ± 1 -2 ± 2 
AST (U/L) 2 ± 3 9 ± 9 
AP (U/L) 0 ± 3 -6 ± 7 
Creatinine (/vmol/L) 1 ± 7 -5 ± 6 
0.65 (0.41 to 0.89) 
0.30 (-0.02 to 0.62) 
18 (4 to 32) 
-3 ( -4 to-1) 
7 (-0 to 14) 
-6 (-12 to -1) 
-6 (-13 to 1) 
<0 .001 
0.05 
0.02 
0.01 
0.05 
0.03 
0.06 
1
 To convert cholesterol values to mg/dL multiply by 38.67, triglycerides by 88.54. 
TABLE 4 . S T U D Y 2 . mean ( ± SD) values of serum lipids, liver enzymes, and creatinine of 
15 healthy volunteers upon daily consumption of hopjes-caramelvla with 6.6 g of fine, and 
with 7.1 g of coarse grounds for 10 days each in a cross-over design \ 
Cholesterol (mmol/L) 
Triglycerides (mmol/L) 
ALT (U/L) 
K-GT (U/L) 
AST (U/L) 
AP (U/L) 
Creatinine (/ymol/L) 
Value on fine 
grounds 
4.89 ± 0.73 
1.31 ± 0.54 
29 + 18 
13 ± 4 
26 ± 7 
63 ± 18 
86 ± 13 
Value on coarse 
grounds 
4.86 ± 0.65 
1.01 ± 0.45 
21 ± 9 
15 ± 4 
22 ± 5 
63 ± 15 
85 ± 13 
Difference 
fine-coarse 
0.03 ± 0.71 
0.31 ± 0.51 
8 ± 14 
-2 ± 1 
5 ± 4 
-0 ± 6 
0 + 8 
P-value 
0.43 
0.02 
0.02 
<0 .001 
<0 .001 
0.41 
0.42 
1
 To convert cholesterol values to mg/dL multiply by 38.67, triglycerides by 88.54. 
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FIGURE 1. STUDY 1. Mean levels of serum cholesterol and alanine aminotransferase in two 
groups of 7 healthy volunteers at baseline (o), after daily consumption of 125 mL of 
hopjes-caramelvla with (•) or without (o) 7.8 g of fine spent coffee grounds, and 59 days 
after the experiment (o). The grey area indicates the period during which grounds were 
administered. 
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FIGURE 2. STUDY 2. Mean levels of serum cholesterol and alanine aminotransferase in 15 
healthy volunteers at baseline (o), after daily consumption of 6.6 g of fine (•) or 7.1 g of 
coarse grounds (• ) , and 99 days after the experiment (o) (n= 7 or 8 per group). The grey 
areas indicate the periods during which grounds were administered. 
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DISCUSSION 
Particle content of coffee brews 
Scandinavian boiled coffee, the coffee type most commonly associated with 
raised cholesterol levels [1-4], contained 2.1 g coffee fines/L. If we assume that 
the diterpene content of these coffee fines is similar to that of the fine grounds 
used in our trial (39 mg cafestol and 49 mg kahweol in 7.8 g of fines), then the 
grounds in boiled coffee would provide 11 mg cafestol and 13 mg kahweol per liter 
of brew. This is 22% of the total amount of 108 mg of diterpenes per liter [8]. 
Levels for Middle Eastern brews, known variously as "Turkish", "Greek", "Arab" 
or "Israeli mud", were even higher. Middle Eastern boiled coffee contained 5.3 g/L 
of fines, which would provide 27 mg of cafestol and 33 mg of kahweol, 
accounting for about half of the total amount of diterpenes present in Middle 
Eastern brew [8]. Obviously, diterpene contents in such turbid brews will be 
affected strongly by the amount of particles decanted with the brew. This 
underlines the importance of an analytical method which includes the contribution 
of ingested coffee fines to the total amount of diterpenes in the brew. 
Effect of coffee grounds on serum lipids and enzymes 
STUDY 1. In this parallel study, daily ingestion of 8 g of coffee grounds 
significantly raised serum cholesterol and ALT levels compared to controls. 
Elevations in these parameters were similar to those caused by boiled coffee, 
coffee oil, or similar amounts of cafestol and kahweol as pure compounds 
dissolved in oil [5]. In the present study a mean daily intake of 39 mg of cafestol 
and 49 mg of kahweol with coffee grounds resulted in a rise in serum total 
cholesterol of 0.65 mmol/L (26 mg/dL). We have earlier estimated that each extra 
2 mg of cafestol ingested in oily solutions increases serum total cholesterol by 
0.03 mmol/L (1 mg/dL) [5]. If cafestol absorption from coffee oil and boiled 
grounds were equal, the predicted rise for the present study would be 0.52 mmol/L 
(20 mg/dL). This is only slightly lower than the observed rise. In our previous 
studies serum ALT levels rose on average by 1 U/L for every 2 mg cafestol 
ingested [5]. If cafestol in bean particles were as available as cafestol in oil, then 
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the boiled grounds should have raised serum ALT by 20 U/L. The observed rise 
was 18 U/L. These results suggest that cafestol availability from ingested grounds 
is comparable to that from coffee oil. Furthermore, the changes in the other liver 
enzymes -- y-GT, alkaline phosphatase and AST -- and the changes in serum 
triglycerides and creatinine were all in the same directions as in previous studies 
[5]. 
The duration of grounds consumption was three weeks. In previous studies 
[5,9], the effects of cafestol and kahweol on serum cholesterol and ALT did not 
stabilise within four weeks of administration. Thus, some underestimation due to 
treatment duration may be present. 
STUDY 2. The effect of particle size on the availability of cafestol and 
kahweol was examined in a cross-over study. Comparison of the two particle sizes, 
however, was complicated by the unexpectedly different cafestol content of the 
samples, 48 mg of cafestol in fine versus 37 mg in coarse grounds. Later 
experiments (unpublished) confirmed that grinding and sieving of beans led to 
fractionation of lipid material, with fine grounds having a higher cafestol content. 
The larger effect of fine grounds on ALT and y-GT activity and triglycerides could 
therefore be due to their higher cafestol content, rather than to particle size. 
However, despite the difference in cafestol, responses of serum cholesterol were 
highly similar for both treatments (figure 2). Possibly, the effect on serum 
cholesterol can be induced by lower levels of cafestol than the effect on serum 
ALT. Furthermore, kahweol could have lessened the difference between the two 
groups in this study, since the grounds were comparable in kahweol content (56 
mg kahweol in fine grounds and 54 mg in coarse grounds). The separate effects 
of cafestol and kahweol on blood lipids and parameters of liver and kidney function 
still have to be established. However, it would appear that an appreciable amount 
of cafestol and kahweol is already absorbed from the coarse grounds. 
Conclusions 
Cafestol and kahweol from coffee grounds raise serum cholesterol and ALT 
activity similar to cafestol and kahweol from boiled coffee or coffee oil. Since 
appreciable amounts of diterpenes are carried by floating coffee bean particles in 
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turbid brews, especially of the Middle Eastern types, analyses of these brews 
should include the contribution of fines. Finally, frequent ingestion of coffee bean 
particles or of grounds with turbid coffee brews should be avoided. 
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ABSTRACT 
The coffee diterpenes cafestol and kahweol raise serum cholesterol in humans. Each 
10 mg of cafestol consumed per day elevates cholesterol by 5 mg/dL (0.13 mmol/L). We 
examined diterpene levels in various coffee brews. Scandinavian boiled coffee contained 
(mean ± SD) 3.0 ± 2.8 mg, French press (also called 'cafetière') coffee 3.5 ± 1.2 mg, 
andTurkish/Greek coffee 3.9 ± 3.2 mg of cafestol per cup. Consumption of five cups per 
day of any of these coffee types could thus elevate serum cholesterol by 8-10 mg/dL. 
Italian espresso coffee contained 1.5 ± 1.0 mg of cafestol per cup, five cups theoretically 
raising cholesterol by 4 mg/dL. Brewing time had little effect on diterpenes. Brewing 
strength increased diterpenes in boiled, French press, and espresso coffee but not in 
Turkish/Greek coffee. Diterpenes in instant, drip filtered, and percolated brews were 
negligible. Regular and decaffeinated coffee had similar diterpene contents. High chronic 
intake of French press coffee or Turkish/Greek coffee could increase serum cholesterol and 
thus coronary risk similar to that reported previously for Scandinavian boiled coffee 
(JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 1995; 43: 2167-72). 
INTRODUCTION 
Scandinavian-type boiled coffee raises serum cholesterol in man [1 ,2 ] . The 
diterpenes cafestol and, possibly, kahweol are responsible for this effect [3 ,4 ] . 
Addit ional ly, cafestol and kahweol appear to affect liver cell metabol ism; they 
increased the activi ty of alanine aminotransferase and depressed that of gamma-
glutamyltransferase in serum. In controlled trials, serum cholesterol rose by about 
1 mg/dL (0.03 mmol/L) and alanine aminotransferase by about 1 U/L for each extra 
2 mg of cafestol ingested [4] . Levels of cafestol and kahweol in various coffee 
brews could be used to predict their capacity to affect l ipoprotein and liver cell 
metabolism and are thus an important health issue. 
Cafestol and kahweol represent the major part of the unsaponifiable lipid 
fract ion in coffee beans. They are mainly present as fat ty acid esters, but small 
amounts of free alcohols also occur. The total diterpene content is 1.3% w / w in 
green beans of Coffea arabica (commonly called Arabica beans) and 0 . 2 % in beans 
of Coffea canephora (commonly called Robusta beans) [5 ] . Robusta beans are 
almost devoid of kahweol [6] but contain a third diterpene - 16-O-methylcafestol -
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- which is absent in Arabica beans [7]. Other diterpenes, such as decomposition 
products of cafestol and kahweol, are present in very low quantities and are there-
fore unlikely to affect serum lipids and liver enzymes substantially. 
Brewing releases oil droplets containing diterpenes from ground coffee 
beans. The oil is retained by a paper filter [8], which explains why paper-filtered 
coffee shows no [9,10] or only little [11] effect on serum cholesterol. With 
espresso and mocha coffee, and with French press coffee, also known as cafetière 
coffee, lipids readily pass the metal filter [8] and the hypercholesterolaemic 
diterpenes may thus be removed less efficiently from the brew. Other brews, such 
as Scandinavian boiled coffee and Middle Eastern coffee types, are decanted 
directly from the boiling state into the cup without applying a filter at all [5]. 
We report diterpene contents of various coffee brews, and their potential 
impact on serum cholesterol levels. 
Percolator French press Mocha 
FIGURE 1. Brewing principles for percolated, French press (cafetière), and mocha coffees. 
METHODS 
Collection of field samples 
Boiled coffee was collected from regular consumers in Norway and Finland 
(n = 14); Turkish/Greek coffee from Turkish and Greek restaurants operated by 
immigrants in the Netherlands (n = 7) and from retail outlets in Greece and Egypt 
(n = 4); espresso from bars and restaurants in Italy (n = 10), Spain (n = 2), Switzer-
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land (n = 4) and the Netherlands (n = 15); and French press coffee (figure 1) from 
consumers in the Netherlands (n = 5). Brews were poured into plastic containers 
so as to mimic the amount of the brew that is consumed from the cup, and frozen 
at -20 °C. Cup size was defined as the amount poured into the container. 
Thirteen regular and 6 decaffeinated instant (soluble) coffees were analysed. 
Instant brands included Folgers red and green, Tasters Choice red and green, Sanka 
To Go decaffeinated (decaf) and Maxwell House (USA), Nescafé Espresso, Nescafé 
Cappuccino, Nescafé Classico roodmerk and decaf, Nescafé Cap Colombie, Douwe 
Egberts Moccona roodmerk and decaf, Douwe Egberts Moccona Espresso, and 
Koffie Hag (The Netherlands), MISR Cafe and Mister Cafe (Egypt), Nescafé Classic 
(South Africa), and Africafe (Tanzania). 
Twenty regular and 5 decaffeinated brands of roast and ground coffee beans 
were analysed. Brands included Hills Bros red and green, Folgers Mountain Grown 
regular and decaf, Maxwell House Master Blend and Maxwell House decaf (USA), 
Albert Heijn Perla, Van Nelle Supra, Cafe Idee, Douwe Egberts Kleintje Koffie and 
decaf, Douwe Egberts Piazza Espresso, Douwe Egberts roodmerk (The 
Netherlands), Jacobs Espresso Mastro Lorenzo regular and decaf, and Jacobs 
Espresso Medaille d'Or (Germany), Rombouts Espresso (Belgium), Evergood Kaffe 
and Friele Frokost Kaffe (Norway), Paulig Juhla Mokka (Finland), Elite ALAD IN 
(Israel), MISR Cafe (Egypt), Kopi Tora Bika (Indonesia), and Yambone Coffee and 
Banja Coffee (Malawi). 
To examine the influence of roasting, we roasted samples of 250 g of 
Mexican Arabica beans (Cafe Organico, Simon Levelt, Amsterdam, the 
Netherlands) with a Type B3 sample roaster (Probat, Germany) for 4.5 (light roast), 
5.0 (medium), and 5.8 min (dark). 
Preparation of brews in the laboratory 
We studied the effect of brewing method and duration and of the ratio of 
coffee grounds to water (brewing strength) under laboratory conditions. We used 
one large batch of medium-roasted Mexican Arabica beans (Simon Levelt, 
Amsterdam) for all brews. Beans were ground with a commercial coffee bean 
grinder (La Pavoni, Italy) to coarse or fine grind. Particle size distribution (w/w) as 
determined with metal sieves (Haan, Retsch, Germany) was for coarse grounds: 
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)% between 0.6 and 1.0 mm, and 25% between 0.42 
founds: 17% larger than 0.6 mm, 26% between 0.42 
0.2 and 0.42 mm and 9% between 0.075 and 0.2 
obtained by pulverizing fine grounds in a beaker with 
15, Solingen, Germany). Ten percent of the powdery 
than 0.42 mm, 38% between 0.2 mm and 0.42 mm, 
|md 0.2 mm, and 18% smaller than 0.075 mm. 
in triplicate and stored at -20 °C for a maximum of 3 
"Scandinavian" boiled coffee was brewed in the 
bely ground beans with water, followed by 5 min of 
las decanted until particles of the sediment started to 
|ypes of Middle Eastern coffee. "Turkish/Greek" coffee 
powdery grounds to a foamy boil with water in a 
Ipot. Then the brew was decanted into a cup. "Israeli 
lared by pouring boiling water onto powdery grounds in 
ps, the contents of each cup were decanted again after 
as to mimic usual consumption. 
French press coffee (figure 1) was brewed by pouring 
ground beans in a glass plunger pot of 1 L (Bodum AG, 
pushing down the metal screen strainer (plunger) after 
brewed with fine grind. We compared espresso brewed 
lo machines for household use from Philips (Eindhoven, 
from Krups (Solingen, Germany), using three extraction 
)0 mL), and three roasting grades (light, medium, and 
I brewed with fine grind in an aluminum mocha-maker 
\, Italy) (figure 1). 
i/as prepared by recirculating boiling water for 20 min 
ïing a household percolator of 1 L (figure 1). 
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Drip-filtered brews were prepared with fine grind in an electric coffee maker 
(Ebony 053, Moulinex, France) with a paper bag filter (Melitta, Gorinchem, The 
Netherlands) or with a cotton (Bean Bag, USA), nylon (Prestige, France), or gold-
plated (Swissgold, Elfo Ag Sachsein, Sachsein, Switzerland) "permanent" filter. 
Analysis of diterpenes 
Coffee brew was heated to 60-90 °C under continuous stirring, and 4 mL 
was pipetted into a screw capped tube. Two millilitres of 5a-cholestane (Pierce, 
Eurochemie, Oud-Beijerland, The Netherlands, no. 17060) in ethanol was added as 
internal standard. Its concentration in ethanol was 25, 200, or 500 mg/L, if 
cafestol in the brew was expected to be < 12.5, between 12.5 and 100, or > 100 
mg/L, respectively. 
Lipids were extracted by adding 4 mL of diisopropyl ether (Merck, 
Darmstadt, Germany, no. 867), shaking for 10 min at 250 oscillations/min in a 
mechanical shaker (Swip SM25, Buehler, Switzerland), and centrifuging for 5 min 
at 3000 rpm (Centaur 2, MSE, England). The ether phase was taken off. The water 
phase was re-extracted once with 4 mL and once with 2 mL of diisopropyl ether. 
The combined extracts were 
evaporated at 45 °C with nitrogen and redissolved in 200 //L of absolute ethanol 
(Merck, no. 983). One millilitre of 0.5 M potassium hydroxide in ethanol was 
added, and the solution was saponified by incubating for 15 min in a water bath 
at 80 °C. 
Beans or commercial ground coffees were ground in a beaker with a rotation 
blade (Krups, KM75, Solingen, Germany) to pass a 600 /ym sieve (Retsch, Haan, 
Germany). Then, 100-200 mg of grounds was combined with 1 mL of 5a-cholesta-
ne in ethanol (1 g/L) and 1 mL of 5 M potassium hydroxide in ethanol and 
saponified for 60 min in a shaking water bath at 80 °C. 
After saponification, the procedure was identical for brews and grounds. One 
millilitre of demineralised water was added, and the water phase was extracted 
three times with 2 mL of diisopropyl ether. Three millilitres of demineralised water 
were added to the combined solvent fractions, and the mixture was shaken for 10 
min at 250 oscillations/min and centrifuged for 5 min at 3000 rpm. The ether 
phase was dried at 45 °C with nitrogen, and the residue was redissolved into 1.5 
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mL of diisopropyl ether. The solution was transferred into a 2 mL sampler vial and 
dried at 45 °C with nitrogen, and the residue was dissolved in 0.5 mL of dried 
pyridine (Merck, no. 7463). Then 150 //L of a 2:1 (v/v) mixture of hexa-
methyldisilazane (Pierce, no. 84770) and trichloromethylsilane (Pierce, no. 88530) 
was added. After 30 min at ambient temperature, excess pyridine was removed 
under a stream of nitrogen, and 1.0 mL of HPLC grade hexane (Rathburn, Chemi-
cals Ltd., Scotland) was added. The vial was shaken and centrifuged, and the 
supernatant was diluted with hexane 8 times if cafestol in the brew was expected 
to be between 12.5 and 100 mg/L, and 20 times if cafestol was > 100 mg/L. The 
sample was transferred to a clean vial, and 1.0 JJL was injected splitless into a 
Hewlett-Packard 5890 Series II gas Chromatograph (Avondale, PA, USA) equipped 
with a 25 m x 0.22 mm fused silica CP SN5CB column (Chrompack, Middelburg, 
The Netherlands). The initial oven temperature was 70 °C for 2.5 min followed by 
a rise to 200 °C at a rate of 40 °C/min. After 10 min, the temperature was raised 
to 235 °C at a rate of 6 °C/min and then to 285 °C at a rate of 30 °C/min, at 
which it was held for 6.75 min. Other conditions were as follows: carrier gas, 
hydrogen; pressure, 100 kPa; makeup gas, nitrogen; splitless injection after 2.5 
min with a injector purge flow of 100 mL/min at 300 °C; flame ionization detector 
temperature, 305 °C. A typical gas chromatogram for a Turkish/Greek coffee 
sample is shown in figure 2. The system was calibrated with a mixture of authentic 
cafestol, kahweol, and 16-O-methylcafestol provided by Nestec Ltd., Switzerland. 
Authenticity and purity of the peaks were verified on a Hewlett-Packard G1019A 
GC mass spectrometer. We also detected small amounts of decomposition 
products of cafestol and kahweol (figure 2), formed by loss of the 16-OH function 
by dehydration during processing. 
The coefficients of variation for a control pool of boiled coffee were 3.0% 
within and 6.3% between runs over a 6-month period for cafestol, and 2.9% and 
5.2%, respectively, for kahweol. Recoveries of cafestol and kahweol (mean ± SD) 
were 102.2 ± 2.3% and 100.3 ± 2.5%, respectively, if added in the form of 
coffee oil to paper-filtered coffee (n = 6), and 100.1 ± 3.4% and 99.3 ± 3.2%, 
respectively, if added as diterpene-containing coffee grounds (n = 6). Measurements 
were linear over the range of 0.01-40 mg/100 mL of brew. 
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TABLE 1. Mean levels ± SD (ranges) of cafestol, kahweol, and 16-O-methylcafestol in 
coffees collected from bars and restaurants and from regular consumers in a range of 
countries (cf Methods section). Values are given in terms of mg of free diterpene alcohols 
per cup. For brews collected from bars and restaurants, cup size was defined as the 
amount of brew served per cup. For brews of Scandinavian and French press coffee made 
at home by regular consumers, cup size was 150 mL. 
Type of coffee Cafestol Kahweol 16-O-Methyl-
cafestol 
Scandinavian boiled (n = 14) 
Turkish/Greek (n = 11) 
French press (n = 5) 
Espresso 
Italy (n = 10) 
Other countries (n = 21) 
3.0 ± 2.8 
(0.8 to 12.1) 
3.9 ± 3.2 
(0.5 to 10.0) 
3.5 + 1.2 
(2.3 to 5.5) 
1.5 ± 1.0 
(0.2 to 2.9) 
1.2 ± 0.9 
(0.0 to 3.1) 
mg per cup 
3.9 ± 3.4 
(1.1 to 14.6) 
3.9 ± 3.9 
(0.1 to 10.7) 
4.4 ± 2.1 
(2.6 to 8.0) 
1.8 ± 1.3 
(0.2 to 3.9) 
1.4 ± 1.1 
(0.0 to 3.9) 
0.0 ± 0.0 
(0.0 to 0.1) 
0.5 ± 0.6 
(0.0 to 1.4) 
0.1 ± 0.1 
(0 to 0.2) 
0.1 ± 0.1 
(0.0 to 0.3) 
0.1 ± 0.1 
(0.0 to 0.3) 
RESULTS 
Field samples 
Scandinavian boiled and Turkish/Greek coffees showed high variabil ity in 
diterpene levels. They ranged f rom as low as 1 mg to more than 10 mg of cafestol 
per cup. On average, they contained 3-4 mg of cafestol per cup. French press 
coffees contained 3.5 mg of cafestol per cup of 150 mL (range 2.3-5.5 mg). 
Espresso coffees ranged f rom 0 - 3 . 1 mg per cup (table 1). 
Instant coffees on average contained 0.2 mg (range 0-0.6 mg) of cafestol 
per cup prepared wi th 2 g of soluble granules for both regular and decaffeinated 
coffees (figure 3). Mean levels of cafestol, kahweol , and 16-O-methylcafestol were 
4 8 6 , 4 6 9 , and 34 mg/100 g of regular coffee grounds (n = 20) and 4 8 5 , 4 1 1 , and 
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44 mg/100 g of decaffeinated coffee grounds (n = 5), respectively (figure 3). 
Roasting did not reduce diterpenes in Arabica beans (figure 4). 
ujl \jX _A_LJL—A__^V, 
FIGURE 2. Gas chromatogram of silyl derivatives of coffee diterpenes in a Turkish/Greek 
coffee sample. Peaks: decomposition products of cafestol and kahweol (1 , 2), 16-0-
methylcafestol (3), kahweol (4), cafestol (5), and 5cr-cholestane (6). Other peaks represent 
mostly free fatty acids and phytosterols. For further details, see Methods section. 
Decaf 
1.50 
Roast & ground coffees 
0.00 
Instant coffees 
FIGURE 3. Levels of cafestol (solid bar), kahweol (slashed bar) and 16-O-methylcafestol 
(open bar) in instant (soluble) coffee granules and in commercial roast and ground coffees. 
For instant coffees, values are given as milligrams of free alcohols per 2 g of soluble 
granules, which is the amount that goes into one cup [5]. For coffee grounds, values are 
milligrams per 100 g. 'Regular' refers to caffeine-containing products, 'decaf' refers to 
decaffeinated products. 
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Brews prepared in the laboratory 
The Arabica beans we used contained 573 mg of cafestol and 736 mg of 
kahweol per 100 g. The ratio of cafestol to kahweol was the same in beans and 
brews, indicating that they were extracted to the same extent. 
BOILED COFFEE TYPES. Scandinavian-type boiled coffee of regular strength 
provided 4-5 mg of cafestol per cup of 150 mL (figure 5), slightly higher than 
levels in field samples; however, variability in the laboratory-prepared brews was 
much lower. Brewing strength highly determined diterpene content; each extra 10 
g of coffee grounds (equivalent to 1-2 household scoops) used per liter of water 
for brewing increased cafestol by 0.7 mg per cup. Duration of brewing was less 
important; increasing boiling t ime f rom 5 to 10 min increased cafestol and kahweol 
by 9 % and f rom 5 to 30 min by 3 3 % . 
Diterpenes (mg/100 g) 
- L | N 3 C O ^ U 1 O ) > I 0 0 
O O O O O O O O 
o o o o o o o o o 
raw 
light 
medium 
dark 
• • 
FIGURE 4. Effect of roasting on levels of cafestol (solid bar) and kahweol (slashed bar) in 
Mexican Arabica beans, expressed as milligrams per 100 g of roasted product. 
Corresponding weight losses were 24.5% for light, 26.0% for medium, and 26.5% for 
dark roasted beans. 
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FIGURE 5. Influence of brewing strength (concentration of coffee grounds per liter of fresh 
water used for brewing) on levels of cafestol (solid bar) and kahweol (slashed bar) in 
Scandinavian boiled, Turkish/Greek, French press, and espresso coffee prepared in the 
laboratory under standard conditions. Brews were prepared in triplicate. Values are given 
as milligrams of free alcohols per cup of 150 mL (for espresso: 25 mL). 
Cafestol levels in Turkish/Greek coffee made in the laboratory were 1 -2 mg per cup 
of 60 mL and were unaffected by brewing strength (figure 5). Israeli type "mud" coffee 
made in the laboratory contained 0.8 ± 0.0 mg of cafestol and 1.1 ± 0.1 mg of kahweol 
per cup of 60 mL. 
OTHER COFFEE TYPES. French press coffee of regular strength provided 3-4 mg of 
cafestol per cup of 150 mL (figure 5). Increasing brewing strength by 10 g/L increased 
cafestol by 0.6 mg per cup. Applying an incubation time of 1 instead of 5 min only 
decreased diterpenes by 4%. 
Espresso coffee made in the laboratory contained 1-2 mg of cafestol per cup of 25 
mL (figure 5). All of the extractable diterpenes were already extracted with the first 100 
mL of water that had been forced through the coffee grounds. Mocha coffee (100 g/L) 
contained 1.1 ± 0.1 mg of cafestol and 1.4 ± 0.2 mg of kahweol per cup of 60 mL. 
Percolated coffee and coffee prepared with a paper or permanent filter in an 
automatic drip filter machine maximally provided 0.5 mg of cafestol per cup of 150 mL. 
Pouring boiling water by hand resulted in 2.5 ± 1.2 mg of cafestol per cup for gold-plated 
(n = 21), 0.8 + 0.1 mg for nylon (n = 3), and 0.1 ± 0.0 mg for paper filters (n = 3). 
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A Serum cholesterol (predicted) 
1 0 2 0 3 0 mg/dL 
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instant 
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FIGURE 6. Predicted effect on serum cholesterol of daily consumption of 5 cups of various 
types of coffee. Black dots represent individual and bars mean values of field samples. 
Estimations of the rise in serum cholesterol are based on the observation of Weusten-van 
der Wouw et al [4] that every 10 mg of cafestol consumed per day raises serum 
cholesterol by 5 mg/dL (0.13 mmol/L). 
DISCUSSION 
The major f inding f rom this study is that Turkish/Greek and French press, 
also known as plunger or cafetière coffee, may have cafestol and kahweol levels 
similar to those of Scandinavian boiled coffee, the coffee type most frequently 
associated w i th elevated serum cholesterol levels. 
Boiled coffee types 
Field samples of Scandinavian and Turkish/Greek coffee varied strongly in 
diterpene content, probably attributable to differences in brewing strength and 
amount of coffee bean particles decanted w i th the brew. They both ranged f rom 
1 to more than 10 mg of cafestol per cup of 150 mL, wi th averages of 3.0 and 3.9 
mg, respectively. Five cups of either of these coffee types per day thus on average 
provide 15-20 mg of cafestol, which wil l raise serum cholesterol by about 8-10 
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mg/dL or 0.2-0.25 mmol/L [4] (figure 6). Finnish men and women chronically 
drinking 7-9 cups of boiled coffee per day indeed had cholesterol levels 23 mg/dL 
higher than their peers consuming filter coffee [13], and Norwegians consuming 
5 or more cups had levels 12 mg/dL higher [4]. Thus, our figures allow a valid 
prediction of the effect of coffee consumption on serum cholesterol. 
Cafestol levels of Turkish/Greek coffee prepared in our laboratory were lower 
than field samples. This may be due to a more careful décantation of laboratory-
made brews. In Turkish/Greek coffee brew as consumed, 75-90% of the 
diterpenes were carried by floating coffee fines (data not shown). Since cafestol 
and kahweol from such coffee grounds raise serum cholesterol [14], the amount 
of coffee fines in Middle Eastern coffee brews will largely determine their 
hyperlipidaemic effect. Cross-sectional studies in Israel, where coffee is mostly 
brewed by boiling or incubating powdery grounds, have indeed shown higher cho-
lesterol levels in coffee consumers [12, 15, 16], but to our knowledge this has not 
yet been confirmed experimentally. 
Other coffee types 
French press coffee, also known as plunger or cafetière coffee, is becoming 
popular in North America, northern Europe, and Australia [5]. It provided 3-5 mg 
of cafestol per cup, which is similar to levels in Scandinavian boiled coffee and 
Turkish/Greek coffee. Therefore, French press coffee will raise cholesterol if drunk 
in large quantities (figure 6), and people at elevated risk of coronary heart disease 
should be advised not to drink more than a few cups of French press coffee per 
day. 
In our study, cafestol concentrations per 100 mL were highest in espresso 
coffee, but since espresso is consumed in small servings [17], cafestol content per 
cup was only 1-2 mg. It thus remained well below those of Scandinavian, 
Turkish/Greek, and French press coffee. In Italy, most of the coffee consumed is 
mocha coffee (figure 1) [5], which contained about 1 mg of cafestol per cup. 
Cross-sectional data from Italy indicated higher serum lipid levels in coffee drinkers 
[18, 19, 20], but experimental studies have not confirmed a cholesterol-elevating 
effect of mocha or espresso [21,22]. 
Espresso samples from other countries contained less cafestol despite larger 
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serving sizes (table 1 ). This might be attributable to differences in brewing strength 
[5], which in the present study was a major determinant of cafestol content. 
Diterpene levels also varied slightly with espresso device and with roasting grade 
of the beans used (data not shown). Other factors that might influence lipid levels 
are steam pressure, contact time of steam with grounds, and mesh width of the 
filter grid. However, at an average cafestol content of 1 mg per cup of espresso 
or mocha coffee, consumption of 5 cups per day will raise cholesterol by only 2.5 
mg/dL (0.06 mmol/L). Thus moderate intakes of espresso will have negligible 
effects on serum cholesterol and coronary heart disease risk. 
Pouring boiling water by hand on grounds in a gold-plated permanent filter 
resulted in 2.5 mg of cafestol per cup; possibly, the grounds are swirled up so that 
smaller coffee particles pass through the filter. When we applied permanent gold 
or nylon filters in an electric drip filter coffee maker, resulting diterpene levels were 
negligible, as were those for all paper-filtered brews. 
The low levels in percolated coffee were surprising. Possibly the bed of 
coffee grounds (figure 1 ) acts as a filter that retains cafestol and kahweol. Prior to 
the advent of drip filters in the 1960s, percolators were the major type of coffee 
makers used in the United States. Our data suggest that percolated coffee does 
not raise serum cholesterol and that changes in coffee brewing practices thus have 
had little effect on coronary heart disease risk in the United States. 
Instant (soluble) coffees and coffee grounds 
Predicted effects of consumption of instant coffee on serum lipids through 
its cafestol content are minimal (figure 6), which is in line with results of clinical 
trials [23,24]. 
Cafestol levels in commercial ground coffees varied little and were 
unaffected by decaffeination. Our measurements thus provide no support for a 
presumed relation of decaffeinated coffee with raised serum cholesterol [25] or 
with a higher risk of cardiovascular disease [26]. 
Coffee grounds with low levels of cafestol were blends containing Robusta 
beans, as was indicated by concurrent higher levels of 16-O-methylcafestol [7] and 
lower levels of kahweol [6]. Higher proportions of Robusta beans in commercial 
coffee blends would cause lower intake levels of coffee diterpenes. Consumers in 
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most European countries and in the United States of America prefer Arabica beans, 
and the contribution of Robusta beans to blends is usually minimised in those 
countries [27]. 
Roasting has been reported to eliminate cafestol and kahweol [28], but in 
dark-roasted Arabica beans -- which had lost 26.5% of their initial mass - we 
found no decrease in diterpene concentration (figure 5). Although our roasting 
procedure might have been slightly different from industrial procedures -
commercial roasts range from 13% to 22% roasting loss [6] -- there appears to be 
only little effect of roasting on diterpenes in commercial grounds. 
Conclusions 
Our results predict that chronic consumption of 5 or more cups of French 
press coffee or Turkish/Greek coffee per day could increase serum cholesterol and 
thus coronary risk similar to that reported previously for Scandinavian boiled 
coffee. For espresso and mocha coffee, consumption of 15 or more cups per day 
is required for the same effect. Effects of instant, filtered, and percolated brews 
are negligible. 
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ABSTRACT 
The coffee diterpene cafestol occurs in both robusta and arabica beans. It is present 
in unfiltered coffee brews, and raises serum concentrations of cholesterol and 
triacylglycerols, and of alanine aminotransferase in humans. The effects are linear with the 
cafestol dose. Un filtered coffee also contains the related compound kahweol, which occurs 
only in the major coffee strain arabica. The activity of kahweol is unknown. In a 
randomised, double-blind cross-over study, we gave ten healthy male volunteers either 
pure cafestol (61 - 64 mg/day) or a mixture of cafestol (60 mg/day) and kahweol (48-54 
mg/dayl for 28 days. Relative to baseline values, cafestol raised mean (± SEM) total 
serum cholesterol by 0.79 ± 0.14 mmol/L (31 ± 5 mg/dU, low-density lipoprotein (LDL) 
cholesterol by 0.57 ± 0.13 mmol/L (22 ± 5 mg/dL), fasting triacylglycerols by 0.65 ± 
0.12 mmol/L (58 ± 11 mg/dL), and alanine aminotransferase by 18 ± 2U/L (all P< 0.01). 
Relative to cafestol a/one, the mixture of cafestol plus kahweol increased total cholesterol 
by another 0.23 ± 0.16 mmol/L (9 ± 6 mg/dL) (P=0.08), LDL cholesterol by 0.23 ± 
0.16 mmol/L (9 ± 6 mg/dL) (P=0.09), triacylglycerols by 0.09 ± 0.10 mmol/L (8 ± 9 
mg/dL) (P=0.20), and alanine aminotransferase by 35 ± 11 U/L (P= 0.004). Thus, the 
effect of cafestol on serum lipid concentrations was much larger than the additional effect 
of kahweol, and the hyperlipidaemic potential of unfiltered coffee mainly depends on its 
cafestol content. Both cafestol and kahweol raised alanine aminotransferase 
concentrations, and their hyperlipidaemic effect thus seems not to be coupled with their 
effect on liver cells (AMERICAN JOURNAL OF CLINICAL NUTRITION 1997; 65: 519-524). 
INTRODUCTION 
Unfi l tered, boiled coffee raises serum concentrations of low-density 
l ipoprotein (LDL) and very-low-density lipoprotein (VLDL) cholesterol in humans 
[1-7] . Coffee brews prepared wi thout a filter contain 1 to 2 g of lipids per liter, of 
which about 10 percent are diterpenes [8] . In a series of controlled experiments 
[9 ,10 ] , we showed that these diterpenes are responsible for the cholesterol-raising 
effects of unfi ltered coffee. The relation appeared to be linear up to doses of 200 
mg of diterpenes per day [10 ] , the amount present in 20 to 30 cups of 
Scandinavian boiled or French press (also called cafetière) coffee [11] . 
The mode of action of coffee diterpenes is largely unknown. They raised 
serum concentrat ions of alanine aminotransferase (ALT, formerly called SGPT), and 
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reduced those of K-glutamyltransferase in humans [10,12]. These alterations may 
point to changes in the integrity of the liver cell [13]. In addition, coffee diterpenes 
reduced circulating lipoprotein(a) levels (see chapter 7), which may also be related 
to changes in liver cell metabolism [14]. We therefore suggested that coffee 
diterpenes influence lipoprotein metabolism via effects on the liver. 
The major coffee diterpenes are cafestoland Ara/?weo/(throughoutthis paper, 
cafestol and kahweol refer to the fatty acid esters of these compounds, but 
amounts are expressed in terms of the unesterified alcohols). Robusta beans 
contain mainly cafestol, whereas arabica beans also contain high amounts of 
kahweol. Daily ingestion of oils pressed from robusta beans increased serum lipid 
concentrations [15,16], indicating that cafestol has hyperlipidaemic potential. 
However, in the United States of America and in western Europe, arabica beans 
are preferred over robusta beans [17]. As a result, levels of kahweol in unfiltered 
coffee brews are higher than those of cafestol [11]. However, previous studies did 
not allow conclusions on the activity of kahweol [15,16]. 
We studied the effects of kahweol on serum concentrations of lipoproteins 
and liver enzymes by comparing the effects of pure cafestol with a mixture of 
cafestol and kahweol in a cross-over trial with healthy volunteers. 
MATERIALS, SUBJECTS AND METHODS 
Preparation of diterpenes 
Because it proved impossible to prepare pure kahweol in sufficient quantities 
(Kosmeijer - Schuil et al, unpublished observations, 1 996), we decided to compare 
the effects of a mixture of cafestol and kahweol with those of cafestol alone. 
The purified diterpenes were prepared from coffee oil by Nestec Ltd (Vevey, 
Switzerland) for the first treatment period and by our own laboratory for the 
second treatment period. Diterpenes naturally occur as fatty acids esters, mostly 
of palmitic acid [18]-. Esters were saponified with anhydrous potassium hydroxide, 
and the diterpene alcohols extracted with methanol-water and dichloromethane-
methanol solutions. Active carbon was used to bind non-diterpene compounds. 
Finally, warm methanol was added, and the solution cooled to allow the mixture 
61 
CHAPTER 4 
of diterpenes to crystall ize. Pure cafestol was obtained by adding gaseous 
hydrogen to a mixture of cafestol and kahweol w i th Pd - Pb - CaCo3 as a catalyst. 
The diterpene alcohols were re -es te r i f ied w i th palmitoylchloride in a pyridine 
solut ion. The solvent was purified over a chromatographic column charged w i th 
aluminium oxide. 
The purif ied diterpenes were dissolved in sunflower plus palm oi l , w / w 3/2. 
Red palm oil was used so as to mask the yel lowish colour of kahweol . ß - carotene 
in the supplements provided less than t w o percent of the recommended daily 
intake of vi tamin A for Dutch adult men [19] . Diterpene contents of the final 
capsules were assayed as described [10] . Purities of the diterpenes ranged f rom 
92 .2 to 99 .7 percent; impurities consisted of cafestol and kahweol dipalmitates 
and free palmitic acid. The pyridine content was less than the detection limit of 
0.25 mg/g. 
Design and subjects 
The study lasted f rom September 1994 to April 1995 (figure 1). Prio 
approval was obtained f rom the human ethics committee of our department, and 
f rom the Nijmegen University Hospital Ethical Committee. 
RUN-IN TREATMENT WASH-OUT RUN-IN TREATMENT FOLLOW-UP 
1-14 
placebo 
15-42 
Cafestol 
Mixture 
43-91 
no treatment 
92-105 
placebo 
106-133 
Mixture 
Cafestol 
134-183 
no treatment 
t Î t t 1 1 1 t 
FIGURE 1. Experimental design. 'Cafestol' refers to the palmitate esters of cafestol alone, 
and 'Mixture' refers to the palmitate esters of cafestol and kahweol. Blood samples ( t ) 
were obtained on days 15 (run- in) , 36, 39, 43 (treatment), 57 (wash-out ) , 106 
(run - in), days 127,130, 134 (treatment), and days 148 and 183 (follow - up). Additional 
serum samples (*) were obtained to monitor adverse effects during the treatment periods. 
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We estimated that ingestion of 60 mg of cafestol plus a similar amount of 
kahweol per day would raise serum cholesterol by 1.1 mmol/L [10]. If cafestol and 
kahweol were similarly active, each would account for a rise of 0.55 mmol/L. 
Calculations showed that we needed ten subjects to detect a difference of 0.55 
mmol/L with a statistical power of 90%, using a cross-over design (a = 0.05). 
We recruited ten volunteers by displaying posters in university buildings and 
through personal contact. All were male, and most were students at Wageningen 
Agricultural University. We carefully explained to them the study protocol and the 
expected changes in serum lipids and liver enzymes. Subjects then provided their 
written informed consent. The subjects filled out a medical questionnaire which 
was reviewed by an independent internist at the Department of Gastroenterology, 
Nijmegen University Hospital. None of the subjects reported a history of 
gastrointestinal, liver or kidney disease; none had glucosuria or proteinuria; all were 
considered to be in good health upon examination by the internist; and none were 
taking medication known to affect serum lipids or liver enzymes. All test results 
were within normal limits, and none of the subjects had serum antibodies to 
hepatitis B core antigen or to hepatitis C virus. The mean age ( ± SD) was 24 ± 
4 y, and the mean body mass index was 21 ± 2 kg/m2. Two of the subjects 
smoked. 
An independent investigator grouped the subjects into pairs on the basis of 
similar cholesterol concentrations. Within each pair, subjects were randomly 
allocated to one of two treatment sequences by tossing a coin. During the run - in 
periods, subjects swallowed 5 placebo capsules providing a total of 2 g of a 3:2 
(w:w) mixture of sunflower and palm oil per day. During the first treatment period, 
five subjects swallowed 5 capsules per day providing 64 mg of cafestol and 1 mg 
of kahweol (amounts expressed as free alcohols) dissolved in 2 g of the placebo 
oil mixture. The other five subjects swallowed capsules with 60 mg of cafestol and 
54 mg of kahweol, again dissolved in oil. Supplements were switched in the 
second treatment period; analysed doses of cafestol and kahweol were now 61 
and 0 mg for pure cafestol, and 60 and 48 mg for the mixture, respectively. Every 
two weeks, the subjects were provided with new capsules which they stored in 
a refrigerator. They took two capsules at breakfast and three capsules with their 
evening meals, and reported the time of consumption in a special diary. No 
supplements were given during the wash-ou t and the fo l low-up periods. 
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Subjects as well as investigators were blinded to the supplement sequences. The 
code was broken after completion of both the blood assays and the statistical 
analyses. 
Subjects were asked to maintain their usual dietary and living habits during 
the run - in and treatment periods, to abstain from types of coffee other than 
paper - filtered or instant (soluble) coffee, and to restrict alcohol use to a maximum 
of twenty alcohol - containing beverages per week. Subjects kept daily records of 
coffee and alcohol consumption, medication use, and any deviations from their 
dietary and living habits. Body weights were measured at every blood sampling in 
subjects without shoes and heavy clothes. 
Venous blood samples were obtained after an overnight fast on days 15 
(run- in) , 36, 39, 43 (treatment), 57 (wash-out) , 106 (second run- in ) , 127, 
130, 134 (second treatment), and 148 and 183 (fol low-up) (figure 1). Additional 
serum samples were obtained on the 15th day of either treatment period, and were 
analysed instantly for total cholesterol and alanine aminotransferase so as to 
monitor adverse effects. These values were seen by the internist and not by the 
investigators. Predefined safety limits were a concentration of alanine 
aminotransferase higher than the upper limit of normal (53.5 U/L), or a rise in total 
cholesterol of more than 2.0 mmol/L over baseline. As a result, three subjects (two 
in the first and one in the second treatment period) were switched to placebo oil 
capsules, because of raised alanine aminotransferase. All three subjects later 
turned out to have been taking supplements with cafestol plus kahweol. Statistical 
analyses were done both with and without their values, as described under 
'statistics'. 
Blood sampling and assays 
Serum was obtained by centrifugation, and stored at - 8 0 ° C . Sera were 
analysed enzymatically for total [20] and HDL cholesterol [21 ], and triacylglycerols 
[22]. Mean bias for control serum provided by the Centers for Disease Control and 
Prevention (Atlanta, USA) was - 1 percent for total and high-density lipoprotein 
(HDL) cholesterol, and 10 percent for triacylglycerols. The coefficient of variation 
within runs ranged from 0.9 to 1.7 percent. LDL was calculated by using the 
Friedewald method [23]. Creatinine was measured with a modified Jaffé method 
64 
SEPARATE EFFECTS OF COFFEE DITERPENES 
using a Spectrum kit [Abbott Laboratories, North Chicago, IL, USA) [24]. 
Concentrations of alanine aminotransferase and aspartate aminotransferase [25], 
y- glutamyltransferase [26] and alkaline phosphatase [27] were measured at 37°C 
using Abbott Spectrum reagents. The mean bias for these enzymes in Monitrol 
control serum (Baxter Dade, Diidingen, Switzerland) ranged from - 1 to 3 percent. 
The coefficient of variation within runs ranged from 2 to 8 percent. Upper limits 
of normal according to the manufacturer were 53.5 U/L for alanine 
aminotransferase, 39.7 U/L for aspartate aminotransferase, 92 U/L for alkaline 
phosphatase, and 63 U/L for y- glutamyltransferase. All samples from one subject 
were analysed in the same run, except for serum samples obtained at the end the 
second fo l low-up period (day 183) which were analysed in a separate run. 
Statistics 
For each subject, treatment values were means of the three values obtained 
at the end of the treatment periods. The effects of either treatment were analysed 
by subtracting the values obtained after the preceding run - i n period from the 
treatment values, and the effects of the mixture relative to cafestol alone were 
analysed by subtracting the values after cafestol from those after the mixture. 
Three subjects were switched to placebo halfway through the treatment 
(see: Design and subjects). Their final values were estimated as follows. We 
calculated the mean daily change from treatment day 15 until the end of the 
treatment period for the seven subjects who completed the treatment period. The 
mean daily change amounted 0.029 mmol/L for total cholesterol, 0.031 mmol/L for 
LDL, - 0 . 0 0 3 mmol/L for HDL, 0.003 mmol/L for triacylglycerols, 1.7 U/L for 
alanine aminotransferase, 0.4 U/L for aspartate aminotransferase, - 0 . 2 U/L for 
alkaline phosphatase, and - 0 . 1 U/L for y- glutamyltransferase. This change was 
multiplied by the number of days of treatment that the other three subjects had 
missed, and this value was added to their value obtained at the time when 
treatment was stopped. We also did analyses by using their actual values at the 
time they were taken off treatment as end values, as well as analyses without 
these three subjects. All variables were normally distributed, and none showed 
significant carry - over or period effects. Differences were therefore tested against 
zero with one-sided paired t tests [28]. 
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RESULTS 
According to the diaries kept by the subjects, more than 99 percent of the 
capsules were taken. During the treatment periods none of the subjects took any 
medication known to affect liver function, and the mean use of alcohol - containing 
beverages was less then 1 consumption per day. The mean change ( ± SD) in body 
weight was 0.3 ± 0.8 kg (range - 0 . 4 to 2.3 kg) over the first, and - 0 . 7 ± 0.9 
kg (range - 1.8 to 1.3 kg) over the second treatment period. 
Serum lipids 
Relative to baseline values, consumption of cafestol alone raised the mean 
(± SEM) concentration of total cholesterol by 0.79 ± 0 . 1 4 mmol/L (P<0.001), 
LDL-cholesterol by 0.57 ± 0.13 (P = 0.002), and fasting triacylglycerols by 0.65 
± 0 . 1 2 mmol/L (P<0.001); it reduced HDL cholesterol by 0.06 ± 0.04 mmol/L 
(P = 0.06). Relative to cafestol alone, consumption of the mixture of cafestol and 
kahweol raised total cholesterol by 0.23 ± 0.16 mmol/L (P = 0.08) and LDL 
cholesterol by 0.23 ± 0.16 mmol/L (P = 0.09), and triacylglycerols by 0.09 ± 0 . 1 0 
mmol/L (P = 0.20) (table 1, figure 2). 
Three subjects were switched to receive placebo halfway through treatment 
with the mixture of cafestol and kahweol. When we took their serum values at the 
time of switching as end values, the effects of the mixture relative to cafestol 
alone were 0.17 ± 0.15 mmol/L for total cholesterol (P = 0.15), 0.15 ± 0.15 
mmol/L for LDL cholesterol (P = 0.16), and 0.08 ± 0.10 mmol/L for triacylglycerols 
(P = 0.23) (n = 10). 
When we excluded from the analyses the three subjects who were taken off 
treatment, cafestol raised total cholesterol by 0.83 ± 0 . 1 9 mmol/L (P = 0.003), 
LDL - cholesterol by 0.74 ± 0.13 mmol/L (P< 0.001 ), and triacylglycerols by 0.64 
± 0 . 1 0 mmol/L (P<0.001), relative to baseline. Relative to cafestol alone, the 
mixture raised total cholesterol by 0.08 ± 0.16 mmol/L (P = 0.31), LDL cholesterol 
by 0.06 ± 0 . 1 6 mmol/L (P = 0.36), and triacylglycerols by 0.05 ± 0 . 1 2 mmol/L 
(P = 0.34) (n = 7). 
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Other serum variables 
Cafestol alone raised alanine aminotransferase by 18 ± 2 U/L over baseline 
values [P< 0.001). Intake of the mixture further raised alanine aminotransferase by 
35 ± 11 U/L for the full group of 10 subjects (P = 0.004) (table 1, figure 2). With 
serum values at the time of switching as end values for the three subjects who 
were taken off treatment, the effect of the mixture relative to cafestol was 31 ± 
9 U/L (P = 0.004). When the three subjects who were switched to placebo were 
excluded, alanine aminotransferase rose by 18 ± 2 U/L with cafestol alone 
(P<0.001), and by another 20 + 7 U/L (/> = 0.02) with the mixture (n = 7). 
Aspartate aminotransferase increased less than alanine aminotransferase, 
whereas K_glutamyltransferase decreased after both cafestol and the mixture. 
Two weeks after cafestol treatment ended, K-g'utamyltransferase had risen by 7 
± 2 U/L over baseline values, and two weeks after treatment with the mixture 
ended, p-glutamyltransferase had risen by 4 ± 2 U/L over baseline values (both 
P< 0.05). Alkaline phosphatase and creatinine in serum tended to be lowered both 
by cafestol alone and by the mixture of cafestol and kahweol (table 1). 
Seven weeks after withdrawal of the supplements, all serum variables had 
returned to baseline values (data not shown). 
DISCUSSION 
Intake of cafestol raised the serum concentrations of total and LDL 
cholesterol, and those of fasting triacylglycerols in healthy male volunteers. The 
supplement providing a mixture of cafestol and kahweol had little additional effect 
on serum lipids. This finding suggests that kahweol has less capacity than cafestol 
to interfere with lipid metabolism in humans. Cafestol and kahweol both raised 
aminotransferase concentrations in serum, which suggests that they both affect 
liver cells. 
Three subjects were switched to placebo halfway through the cafestol and 
kahweol treatment, because their serum concentration of alanine aminotransferase 
had exceeded the upper limit of normal. Their final values were recalculated by 
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FIGURE 2. Individual baseline values and changes in serum concentrations of cholesterol, 
triacylglycerols, and alanine aminotransferase after ingestion of either 6 1 - 6 4 mg/day of 
cafestol alone (cafestol treatment), or of a mixture of 60 mg/day of cafestol plus 48 - 54 
mg/day of kahweol (mixture treatment) for 28 days each in a cross - over study with ten 
healthy male volunteers. Subjects indicated by ' • ' first received cafestol and then the 
mixture, those indicated by 'o' received the opposite sequence. The three subjects who 
were switched to placebo halfway through the mixture treatment are indicated by broken 
lines. 
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imputation from the remaining seven subjects. However, statistical analyses based 
only on the seven subjects who completed the full treatment, as well as analyses 
in which the values obtained at the time of switching to placebo were taken as end 
values for the three subjects who were taken off treatment, led to the same 
conclusions: cafestol was the main lipid-raising factor from coffee beans, and 
both cafestol and kahweol raised alanine aminotransferase. 
The amount of coffee diterpenes we supplied per day was equivalent to that 
in 1 0 - 2 0 cups of boiled, Turkish, or French press coffee [11]. We chose a high 
dose so as to reach the necessary power with the limited amount of purified 
diterpenes available. Lower doses of diterpenes applied to a larger population 
would have decreased the power of our study, because previous studies showed 
that the responses would be smaller, but the standard deviations of the responses 
would not [10]. As women tend to respond less to coffee diterpenes than men 
(unpublished observations), we included only male volunteers in the study so as 
to further minimize possible variation in responses. 
Although we could separate cafestol and kahweol on an analytical scale 
[11], semi-preparative HPLC gave very low yields for purified diterpenes, 
especially of kahweol. We therefore decided to compare supplements of cafestol 
alone with a mixture of cafestol and kahweol. 
Effects of cafestol and kahweol on serum lipids 
Consumption of pure cafestol increased serum total cholesterol by 17 
percent, LDL-cholesterol by 19 percent, and fasting triacylglycerols by 86 
percent, whereas consumption of a mixture of cafestol and kahweol further 
increased total cholesterol by only two percent, LDL-cholesterol by four percent, 
and triacylglycerols by seven percent. The effect of coffee diterpenes on lipid 
cholesterol follows a dose-response relation, which appears to be linear up to a 
dosage of 200 mg of cafestol plus kahweol per day [10]. Thus, if cafestol and 
kahweol were similarly active, the effect of the mixture on cholesterol 
concentrations should have been about twice that of the pure cafestol. Kahweol 
thus appears to be less hyperlipidaemic than cafestol. 
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Bä Cafestol 
D Kahweol 
16-O-MC 
Mens ink (16) 
Van Rooij (15) 
This study 
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Diterpenes 
(mg/day) 
0 5 10 15 20 25 
Cholesterol response 
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FIGURE 3. Comparison of present results with studies that examined effects of coffee oils 
containing mixtures of cafestol, kahweol, and 16 - O - methylcaf estol ( 1 6 - O - M C ) (left 
panel) on cholesterol responses (right panel). Mensink et al [16] gave 5 volunteers placebo 
versus robusta oil (upper bar), and 6 placebo versus arabica oil (lower bar) for 2 x 3 weeks 
in a cross-over design. Van Rooij et al [15] gave placebo, robusta (upper bar) or arabica 
oil (lower bar) to three groups of 12 subjects for 6 weeks in a parallel design. We gave 10 
volunteers pure cafestol (upper bar) or a mixture of cafestol plus kahweol (lower bar) for 
2x4 weeks in a cross-over design. 
The separate effects of coffee diterpenes were examined earlier indirectly in 
studies comparing the effects of robusta oi l , which contains mainly cafestol , and 
arabica oi l , wh ich contains cafestol and kahweol (figure 3). Van Rooij et al [15] 
found that robusta oil increased serum cholesterol by 11 percent, which is 
consistent w i th our f inding that cafestol is hypercholesterolaemic. The supplement 
of arabica oil in their study contained five t imes as much cafestol plus kahweol as 
the supplement of robusta oil, largely because of higher amounts of kahweol . 
However, the effect of arabica oil on serum cholesterol was only tw ice that of 
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robusta oil. Mensink et al [16] found increases of 13 percent with both arabica and 
robusta oil, even though the intake of cafestol plus kahweol was three times higher 
with arabica oil than with robusta oil. These results are consistent with our finding 
that kahweol has only little additional effect on the serum concentration of 
cholesterol. 
The mechanisms by which coffee diterpenes affect cholesterol synthesis or 
breakdown in the human body are largely unknown. Kahweol only differs from 
cafestol in that it has a double bond between the C, - C2 carbon atoms. Possibly, 
this double bond allows faster biotransformation into compounds that are rapidly 
excreted, or that have less hyperlipidaemic capacity. 
It is not known whether 16 - O - methylcafestol present in robusta but 
not in arabica beans [29] also affects serum lipoproteins. However, this 
diterpene accounts for only 3 percent of the diterpenes present in commercial roast 
and ground coffees [11], and intakes are therefore low. 
Effects of cafestol and kahweol on serum liver enzymes 
Intake of cafestol alone raised the mean concentrations of liver 
aminotransferases; the addition of kahweol strongly increased the responses. This 
indicates that the C 1 - C 2 double bond of kahweol does not reduce its 
hepatocellular effect. 
Alanine aminotransferase rose more than did aspartate aminotransferase, 
which is consistent with results from previous studies [10,12,15]. In the liver, 
alanine aminotransferase occurs mainly in the cytoplasm, whereas aspartate 
aminotransferase is predominantly localised in mitochondria [13]. Possibly, coffee 
diterpenes disturb the permeability of cell membranes in the liver parenchyma, but 
do not cause the extensive damage needed to release enzymes from mitochondria. 
Concentrations of p-glutamyltransferase were reduced upon intake of 
coffee diterpenes, and showed a rebound increase of about 30 percent after 
withdrawal of both supplements. A similar pattern was observed in previous 
studies [10]. The serum concentration of p-glutamyltransferase is largely 
determined by the liver, where p-glutamyltransf erase occurs predominantly in 
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epithelial cells of the biliary duct [13]. The discrepant effects of cafestol and 
kahweol on p-glutamyltransferase and alanine aminotransferase suggest that coffee 
diterpenes (or their metabolites) may have various sites of action in the liver. 
Conclusion 
Unfiltered coffee brews elevate serum lipoprotein concentrations mainly 
through their cafestol content, whereas kahweol has little additional effect. Both 
diterpenes elevate serum liver aminotransferases, indicating that lipid metabolism 
and liver cell metabolism may be affected by coffee diterpenes through different 
pathways. Elucidation of the underlying mechanisms may produce new insights 
into lipoprotein metabolism. 
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ABSTRACT 
Objective. To study the effects of prolonged intake of cafetière coffee, which is rich in the 
cholesterol-raising diterpenes cafestol and kahweol, on serum aminotransferase and lipid 
concentrations. 
Design. Randomised, parallel controlled trial. 
Subjects. 46 healthy men and women, ages 19 to 69. 
Intervention. Consumption of five to six strong cups (0.9 L) per day of either cafetière 
(n = 22) or paper-filtered coffee (n = 24) for 24 weeks. 
Main outcome measures. Mean changes in serum aminotransferase and lipid 
concentrations. 
Results. Cafetière coffee raised alanine aminotransferase by up to 80 percent over 
baseline, relative to filtered coffee. After 24 weeks, the rise was still 45 percent (9 U/L, 
95 percent Confidence Interval 3 to 15 U/L, P=0.007). Alanine aminotransferase 
exceeded the upper limit of normal in eight, and twice the upper limit in three out of the 
22 cafetière coffee consumers. Cafetière coffee raised low-density lipoprotein cholesterol 
(LDL) concentrations by 9 to 14 percent. After 24 weeks, the rise was 0.26 mmol/L (95 
percent Confidence Interval 0.04 to 0.47 mmol/L, P=0.03), relative to filtered coffee. 
Triglycerides initially rose by 26 percent on cafetière coffee, but returned close to baseline 
within half a year. All rises were reversible after treatment was stopped. 
Conclusions. Daily consumption of five to six cups of strong cafetière coffee affects the 
integrity of liver cells, as suggested by small increases in serum alanine aminotransferase. 
The effect does not subside upon prolonged intake. High intakes of coffee brews rich in 
cafestol and kahweol may thus be responsible for unexplained elevations of this enzyme 
in apparently healthy individuals. Cafetière coffee also raises low-density lipoprotein 
cholesterol, and thus coronary heart disease risk (BRITISH MEDICAL JOURNAL 1996; 313: 
1362-66). 
INTRODUCTION 
Scandinavian boiled coffee raises serum cholesterol concentrat ions in man 
[1-4] . The diterpenes cafestol and kahweol are responsible for this effect [5 ,6 ] . 
They do not pass through paper f i l ters, which explains why fi ltered coffee does not 
raise blood cholesterol concentrations [7 ,8 ] . However, cafestol and kahweol do 
occur in other unfi ltered coffee brews, such as cafetière coffee and Turkish coffee 
[9 ] . 
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Cafestol and kahweol seem to affect liver cells; short-term intake of boiled 
coffee [5] or preparations rich in cafestol and kahweol [5 ,10-12] raises the serum 
concentrat ion of alanine aminotransferase (ALT, formerly SGPT). However, life-long 
consumers of boiled coffee in Norway did not have higher alanine aminotransferase 
concentrat ions than matched filtered coffee drinkers [5] . One explanation for this 
could be that alanine aminotransferase concentrations return to normal w i th 
prolonged intake of cafestol and kahweol. 
We examined this hypothesis and the effects on serum lipid concentrat ions 
in a randomised trial of cafetière versus filtered coffee. 
SUBJECTS AND METHODS 
Design and subjects 
The trial lasted f rom October 1994 to July 1995. It consisted of a four week 
run in period, 24 weeks of treatment (intervention), and 12 weeks of fo l low-up. 
The study was approved by the local human ethics commit tee. 
Volunteers were recruited through advertisements in newspapers and 
university buildings. We carefully explained the study protocol to them before they 
gave wr i t ten informed consent. Subjects were eligible if they had a Body Mass 
Index < 30 kg/m 2 ; did not use any medication known to affect serum liver enzymes 
or lipids; were not pregnant, lactating, or on a prescribed diet; and drank more than 
four cups of coffee and less than three drinks containing alcohol per day. 
Candidates filled out a medical questionnaire, which was reviewed by an 
independent internist. Candidates w i th a history of gastro-intestinal, liver, or kidney 
diseases were excluded, as were those w i th glucosuria; proteinuria; anaemia; a 
serum concentrat ion of total cholesterol > 6 . 5 mmol/L; of fasting triglycerides 
> 2 . 3 mmol/L; or concentrations of alanine or aspartate aminotransferase, or 
K-glutamyl t ransferase above the upper limits of normal. 
Sixty-four subjects entered a run-in period which served to select those who 
were able to comply w i th our requirements. All subjects consumed 0.9 litre of 
fi ltered coffee per day. Eleven subjects reported that they could not comply, mainly 
because they thought the coffee was too strong. We stratif ied the remaining 53 
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subjects for sex and alanine aminotransferase concentration (above/below median), 
and allocated them to either filtered or cafetière coffee by tossing a coin. 
In the treatment period, subjects consumed 0.9 litre per day of either filtered 
or cafetière coffee. They were asked to maintain their usual diet and lifestyle. 
Intakes of dietary fatty acids and cholesterol were estimated once in the run-in 
period and three times in the treatment period [13]. All subjects kept daily records 
of illness and deviations from the protocol. Body weights were measured monthly. 
TABLE 1. Characteristics of the participants at the end of the run-in period a. 
Variable 
Sex (male/female) 
Age (years) [range] 
Body Mass Index (kg/m2)b 
Smoking (yes/no) 
Women using contraceptives (yes/no) 
Alcohol use (drinks/day)c 
Coffee consumption (cups/day)c 
Cream in coffee (yes/no) 
Filtered 
coffee (n = 24) 
12/12 
29 ± 9 [19-52] 
22 ± 3 
10/14 
6/6 
1.0 ± 0.6 
5 ± 2 
10/14 
Cafetière coffee 
30 
(n = 22) 
11/11 
± 11 [20-69] 
23 ± 3 
6/16 
5/6 
0.7 ± 1.0 
5 ± 1 
8/14 
a
 Values are numbers, or means ± SD 
b
 Body weights were measured without shoes or heavy clothing. 
c
 Self-reported consumption prior to the study 
Six subjects withdrew during the treatment period; two had problems 
complying, two became ill, one moved, and one had personal reasons. Another 
subject was withdrawn after 20 weeks as his aminotransferase concentrations 
exceeded our predefined limits. He had started daily use of medications of potential 
hepatotoxicity during the treatment period, and his data were excluded. Inclusion 
of his values did not materially alter the results (for instance, a rise of alanine 
aminotransferase after 8 weeks of treatment of 19 instead of 16 U/L). Forty-six 
subjects completed the study (table 1). 
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Preparation of coffee 
Subjects brewed their coffee at home according to instructions that we gave 
them before the study. All ground coffee was "Roodmerk" (Douwe Egberts, 
Utrecht, The Netherlands), a blend of Arabica and Robusta beans widely used in 
the Netherlands [8] . 
FILTERED COFFEE. Subjects scooped 78 millilitres (33 grams) of f ine grounds 
into a paper filter (Melit ta, Gorinchem, The Netherlands) in a conical holder, wh ich 
was placed on a 0.5 litre thermos jar. They poured boiling water onto the grounds 
until the jar was ful l . 
CAFETIÈRE COFFEE. Subjects scooped 92 millilitres (39 grams) of coarse 
grounds into a cafetière (Kaffee Primo, BMF, Germany, 1 litre), and poured 0.6 litre 
of boiling water onto the grounds. More coffee was used so as to provide the same 
amount of caffeine as filtered coffee [14] . Subjects stirred the brew for 10 
seconds, al lowed it to stand for 2 to 5 minutes, pushed down the screen strainer 
(plunger) to separate the grounds f rom the brew, and decanted the brew into a jar. 
One jar provided 2 to 3 cups of coffee, and t w o jars were prepared and 
consumed each day. Subjects were allowed to dilute the brew wi th water, if they 
considered it too strong. Cafetière coffee provided 38 (SD 6) milligrams of cafestol 
and 33 (SD 5) milligrams of kahweol per day (mean of 22 samples). Filtered coffee 
provided lesc than 1 milligram of either diterpene per day (mean of 6 samples). 
Blood sampling and assays 
Venous blood samples were taken after an overnight fast after 3 and 4 
weeks in the run-in period, after 2, 4 , 6, 8, 12, 16, 20 , 23 and 24 weeks of 
t reatment, and after 4 , 8 and 12 weeks in the fol low-up period. Sera were obtained 
by centr i fugat ion, and stored at - 8 0 ° C . Alanine and aspartate aminotransferase 
[15 ] , alkaline phosphatase [16 ] , and p-glutamyl t ransferase [17] were measured 
at 3 7 ° C using Abbot t Spectrum reagents. The mean bias for 'Moni t ro l ' control sera 
(Baxter Dade, Switzerland) ranged f rom 0 to 2 percent. The coeff icient of variation 
wi th in runs ranged f rom 2 to 8 percent. Upper limits of normal were 54 U/L for 
alanine aminotransferase, 40 U/L for aspartate aminotransferase, 92 U/L for 
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alkaline phosphatase, and 63 U/L and 35 U/L for K-g'utamyltransferase in men and 
women, respectively. Sera were analysed enzymatically for total [18] and high-
density lipoprotein cholesterol [19], and triglycerides [20]. Mean bias for control 
sera provided by the Centers for Disease Control (Atlanta, USA) was -1 percent for 
total and high-density lipoprotein cholesterol, and 10 percent for triglycerides. The 
coefficient of variation within runs ranged from 0.9 to 1.7 percent. Low-density 
lipoprotein cholesterol was calculated [21]. 
Alanine aminotransferase and cholesterol were analysed in three separate 
sessions, each comprising 1 2 weeks of the trial. All other variables were analysed 
in a single session. Sera from one subject were analysed within the same run. 
Statistics 
Baseline values were calculated as the means of the two values obtained 
after the run-in period. Responses were calculated by subtracting baseline values 
from values obtained during the treatment period. The means of the values 
obtained after 23 and 24 weeks of treatment were used as end values. Differences 
in responses between the groups were compared using Mann Whitney U and 
unpaired t tests. As the results were similar, only the latter are presented. 
RESULTS 
Diaries kept by the subjects and anonymous questionnaires administered 
after the trial showed that over 98 percent of the prescribed amount of coffee was 
consumed. In both groups, mean changes in body mass index during treatment 
were less than 0.5 kg/m2, and changes in intake of saturated, mono-unsaturated, 
or poly-unsaturated fatty acids less than 1 percent of energy. 
Liver enzymes 
The mean alanine aminotransferase concentration rose on cafetière coffee_^ 
by up to 80 percent (table 2). After 24 weeks, the rise was 9 (SE 3) U/Hor 45 
percent over baseline, relative to filtered coffee (P = 0.007). In eight out of 22 
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subjects drinking cafetière coffee, the concentrat ion of alanine aminotransferase 
exceeded the upper limit of normal at least one occasion, as opposed to one out 
of 24 subject drinking filtered coffee. Alanine aminotransferase exceeded tw ice the 
upper l imit of normal in three cafetière coffee drinkers. Concentrations of aspartate 
aminotransferase, alkaline phosphatase, and / -g lu tamy l t rans fe rase were less 
affected (figure 1). After discontinuation of cafetière coffee, enzyme 
concentrat ions returned to normal in all subjects. 
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FIGURE 1. Mean changes from baseline values in serum concentrations of alanine (•) and 
aspartate aminotransferase ( A ) , alkaline phosphatase (o) and K-g'utamyltransferase (•) 
in 22 subjects drinking 0.9 litre per day of cafetière coffee for 24 weeks. For each time 
point, the mean changes from baseline occurring in 24 subjects drinking filtered coffee 
were subtracted from the mean changes in cafetière coffee consumers, to correct for 
random drifts in time. The treatment period is indicated by a horizontal black bar. No 
treatment was given in the follow-up period. 
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CAFETIERE COFFEE, AND ALT AND CHOLESTEROL 
Lipids 
Cafetière coffee raised cholesterol concentrat ions, mostly because of an 
increase in low-density l ipoprotein cholesterol (figure 2, table 2). After 24 weeks, 
low-density l ipoprotein cholesterol concentrations were raised by 0 .26 (SE 0.11) 
^-— ^ 
mmol/L o f 9 percent over baseline, relative to fi ltered coffee (P = 0.03) . High-
density lipoprötèlini cholesterol was n^t affected. Triglycerides were raised by 2 6 ) 
percent wi th in t w o weeks, ^ n d by 7 jâej-cent after 24 weeks; of "treatment. Af ter 
discontinuation of cafetière coffee, concentrations of total and low-density 
l ipoprotein cholesterol, and of triglycerides fell below baseline (figure 2). 
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FIGURE 2. Mean changes from baseline in serum concentrations of total cholesterol ( • ) , 
triglycerides (A ) , low-density lipoprotein cholesterol (LDL,o) and high-density lipoprotein 
cholesterol (HDL.n) in 22 subjects drinking 0.9 litre of cafetière coffee per day for 24 
weeks. For each time point, the mean changes from baseline occurring in 24 subjects 
drinking filtered coffee were subtracted from the changes in the cafetière coffee 
consumers, to correct for random drifts in time. The treatment period is indicated by a 
horizontal black bar. No treatment was given in the follow-up period. Low-density 
lipoprotein cholesterol was calculated according to Friedewald [21]. 
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DISCUSSION 
We found that daily intake of five to six cups of strong cafetière coffee 
raises alanine aminotransferase concentrations for at least half a year, and raises 
low-density lipoprotein cholesterol similarly to Scandinavian boiled coffee. The 
present findings should also apply to Turkish coffee, which contains similar 
amounts of cafestol and kahweol per cup as cafetière and boiled coffee. For Italian 
espresso coffee, about twenty cups per day are required for these effects, due to 
small cup sizes. Instant and percolator coffee will have negligible effects on serum 
aminotransferase and lipid concentrations, due to their very low concentrations of 
cafestol and kahweol [9]. 
Liver enzymes 
We expected that the rise in alanine aminotransferase would be transient 
with prolonged intake of cafetière coffee, as chronic consumers of boiled coffee 
did not have elevated alanine aminotransferase concentrations [5]. However, the 
present study indicates that liver cells only partly adapt to cafestol and kahweol 
within the first half year of consumption. 
Alanine aminotransferase concentrations exceeded the upper limit of normal 
in one out of three, and twice the upper limit in one out of seven subjects on 
cafetière coffee. Thus, a high intake of strong, unfiltered coffee might explain some 
cases of elevated alanine aminotransferase concentrations in apparently healthy 
individuals. It might be prudent for patients with raised alanine aminotransferase 
not to drink more than a few cups of cafetière, Turkish, or boiled coffee per day 
on a regular basis. 
However, should we really expect unfiltered coffee to affect the risk of liver 
disease in healthy individuals? Cafetière coffee only marginally raised aspartate 
aminotransferase concentrations, which excludes extensive damage to liver cells. 
y-Glutamyltransf erase and alkaline phosphatase concentrations were reduced rather 
than raised (figure 1), and reduced concentrations of K-glutamyltransferase were 
also observed in chronic consumers of boiled coffee [22,23]. In Scandinavian 
countries, which used to have high intakes of boiled coffee, death rates from liver 
cirrhosis are low, and seem to be unaffected by the change from drinking boiled 
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to drinking fi l tered coffee over the past decades [24] . Therefore, clinically relevant 
damage to liver cells w i th regular use of unfiltered coffee appears unlikely, although 
we cannot yet ful ly exclude subclinical injury to hepatocytes. 
Lipids 
Cafetière cof fee ja ised total cholesterol bV 6 to 10 percent, a^id low-density 
l ipoprotein cr^oîësterol by 9 to 14 percent^Phis is"~s7rrïîtaT~TuTFîéf effects observed 
in experiments w i th Scandinavian boiled coffee [2-4 ,7 ,8 ] . 
The rises in total and low-density l ipoprotein cholesterol persisted w i th 
prolonged consumption of cafetière coffee. Our experiment thus shows that 
cholesterol metabolism remains disturbed w i th prolonged intake of cafestol and 
kahweol , as was previously suggested by observational studies in boiled-coffee 
drinkers [5 ,25-28 ] . Therefore, high intakes of cafetière coffee wil l be associated 
w i th an increased risk of coronary heart disease, similar to boiled coffee [29] . An 
elevation of cholesterol of 6 to 10 percent is estimated to increase coronary risk 
by 12 to 20 percent [30 ] ; larger increases may be expected in young individuals 
[31 ] . 
High tr iglyceride concentrations are also associated w i th increased coronary 
risk [32 ] . Triglycerides initially rose on cafetière coffee by 26 percent, but most of 
the rise disappeared w i th prolonged intake (figure 2). It is unlikely that this was due 
to seasonal influences, as we expressed all changes relative to those in the 
concurrent control group. Experiments w i th boiled coffee [2 ,3,7,8] have shown 
larger responses in triglycerides than observational studies comparing consumers 
of boiled and fi ltered coffee [4 ,27] . Our results may explain this; tr iglyceride 
concentrat ions partly normalize w i th long-term intake of cafestol and kahweol . 
We cannot explain the fall in lipid concentrations below baseline values after 
cessation of cafetière coffee. It is not likely to be due to dietary changes; for 
instance, the observed reduction of low-density l ipoprotein cholesterol of 0 .25 
mmol/L would have required a shift in dietary intake f rom butter to high-linoleic-
acid diet margarine of 32 grams per day [33 ,34 ] . These findings again emphasize 
the prolonged and extensive effects of cafestol and kahweol on lipid metabolism 
in humans. 
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Conclusions 
Daily consumption of large amounts of cafetière coffee raises alanine 
aminotransferase concentrations for at least half a year. Chronic intake of cafetière 
coffee also raises low-density lipoprotein cholesterol. The effects on 
aminotransferases may be innocuous, but those on cholesterol will increase 
coronary risk, and could be a reason to advise patients to switch to filtered coffee. 
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chronic consumers of boiled coffee 
have elevated serum levels 
of lipoprotein(a) 
CHAPTER 6 
ABSTRACT 
Objectives. Lipoprotein(a) consists of an LDL-particle attached to apolipoprotein(a), which 
is made by the liver. Diterpenes present in boiled coffee raise serum levels of LDL 
cholesterol and of the liver enzyme alanine aminotransferase in man. We now investigated 
the association between intake of boiled coffee and serum levels of lipoprotein(a). 
Design, Setting, and Subjects. Healthy Norwegians 40-42 y of age, who habitually 
consumed five or more cups of boiled coffee per day (n= 150) were compared with 
matched filter coffee consumers (n= 159) in a cross-sectional study, as part of the 
Norwegian National Health Screening in 1992. 
Results. The median lipoprotein(a) level was 13.0 mg/dL (10th and 90th Percentile: 2.5 
and 75.0 mg/dL, respectively) on boiled and 7.9 mg/dL ( 10th and 90th Percentile: 1.9 and 
62.5 mg/dL, respectively) on filter coffee (P= 0.048). Means ± SE were 25.8 ±2.4 
mg/dL and 19.6 ± 2.0 mg/dL, respectively (P = 0.047). Although not statistically 
significant, subjects consuming nine or more cups of coffee per day had higher 
lipoprotein (a) levels than those drinking five to eight cups per day in both coffee groups. 
Conclusion. Chronic consumers of un filtered, boiled coffee have higher serum lipoproteinfa) 
levels than filter coffee drinkers (JOURNAL OF INTERNAL MEDICINE 1996; 240: 367-71). 
INTRODUCTION 
Lipoprotein(a) [Lp(a)] consists of a large glycoprotein, apolipoprotein(a). 
attached to an LDL molecule [1 ] . A high serum Lp(a) level is a risk factor for 
developing coronary atherosclerosis and other vascular diseases \ 1 -51. Lp(a) levels 
are largely under genetic control [6 ] , and are unaffected by many factors that 
modulate LDL-cholesterol levels [1 ,7 ] , including diet [8 ] . An exception is formed 
by dietary trans fat ty acids, which raise serum Lp(a) levels [9 ,10] . 
Consumption of unfi l tered, boiled coffee is associated w i th raised serum 
cholesterol levels in humans in both intervention trials [11-13] and epidemiological 
studies [14-17] . Recently, it was shown that the diterpenes cafestol and kahweol 
are responsible for the hyperlipidaemic effects of boiled coffee f 18.191. 
Scandinavian boiled coffee provides 3 to 4 mg of each diterpene per cup, whereas 
paper-fi ltered coffee contains less than 0.1 mg of each diterpene per cup [20 ] . 
The liver appears to be the target organ of coffee diterpenes, as cafestol and. 
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kahweol elevate the serum activity of alanine aminotransferase [19,21 ] and reduce 
that of y-glutamyltransferase [19,22]. The liver is also t h p r"3'" tnum* nf 
apoljpoprotein(a) [23], and the serum level of Lp(a) is largely determined by the rate 
ofj-pjaj^production [24]. Whether ingestion of coffee diterpenes with boiled coffee 
results in altered serum levels of Lp(a) is as yet unknown. 
We now compared serum Lp(a) levels in healthy Norwegians consuming 
unfiltered boiled coffee with those in matched filter coffee drinkers. 
TABLE 1 . Characteristics of 309 healthy Norwegians aged 40-42 y chronically drinking five 
or more cups of boiled or filter coffee per day3 
Number of men/women 
Age (years) 
Body Mass Index (kg/m2) 
Women taking contraceptive steroids 
Coffee consumption 
5-8 cups per day 
9 or more cups per day 
Smokers 
Alcohol users 
Medication users" 
Total cholesterol (mmol/L) 
Triglycerides (mmol/L) 
Alanine aminotransferase (U/L) 
Aspartate aminotransferase (U/L) 
K-Glutamyltransferase (U/L) 
Filter coffee 
n=159 
88/71 
41 ± 1 
25 ± 3 
2 
133 
26 
89 
146 
20 
5.67 ± 1.05 
1.92 ± 1.24 
19 ± 10 
22 + 7 
26 ± 24 
Boiled coffee 
n=150 
79/71 
41 ± 1 
25 ± 4 
2 
117 
33 
87 
135 
21 
5.98 ± 1.08c 
2.14 ± 1.55 
2 0 + 1 0 
22 ± 7 
20 ± 17c 
Values are numbers, or means ± SD 
Any medications used in the month previous to the screening. None of the subjects used 
medicines on a daily basis. 
Significantly different from filter coffee group: P<0.05 
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SUBJECTS AND METHODS \ 
OV 
Subjects V
 x . r 
Subjects were recruited as part of the Norwegian National Health Screening 
in 1992, a population-based study in southern Norway [17]. Persons aged 40-42 
years attending the screening were asked to fill out a questionnaire concerning 
their coffee usage. Those who reported drinking 5 or more cups of either boiled or 
filter coffee per day received an oral explanation about the purpose of our study. 
The questionnaire did not provide information on duration and history of coffee 
intake. Subjects were considered eligible if they were healthy, did not take any 
medication known to affect liver enzymes or serum lipids, and did not consume 
re than 3 alcohol-containing beverages per day. Those who were willing to 
participate gave their written informed consent. Prior approval for the study was 
obtained from the appropriate human ethics committee. 
Blood sampling and assays 
Non-fasting blood was obtained by venepuncture, allowed to dot , and 
pfintrifngfid. Sera were randomly coded, shipped to Wageningen, and stored at -
80°C. Lp(a) was assayed blindly within 12 months with an enzyme-linked immuno-
sorbent assay (Immunozym Lp(a), Immuno GMBH, Heidelberg, Germany). The 
lower limit of detection of Lp(a) was 1 mg/dl, which according to the manufacturer 
is higher than the maximum cross-reactivity of the Lp(a)-antibodies with 
plasminogen and apolipoprotein B. For each subject, Lp(a) was analysed in 
duplicate in separate runs. The intra- and inter-assay coefficients of variation for 
a control pool (target 14-21 mg/dL) were 14.8 and 9.6 %, respectively, over a 
period of 3 months. Serum lipids and serum activities of liver enzymes were 
assayed as described [19]. 
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Statistical analyses 
Unpaired, two-sided t tests were used to compare the means of serum 
variables between the t w o groups. As the distributions of Lp(a) levels were 
posit ively skewed, we also compared the t w o groups w i th Mann-Whitney U tests. 
c 
'ö> 
o 
a-
Q. 
O 
o. 
P10 p20 p30 p40 p50 p60 p70 p80 p90 
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FIGURE 1. Serum lipoprotein(a) levels among 309 healthy Norwegians aged 40-42 y, 
chronically consuming five or more cups of boiled (n = 150) or filter coffee (n = 159) per 
day. Values represent the serum Lp(a) level of the 15th, 30th, 45th etc. consumer of 
boiled coffee, and the 16th, 32nd, 48th, etc. consumer of filter coffee when subjects were 
ranked for the serum level of Lp(a) within coffee usage groups. 
RESULTS 
Consumers of boiled (n = 150) and filter coffee (n = 159) were wel l matched 
wi th regard to sex, age, Body Mass Index, use of medicines, smoking habits and 
93 
CHAPTER 6 
alcohol consumption (table 1). The use of boiled coffee was associated w i th higher 
serum levels of cholesterol and lower serum activities of p-glutamyltransferase, jn 
agreement w i th earlier f indings [14-17 ,25 ] . 
The median level of Lp(a) was 13.0 mg/dL (range 0 to 130 mg/dL) among 
consumers of boiled coffee and 7.9 mg/dL (range 0 to 144 mg/dL) among 
consumers of filter coffee (P = 0.048) (figure 1); means ± SE were 25.8 ± 2.4 
mg/dL and 19.6 ± 2.0 mg/dL, respectively (P = 0.047) . 
The median Lp(a) levels were for men 14.1 mg/dL for boiled and 7.8 mg/dL 
for filter coffee, and for women 10.7 mg/dL for boiled and 8.3 mg/dL for fi lter 
coffee. The median Lp(a) level was 13.6 mg/dL in the subjects drinking more than 
nine cups of boiled coffee per day, and 11.7 mg/dL in those drinking less than nine 
cups. For fi lter coffee, the corresponding values were 8.0 mg/dL, and 6.9 mg/dL, 
respectively (all differences P > 0 . 0 5 ) . 
DISCUSSION 
We found that the median level of serum Lp(a) in Norwegians habitually 
nnnfi i iming i infi l torf ir i , hoiled coffee was significantly higher than in their peers 
drinking filter coffee. Our data also suggest that the elevation of Lp(a) may depend 
on the amount of coffee consumed, and that the effect of boiled coffee is stronger 
in men than in women. These results did not reach statistical signif icance, 
however, wh ich may be attributable to reduced power due to limited sample sizes. 
The insensitivity of Lp(a) levels to environmental influences [7,8] renders it 
unlikely that our f inding was biased. In addit ion, the t w o groups were well matched 
w i th respect to age, sex, Body Mass Index, smoking habits, and alcohol use. The 
use of drugs or contraceptive pills during the previous month in the t w o groups 
was infrequent and similarly distributed (table 1). Dietary factors that influence 
Lp(a) levels are limited to trans fat ty acids [9,10] and possibly fish oils [8 ] . It is 
unlikely, however, that consumers of boiled and filter coffee differed enough in 
their intake of fat ty acids to explain the effect seen here. 
The Lp(a) particle contains apolipoprotein(a) [apo(a)], which is remarkably 
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polymorphic [26]. Serum Lp(a) levels correlate inversely with the molecular weight 
of the apo(a) isoform and the size of the corresponding gene [27]. We had no 
information on apo(a) phenotype distribution of the two groups. Although all 
subjects were living in Southern Norway, more people consuming boiled coffee 
may have descended from ancestors that originated from Northern Norway -
where consumption of boiled coffee is more common [17]. Therefore, confounding 
by genetic differences can not be fully excluded. 
The higher level of Lp(a) among boiled-coffee consumers was an unexpected 
finding to us. In four experiments with a large number of Dutch volunteers, coffee 
oil rich in diterpenes significantly lowered serum Lp(a) (Chapter 7). In the present 
study, serum levels of cholesterol were higher in the boiled-coffee group, and v-
glutamyltransferase activities were lower, which is consistent with both 
epidemiological [14-17,25] and experimental studies [19,22]. These variables, as 
well as the Lp(a) concentration of each subject were determined blindly in the same 
set of serum aliquots. In addition, all sera of subjects consuming boiled or filter 
coffee had been stored under the same conditions, and analysed for Lp(a) in 
random order, except for one analysis run which after breaking of the code turned 
out to have comprised sera of 36 boiled-coffee drinkers and no filter coffee 
drinkers, and one run that had contained sera of 42 filter coffee drinkers and only 
9 boiled-coffee drinkers. However, the median level of Lp(a) in the first run was 
11.5 mg/dL (n = 36) against 13.0 mg/dL for the entire boiled-coffee group 
(n = 150), and in the second run 8.6 mg/dL (n = 42) against 7.9 mg/dL for the 
entire filter coffee group (n = 159). Therefore, if any systematic bias was 
introduced at this stage, it should have weakened the association between coffee 
type and Lp(a) levels instead of having strengthened it. 
Therefore, there seems to be a discrepancy between effects on Lp(a) levels 
with short-term and chronic intake of coffee diterpenes. In our short-term trials, we 
observed that coffee diterpenes increased serum activities of alanine 
aminotransferase [19,22]. This suggests that the liver is the target organ for coffee 
diterpenes. Disturbed hepatocyte integrity may reduce circulating Lp(a) levels, as 
seen in patients with biliary cirrhosis or other liver disease [28,29]. In the present 
study, however, the boiled-coffee drinkers had no elevated serum activities of 
alanine aminotransferase ([19], see also table 1). It is therefore possible that the 
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Iiver adapts to the effects of cafestol and kahweol with chronic consumption of 
boiled coffee. Therefore, intervention trials of longer duration are needed to reveal 
the time course of the effect of coffee diterpenes on serum Lp(a). 
Tverdal et al [301 found an effect of boiled-coffee consumption on mortality 
from coronary heart disease, over and above its effect on serum cholesterol. Higher 
serum levels of Lp(a) on boiled coffee as observed in our study might partly 
account for this additional risk. 
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diterpenes from coffee beans 
reduce serum levels of lipoprotein(a) 
in humans 
results from four randomised controlled trials 
CHAPTER 7 
ABSTRACT 
Objective. Un filtered coffee raises serum LDL cholesterol in humans, o wing to the presence 
of the diterpenes cafestol and kahweol. Norwegians with a chronic high intake of unfiltered 
.coffee also had elevated serum levels of lipoprotein(a), an LPL-like particle which is 
insensitive towards dietary interventions. We now experimentally studied the influence of 
coffee diterpenes on lipoprotein(a) levels. 
Design. Four randomised controlled trials. 
Subjects. Healthy, normolipidaemic volunteers. 
Interventions. Coffee, coffee oil, and pure diterpenes for 4 to 24 weeks. 
Main outcome measures. The circulating level of lipoprotein(a). 
Results. In 22 subjects drinking five to six strong cups of cafetière coffee per day, the 
median fall in lipoprotein (a) was 1.5 mg/dL after two months (P=0.03), and 0.5 mg/dL 
after half a year fP> 0.05), relative to 24 filter coffee drinkers. Coffee oil doses equivalent 
to 10-20 cups of unfiltered coffee reduced lipoprotein(a) levels by up to 5.5 mg/dL 
(P<0.05j in two separate trials (n= 12-16 per group). A purified mixture of cafestol amL 
kahweol. as well as cafestol alone, were also effective in reducing Lp(a) levels (n= 10). 
Averaged over the four trials, each 10 mg/day of cafestol (plus kahweol) - the amounts 
present in two to three cups of cafetière coffee — decreased Lp(a) levels by 0.5 ma/dL or 
4% from baseline values after four weeks (n = 63). 
Conclusions. Coffee diterpenes are among the few dietary exceptions shown to influence 
serum lipoprotein (a) levels. However, the Lp(a)-reducing potency ofcoffee diterpenes may 
subside in the long run, and their adverse side effects preclude their use as lipoprotein(a)-
reducing agents (EUROPEAN JOURNAL OF CLINICAL NUTRITION - IN PRESS). 
INTRODUCTION 
Lipoprotein(a) [Lp(a)] is a liver-derived lipoprotein particle that is only 
dist inguished f rom low-density-lipoj^rgtejnJlTPLLby_Jhe covalent at tachment of a 
laxg£_alycoprotein, apolipoprotein(a) [1 ] . An extensive body of laboratory evidence 
indicates a crit ical role of Lp(a) in the development of atherothrombotic diseases 
[21. wh ich is confirmed by most [3-10] , though not all [11-141. prospective cohort 
studies. The circulating level of Lp(a) is largely under genetic control [15 ] , and is 
unaffected by many interventions known to affect LDL metabol ism, including most 
dietary interventions [16] . 
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The diterpenes cafestol and kahweol are lipids that are unique to coffee 
beans [17] . They are responsible for the cholesterol-raising effect of Scandinavian 
boiled coffee [18 ,19 ] . Cafestol and kahweol strongly affect lipid metabolism wi th 
short- term intake [20-25] as well as in life-long consumers of unfi l tered coffee 
[18 ,26-29 ] . We recently found that consumption of boiled coffee was also 
associated w i th Lp(a) levels; the median Lp(a) level in Norwegians who were life-
long consumers of boiled coffee was 6 5 % higher than in matched fi lter cof fee. - .
 v-, 
drinkers [30 ] . \ \ ' ° > 
We now report the effects of preparations rich in cafestol and kahweol on 
Lp(a) levels in healthy, normolipidaemic volunteers in four independent 
experiments. The effects on serum lipids and liver enzymes have been reported 
elsewhere [18 ,25 ,31 ] . 
TABLE 1. Characteristics of the participants of the four randomised, controlled trials. 
Values were obtained at the end of the run-in periods, when subjects had received five 
cups of filtered coffee free from diterpenes for four weeks (trial A), or 2-3 g of placebo oil 
for one or two weeks (trials B-D)a. v ,r,, p , [J 
Number of men/women 
Women using contraceptive steroid (n) 
Smokers (n) 
Age (years) 
Body Mass Index (kg/m2)b 
Serum cholesterol (mmol/L) 
Serum LDL cholesterol (mmol/L) 
Serum HDL cholesterol (mmol/L) 
Serum triglycerides (mmol/L) 
Trial A 
23/23 
11 
16 
29 ± 10 
22 ± 3 
4.9 ± 0.7 
3.0 + 0.8 
1.5 ± 0.3 
1.1 ± 0.4 
Trial B 
15/17 
10 
5 
22 ± 2 
22 ± 2 
4.5 ± 0.5 
2.5 ± 0.5 
1.5 ± 0.3 
1.0 ± 0.3 
Trial C 
21/25 
12 
3 
22 ± 2 
22 ± 2 
4.5 ± 0.7 
2.7 ± 0.6 
1.4 ± 0.3 
0.9 ± 0.3 
Trial D 
10/0 
-
2 
24 ± 4 
2 1 + 2 
4.8 ± 0.9 
3.0 ± 0.7 
1.5 ± 0.4 
0.8 ± 0.2 
Values are numbers, or means ± SD 
Body weights were measured without shoes or heavy clothing. 
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METHODS 
Subjects 
Participants were recruited through advertisements in newspapers and 
university buildings. Most subjects were young, nonobese, and normolipidaemic 
(table 1), and all were apparently healthy as indicated by a medical questionnaire 
and by the absence of anaemia, glucosuria, or proteinuria. None took medications 
\ known to affect serum lipid levels. The experimental protocols, which were appro-
ved by the local human ethics committee, were carefully explained to the 
volunteers and their written informed consent was obtained. 
Subjects were asked to maintain their usual diet and life-style, and not to 
consume more than twenty drinks containing alcohol per week. They were allowed 
to use paper-filtered or instant coffee, as these are free from diterpenes [32]. All 
subjects kept daily records of illness, medication use, and deviations from the 
protocol. 
Treatments and designs 
Between 1991 and 1995, we carried out four randomised trials. We gave 
filtered versus unfiltered coffee in trial A, placebo versus coffee oil in trials B and 
\C, and cafestol versus a mixture of cafestol and kahweol in trial D. The 
experimental designs are given in figure 1. 
TRIAL A - UNFILTERED VERSUS FILTERED COFFEE. This was a randomised, parallel 
controlled study. After a run-in period of four weeks on filtered coffee, subjects 
consumed 0.9 litre of either filtered or cafetière (also called 'French press') coffee 
per day for 24 weeks. All ground coffee was Roodmerk (Douwe Egberts, Utrecht, 
The Netherlands), a blend of Arabica and Robusta beans widely used in the 
Netherlands [22]. Cafetière coffee provided 38 mg of cafestol and 33 mg of 
kahweol and filtered coffee less than 1 mg of either diterpene per day. Six subjects 
withdrew during the treatment period for personal reasons, and one was 
withdrawn as he started taking drugs of potential hepatotoxicity daily during the 
trial. 
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Trial A 
4wk 
Filtered 
coffee 
44 
24 wk 
Filtered coffee (0.9 L/d) 
Cafetiere coffee (0.9 L/d) 
* * * * * 44 
12 wk 
4 
Trial B 
2 wk 
Placebo 
oil 
(3 g/d) 
4 wk 
Placebo oil (3 g/d) 
Coffee oil (3 g/d) 
4wk 
i i !» 
Trial C 
Trial D 
1 wk 
Placebo 
oil 
(2 g/d) 
4 wk 
Placebo oil (2 g/d) 
Coffee oil (2 g/d) 
Stripped oil (2 g/d) 
44 44 
4 wk 
2 wk 
Placebo 
oil 
4wk 
Cafestol 
Mixture 
7wk 2wk 
Placebo 
oil 
4 wk 
Mixture 
Cafestol 
7wk 
4T44 4—ïiï 
FIGURE 1 . Experimental designs of four randomised studies with healthy normolipidaemic 
volunteers. Arrows indicate times of blood sampling. Empty cells indicate wash-out and 
follow-up periods, during which no treatment was given. 
TRIALS B AND C - COFFEE OIL VERSUS PLACEBO OIL. These were double-blind, 
randomised parallel controlled studies. All participants first received for 1 to 2 
weeks placebo oil which was a 3:2 (w/w) mixture of sunflower oil and palm oil. 
After randomisation, subjects continued on either placebo oil or coffee oil for four 
weeks. Daily amounts of diterpenes provided by the coffee oil were 85 mg of 
cafestol and 103 mg of kahweol in trial B, and 57 mg of cafestol and 69 mg of 
kahweol in trial C. In trial C, a third group of subjects received coffee oil that was 
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stripped of cafestol and kahweol. 
There were no dropouts in trial B. Two subjects withdrew from trial C for 
reasons unrelated to treatment. 
TRIAL D - CAFESTOL PLUS KAHWEOL VERSUS CAFESTOL ALONE. This was a double-
blind, randomised cross-over study. Participants received placebo oil during the first 
two weeks. During the next four weeks, half of the subjects received 64 mg of 
cafestol and 1 mg of kahweol dissolved in placebo oil. The other five subjects 
received 60 mg of cafestol and 54 mg of kahweol per day, again dissolved in 
placebo oil. After a wash-out period of 7 weeks, subjects again received placebo 
oil for two weeks, and supplements were switched during the next four weeks; 
analysed dosages of cafestol and kahweol were now 61 and 0 mg for pure 
cafestol, and 60 and 48 mg for the mixture, respectively. Purities of the diterpene 
preparations were higher than 92%; impurities consisted of free cafestol and 
kahweol, cafestol and kahweol dipalmitate, and palmitic acid. 
Three subjects were switched to placebo after two weeks of treatment, 
because they exceeded our predefined safety limits for rises in alanine 
aminotransferase. For these subjects, values obtained after two weeks replaced 
their final values. 
Serum analyses 
Venous blood samples were taken after an overnight fast. Serum samples 
were obtained by centrifugation, stored at -80°C, and analysed blindly within 12 
months after completion of the studies. 
For trials B and C, Lp(a) was measured with a solid phase two-site 
immunoradiometric assay (RIA) from Pharmacia Diagnostics AB (Uppsala, Sweden). 
The intra- and inter-assay coefficients of variation as given by the manufacturer 
were 3.3 and 10.6 %, respectively. The range of measurable serum Lp(a) 
concentrations was 1.7 to 84.0 mg/dL. Sera with concentrations higher than 84.0 
mg/dL were diluted and remeasured. Six out of 78 subjects had Lp(a) levels less 
than 1.7 mg/dL. These were designated undetectable. The results were 
recalculated from arbitrary units to milligrams per decilitre on the basis of the 
results obtained with the kit calibrators, and the value of a serum standard from 
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Immuno A.G. (Vienna, Austria). 
For trials A and D, Lp(a) was measured with an enzyme-linked immuno-
sorbent assay (TintElize Lp(a), Campro Scientific, Veenendaal, the Netherlands). 
The lower limit of detection of Lp(a) was 1 mg/dL. None of the subjects had levels 
below the detection limit. The intra- and inter-assay coefficients of variation for a 
control pool of 44 mg/dL as measured in our laboratory were 5.0 % and 3.5 %, 
respectively. 
For all trials, sera were analysed in duplicate in two separate runs, but with 
one full series of samples obtained from one subject analysed within the same run. 
Lipids, lipoproteins, and liver enzymes in serum [181. and cafestol and kahweol in 
coffee preparations [321. were assayed as described. 
Statistical analyses 
We calculated the Lp(a) response of each subject by subtracting values 
obtained after the run-in period (baseline values) from those obtained during the 
treatment period (treatment values). As some of the responses showed non-
Gaussian distributions, we used Mann Whitney U tests to compare control and 
treatment groups. In trial D, responses were analysed using Wilcoxon Rank Sum 
tests. 
RESULTS 
Diaries kept by the subjects showed that more than 98% of the diterpene 
preparations had been taken in each of the trials. , \ 
TRIAL A - UNFILTERED VERSUS FILTERED COFFEE. Daily consumption of five cups 
of cafetière coffee produced a fall in Lp(a) levels, which reached a maximum of 1.5 
mg/dL after eight weeks (P = 0.03), relative to filtered coffee (figure 2). The 
reduction stabilised around 0.5 mg/dL (P>0.05) between 12 and 24 weeks of 
consumption. 
TRIALS B AND C - COFFEE OIL VERSUS PLACEBO OIL. In trial B, intake of 3 g of 
coffee oil per day for four weeks caused a median fall in Lp(a) levels of 5.3 mg/dL, 
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relative to concurrent controls receiving placebo oil (P<0 .001 ) . In trial C, intake 
of 2 g/d of coffee oil reduced Lp(a) levels by 3.1 mg/dL (P = 0.02) . Coffee oil that 
was stripped of cafestol and kahweol did not affect Lp(a) levels (table 2). 
TRIAL D - CAFESTOL PLUS KAHWEOL VERSUS CAFESTOL ALONE. The mixture of 
cafestol and kahweol as well as cafestol alone both reduced Lp(a) levels by 3 to 
4 mg/dL relative to baseline levels (table 2). Relative to cafestol alone, the mixture 
produced a median fall in Lp(a) levels of 0.8 mg/dL, and a mean fall of 0.5 (SEM 
0.6) mg/dL (both P > 0 . 0 5 ) . 
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FIGURE 2. Trial A: Median changes in serum levels of lipoprotein(a) [(Lp(a)] in subjects 
consuming five cups of cafetière ( • , n = 22) or filtered coffee { A , n = 24) per day for 24 
weeks, and the difference between the changes (•). No treatment was given in the follow-
up period. 
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Changes in Lp(a) were not associated w i th changes in other serum lipids and 
l ipoproteins, or in liver enzymes (P>0 .05 ) . In all four experiments, Lp(a) levels 
returned to baseline values after cessation of treatment. 
We combined the individual data of the four trials and classified all subjects 
according to initial Lp(a) value (figure 3). On an absolute basis, individuals w i th 
high initial Lp(a) values appeared to benefit more from diterpene intake; the median 
fall of Lp(a) was -0.3 mg/dL in the lowest, -3.3 mg/dL in the middle, and -6.5 
mg/dL in the upper ferti le in subjects who received diterpenes, each relative to the 
median change in the corresponding tertile of controls. 
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COFFEE DITERPENES AND SERUM Lp(a) 
DISCUSSION 
Preparations rich in the coffee diterpenes cafestol and kahweol reduced 
serum Lp(a) levels in four independent experiments. Females taking oral 
contraceptives were randomised over control and treatment groups, and none of 
the subjects took medications on a regular basis. Bias due to hormone intake or 
drug therapy [16] is thus unlikely. Furthermore, changes in dietary intakes, body 
mass, and alcohol use were minimal and similar for the control and treatment 
groups wi th in each study [18 ,25 ,31 ] . Therefore, it is unlikely that the reductions 
in Lp(a) levels were due to anything else than treatment w i th coffee diterpenes. 
Despite its structural similarity to LDL, the circulating level of Lp(a) is 
remarkably insensitive to dietary intervention; by now, only dietary trans fa t ty acids 
have consistently been proven to be effective, as they modestly raise Lp(a) levels 
[33-35] . Fish oils [36,37] as well as high doses of ascorbic acid [38] were found 
to reduce Lp(a) levels, but other attempts could not verify this [39-43] . Coffee 
diterpenes are thus among the few dietary components that modulate the 
circulating level of Lp(a). 
Median Lp(a) change (mg/dL) 
100 
Cafestol (mg/day) 
FIGURE 4. Relation of the observed median change in lipoprotein(a) [Lp(a)] after four weeks 
of treatment with the average cafestol intake per day (table 2) across the four trials. The 
responses are given relative to the median changes in the respective control groups. 
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Intake of cafestol alone was effective in reducing Lp(a) levels, and the 
addition of kahweol had little extra effect (trial D). Cafestol may thus be the sole 
Lp(a)-reducing principle in coffee oil. However, this trial was too small to fully 
exclude an additional effect of kahweol. 
Health benefits 
Individuals with high initial values of Lp(a) showed a larger drop in Lp(a) 
levels than those with low initial values (figure 3). The median fall across thé four 
experiments depended on the daily amount of cafestol ingested; each 10 mg - the^ 
amount present in two to three cups of cafetière coffee - reduced Lp(a) levels by 
0.5 mg/dL or 4% from baseline level after four weeks (figure 4). We would expect 
the same effect with Turkish and Scandinavian boiled coffee, as these types 
contain similar diterpene levels per cup as cafetière coffee. For espresso coffee, 
about seven cups per day are needed for a similar effect [32]. 
Could a lowering of Lp(a) levels with consumption of coffee diterpenes 
confer any health benefit? In a meta-analysis of eleven trials with preparations rich 
in cafestol and kahweol, we found that each 10 mg of cafestol ingested per day 
raises serum total cholesterol by 0.15 mmol/L, whjfltuwas mostly_djje__to__an 
increasejn LDL^choleslerol (Chapter 8). The hypercholesterolaemic potency of 
coffee diterpenes thus overrules their potential beneficial impact on Lp(a) levels. 
This is evidenced by a higher rate of coronary heart disease in coffee drinkers in 
Norway [44], where boiled coffee is more common. Coffee diterpenes as such are 
thus unsuitable as a means of treatment for elevated Lp(a) levels, and a switch 
from filtered to unfiltered coffee is not warranted. 
Short-term versus chronic intake 
The present findings contradict our previous observation in a cross-sectional 
study that Norwegian boiled-coffee drinkers had higher Lp(a) levels than filter 
coffee drinkers [301. The reason for this discrepancy is unknown. In our cross-
sectional study and in each of the trials described here, serum samples of subjects 
who had ingested diterpenes and those of control subjects had been stored at -80 
°C for a similar period with a maximum of one year. Therefore, even if sample 
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storing has affected Lp(a) levels, it is unlikely that it has affected the cross-
sectional study and the experiments in opposite directions. 
A second explanation could be the presence of some unknown confounding 
factor in our cross-sectional study, although the insensitivity of Lp(a) levels to 
environmental factors [16] argues against this possibility. Stil l, confounding by 
genetic differences cannot be fully excluded: all subjects were living in Southern 
Norway, but more people consuming boiled coffee may have descended f rom 
ancestors originating f rom the north, where boiled coffee is more common [27] . 
In trial A. Lp(a) levels were depressed by up to 1 5 % in the first t w o months 
of intake of cafetière coffee, but the effect was strongly attenuated w i th prolonged 
use (figure 2). This indicates that the reducing effect of cafestol and kahweol may 
subside w i th prolonged intake. For other agents known to influence the serum level 
of Lp(a), this could have important implications. For instance, the evidence for the 
Lp(a)-elevating of dietary trans fat ty acids is derived f rom short-term experiments 
only [33-35] . The present f indings emphasize the need for intervention trials of 
Ionger duration in studying effects of diet or drugs on Lp(a) levels. 
Mechanism 
Short-term intake of coffee diterpenes raise serum levels of alanine 
aminotransferase [18 ,25 ,31 ,45 ,46 ] , which may point at disturbed hepatocyte 
integrity [47 ] . The alterations in serum lipids and lipoprotein levels caused by 
coffee diterpenes may also be due to effects on liver cell metabol ism. 
Apolipoprotein(a) is synthesised in the liver [48] , and circulating levels of Lp(a) are 
largely determined by the rate of production [49] . Indeed, patients w i th biliary 
cirrhosis [50-52] or other liver diseases [51] have higher levels of lipids and liver 
aminotransferases, but had reduced plasma Lp(a) levels. It is thus possible that the 
reduction of Lp(a) by coffee diterpenes is also due to their effect on liver cell 
metabol ism. Cross-sectional studies showed that chronic consumers of boiled f 181 
oi_esp_resso coffee [53] had no elevated levels of alanine aminotransferase. 
However, it remains speculative whether a transient effect on liver cell integrity 
may also result in an adaptation of Lp(a) metabolism in the human body. 
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Conclusions 
Coffee diterpenes, which are present in unfiltered coffee brews, are among 
the few dietary constituents that modulate Lp(a) levels. An advise to switch from 
filtered to unfiltered coffee is not warranted, as cafestol and kahweol exert a range 
of other, negative health effects. The present findings also indicate that caution is 
needed in extrapolating results from short-term controlled trials to the chronic 
situation. 
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CHAPTER 8 
ABSTRACT 
Certain types of coffee brew raise the serum concentration of total and low-density 
lipoprotein cholesterol in humans, whereas others do not. The responsible factors are the 
diterpene lipids cafestol and kahweol, which make up about 1 % (w:w) of coffee beans. 
Diterpenes are extracted by hot water, but are retained by a paper filter; this explains why 
filtered coffee does not affect cholesterol, whereas Scandinavian "boiled", cafetière, and 
Turkish coffee do. We describe the identification of the cholesterol-raising factors, their 
effects on blood levels of lipids and liver function enzymes, and their impact on public 
health, based on papers published up till December 1996 (ANNUAL REVIEW OF NUTRITION ® 
1997; 17: 305-24). 
INTRODUCTION 
Coffee and coronary heart disease risk 
The relationship between coffee and coronary heart disease has long been 
controversial . In 1963, Paul et al [1] suggested for the f irst t ime that coffee 
drinking predisposes humans to myocardial infarct ion. This was not confirmed by 
epidemiologic studies that fo l lowed, although some did f ind a link [2 ] . One 
complicat ing factor was that coffee drinkers smoke more than abstainers [3 ] ; 
indeed, smoking explained the original f inding of Paul et al [4 ] . 
The uncertainties associated w i th epidemiologic analyses make it important 
to define the effects of coffee on risk factors for coronary heart disease in 
control led experiments. Hypertensive effects may probably be disregarded, as the 
chronic impact of coffee or caffeine on blood pressure is small [2 ] . At tent ion 
should thus be focused on the effect of coffee drinking on serum cholesterol. 
Coffee and serum cholesterol 
Much of the information on coffee and cholesterol has come f rom 
Scandinavia, wh ich has the highest coffee consumption wor ld-wide [5] . In 1983, 
Thelle et al [6] found a strong association between coffee intake and serum 
cholesterol in Norway. They subsequently found in t w o experiments that 
w i thdrawal of coffee reduced cholesterol by 1 0 % [7 ,8 ] . 
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However, such an association was not consistently observed in the United 
States of America or western Europe [9]. The hypothesis was raised that the 
brewing method was critical; Scandinavians traditionally boil coffee grounds in 
water and pour the fluid into a cup without filtering it, whereas Americans and 
western Europeans mostly use a paper filter to separate the grounds from the brew 
[10]. Aro et al [11] showed in an experiment that "boiled" coffee indeed raised 
cholesterol, whereas in a parallel group filtered coffee had no effect. Bak & 
Grobbee [12] showed that actual boiling was not necessary: simply incubating the 
coffee grounds in water of 93 °C in a thermos jar produced the same effect. Later 
experiments showed that boiled coffee lost its entire cholesterol-raising potency 
when it was poured through a paper filter [13,14]. The brewing method thus made 
the crucial difference. 
THE DITERPENES CAFESTOL AND KAHWEOL ARE 
THE CHOLESTEROL-RAISING FACTORS FROM COFFEE BEANS 
The question now became which factor in boiled coffee affected cholesterol. 
While studying the content of solid coffee particles in boiled versus filtered coffee, 
Zock et al [15] fortuitously found that boiled coffee, upon centrifugation, displayed 
a thin floating layer of oil. Analyses confirmed that boiled coffee contains some 1 
to 2 grams of lipid per liter, whereas filtered coffee contains hardly any [13]. 
Ingestion by ten volunteers of 1.3 g/day of such boiled-coffee lipids raised serum 
cholesterol by 23% [15]. Later studies with oils pressed directly from coffee beans 
produced similar effects [16-18]. Thus, the cholesterol-raising factor was a lipid. 
Coffee oil largely consists of triglycerides -- which do not affect serum 
cholesterol when consumed in small amounts [19] - but it also contains some 
15% of diterpene esters of fatty acids [20]. Coffee oil that had been stripped of 
these diterpene esters no longer raised cholesterol in volunteers [16]. Heckers et 
al [21 ] then showed that ingestion of 148 mg of purified diterpene alcohols per day 
raised cholesterol by 32%, and similar rises were observed with purified diterpene 
esters [16,22]. 
The question now remained as to which diterpene was responsible. The 
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major coffee diterpenes are cafestol and kahweol. Pure cafestol can be made by 
hydrogenating a mixture of cafestol and kahweol isolated from coffee oil. However, 
it is difficult to purify kahweol. Urgert et al [22] therefore compared a supplement 
of pure cafestol with a mixture of cafestol and kahweol. Giving 63 mg of cafestol 
per day to ten volunteers raised cholesterol by 17%, whereas a mixture of 60 mg 
of cafestol plus 51 mg of kahweol per day only increased cholesterol by a further 
2%. This suggested that the cholesterol-raising potential of a coffee brew depends 
mainly on its content of cafestol, and less on that of kahweol. 
COFFEE DITERPENES RAISE LDL CHOLESTEROL AND TRIGLYCERIDES, 
AND ALSO AFFECT LIPOPROTEIN(a) 
Experimental evidence 
Eleven trials with humans given supplements of known diterpene content 
had been published by December 1996 (table 1). All subjects were healthy and 
normolipidaemic. For the present review, we performed a meta-analysis on these 
eleven trials, using as the independent variables the intakes of cafestol and 
kahweol per day, and as the dependent variables the mean changes in serum 
variables after four weeks of treatment. 
CHOLESTEROL. In the combined trials, serum total cholesterol rose by 0.13 
mmol/L (5.0 mg/dL) with each 10 mg of cafestol consumed per day and by 0.02 
mmol/L (0.9 mg/dL) with each 10 mg of kahweol consumed per day for four 
weeks. This confirms that cafestol raises cholesterol more than kahweol does. The 
effect was linear up to 100 mg of cafestol per day (figure 1), the amount present 
in 15 to 30 cups of boiled coffee [23,24]. About 80% of the rise in total 
cholesterol was accounted for by low-density lipoprotein (LDL) cholesterol, and the 
rest was due to a rise in very-low-density (VLDL) cholesterol. High-density 
lipoprotein (HDL) cholesterol may fall slightly when cafestol and kahweol are 
ingested [15,16,22]. The pattern of changes induced by various diterpene-rich 
preparations in these eleven trials was in good agreement with that seen with 
boiled coffee [11-14,25]. 
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mmol/L mg/dL 
O 20 40 60 80 100 
Cafestol (mg/day) 
FIGURE 1. Relationship of daily cafestol intake with mean changes in cholesterol (upper 
panel) and triglyceride levels (lower panel) across eleven short-term experiments carried 
out by the Wageningen group ( • ) , and others ( • ) . Responses were adjusted for the mean 
changes in the concurrent control group, if present. Those for cholesterol were 
recalculated to the change after 4 weeks of treatment. Codes refer to treatment groups 
in different studies; A, coffee oil [16]; B, coffee oil enriched in non-triglyceride coffee lipids 
[16]; C, coffee oil depleted in non-triglyceride coffee lipids [16]; D, coffee oil [16]; E, 
mixture of pure diterpene esters [16]; F, mixture of pure diterpene alcohols [21]; G, pure 
cafestol esters [22]; H, pure cafestol plus kahweol esters [22]; I, Robusta oil [17]; J, 
Arabica oil [17]; K, Robusta oil [18]; L, Arabica oil [18]; M and N, coffee grounds [26]; P, 
lipid-rich extract from boiled coffee [15]; Q, cafetière coffee (values measured after 4 
weeks of treatment) [35]. Least square best fit equations were: A Cholesterol (mmol/L) = 
0.015 x cafestol (mg/day), and: A Triglycerides (mmol/L) = 0.009 x cafestol (mg/day). 
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TRIGLYCERIDES. Volunteers given boiled coffee [11-14,25] or preparations rich 
in coffee diterpenes [16-18,21,22,26] showed a marked rise in serum triglycerides. 
Again, cafestol was the major responsible factor; in ten volunteers, cafestol alone 
raised triglycerides by 86%, whereas addition of a similar amount of kahweol to 
the treatment further increased the response by only 7% [22]. 
Our regression analyses of eleven trials produced the same result; 
triglycerides rose by 0.08 mmol/L (7.3 mg/dL) with each 10 mg of cafestol per day 
and by 0.01 mmol/L (1.2 mg/dL) with each 10 mg of kahweol per day for two to 
six weeks (figure 1). However, most of the rise in triglycerides may subside with 
chronic intake of coffee diterpenes (see below). 
LiPOPROTEiN(a). Lipoprotein(a), which consists of an LDL-particle attached to 
apolipoprotein(a),is a risk factor for cardiovascular diseases [27]. Trans fatty acids 
are the only dietary compounds that consistently affect lipoprotein(a) [28-30]. 
Coffee diterpenes also proved effective; in four of the trials done by the 
Wageningen group, each 10 mg of cafestol (plus kahweol) per day reduced serum 
lipoprotein(a) by 0.5 mg/dL or 4% after four weeks (Chapter 7). However, there 
was a marked disparity between short- and long-term intake of diterpenes (see 
below). 
Epidemiologic evidence 
Observational studies in Norway [16,31,32], Finland [33], and Sweden [34] 
that compared chronic users of boiled coffee to those who used filtered coffee 
provide insight into effects of chronic exposure to coffee diterpenes. 
CHOLESTEROL. In the five observational studies, serum cholesterol was raised 
on average by 5% with chronic intake of each five cups of boiled coffee per day. 
Controlled trials with unfiltered coffee yielded an estimate of 6.8% per five cups 
(figure 2). Therefore, the effect as measured in epidemiologic studies may have 
been slightly attenuated by measurement errors. However, a partial return of serum 
cholesterol to baseline values was observed in a long-term experiment with 0.9 liter 
of cafetière coffee per day; serum cholesterol was raised by 10% after three 
months of intake, but the effect was reduced to 6% after six months of intake 
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[35] . Therefore, chronic intake of cafestol permanently raises cholesterol, but trials 
lasting fewer than three months may slightly overestimate the effect. 
TRIGLYCERIDES. Stensvold et al [32] found a negative association between 
intake of boiled coffee and serum triglycerides in Norwegians. An even stronger 
negative trend was observed for fi ltered coffee, leaving a positive net effect of 7 % 
per f ive cups of boiled coffee. A similar difference between boiled- and f i l tered-
coffee drinkers was found by Weusten-van der Wouw et al [16 ] . In control led 
trials, rises in tr iglycerides of up to 2 2 % per f ive cups of boiled or cafetière coffee 
were found (figure 2), which suggests that most of the effect is transient w i th 
chronic intake. Indeed, 0.9 liter of cafetière coffee per day raised triglycerides by 
2 6 % in the f irst month , but the effect had fallen to only 7% after six months of 
intake [35 ] . 
Total cholesterol Triglycerides 
Aro 
Bak 
Aro 
Ahola 
VanDusseldorp 
Urgert 
25' 
12! 
11 
14' 
13' (35)' 
MEAN (95% CI) 
Bdnaa 
Stensvold 
Pietinen 
Lindah I 
Weusten 
(31) 
32 
33 
34 
(16) 
MEAN (95% CI) 
Controlled trials 
Epidemiological studies 
O 2 4 6 8% 0 5 10 15 20 25% 
increase per 5 cups of boiled coffee 
FIGURE 2. Percentage increases in serum cholesterol and triglyceride levels with each five 
cups of boiled or cafetière coffee consumed per day in controlled trials (upper panels), and 
percentage differences with each five cups consumed per day between consumers of 
boiled versus filtered coffee in epidemiologic studies (lower panels). Black bars indicate the 
95% Confidence Interval of the mean response per five cups. 
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LiPOPROTEiN(a). Only one epidemiologic study has examined the effect of 
coffee type on serum lipoprotein(a); in 150 Norwegian boiled-coffee drinkers, the 
median level of lipoprotein(a) was 65% higher than in 159 matched filtered coffee 
drinkers [36]. This contradicts the lipoprotein(a)-reducing capacity of diterpenes 
observed in clinical trials. Although a chance finding cannot be excluded, it may 
imply that coffee diterpenes only reduce lipoprotein(a) levels in the short run. 
In summary, most of the rises in total and LDL cholesterol caused by coffee 
diterpenes persist with chronic intake, whereas most of the rise in triglycerides 
subsides. Coffee diterpenes reduce serum lipoprotein(a) in the first months of 
intake only. These observations have implications for experiments on the 
relationship between diet and lipoproteins in general; caution is needed in 
extrapolating results from studies lasting weeks or even months to chronic intakes, 
and corroborative evidence should always be sought in long-term trials or 
epidemiologic observations. 
HUMANS ARE MORE SENSITIVE TO COFFEE DITERPENES THAN ANIMALS 
The mechanism by which coffee diterpenes affect lipid metabolism is largely 
unknown. The group of Drevon in Norway studied the involvement of the LDL 
receptor, which is located on cell membranes and is responsible for the removal of 
LDL cholesterol from the bloodstream. Cafestol indeed decreased the uptake of LDL 
cholesterol into human fibroblasts [37] and hepatoma cells [38], but raised it in an 
intestinal cell line [39]. More studies are needed to clarify this discrepancy. 
The effects of cafestol and kahweol seem to be unique to Homo sapiens 
(figure 3). The same batch of coffee oil that raised cholesterol in humans [16] 
produced no effect in Cebus or Rhesus monkeys in two different laboratories [40] 
(figure 3). Sanders & Sandaradura [41] did report that Syrian hamsters responded 
to boiled coffee, but an attempt to replicate this was unsuccessful [42], as were 
other studies with hamsters [43,44]. Diterpenes raised cholesterol in only one [45] 
out of three [42,45,46] studies with Wistar rats, and no effect was found in gerbils 
[43] or rabbits [47]. The absence of effect could not be explained by differences 
in dosage, mode of administration, treatment duration, or cholesterol content of the 
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b a c k g r o u n d d ie t . One m a y s p e c u l a t e t h a t d i f f e r e n c e s in a b s o r p t i o n or m e t a b o l i s m 
o f c o f f e e d i t e r p e n e s a c c o u n t f o r t h i s m a r k e d spec ies s p e c i f i c i t y . T h e n e g a t i v e 
resu l t s in a r ange o f an ima l spec ies emphas i ze t h e need t o re ly o n h u m a n d a t a . 
Author Treatment Dose Effect ± 95% CI 
Man-
Terpstra (40) Oil 5.1 
Oil 5.7 
MEAN of 2 5.4 
MEAN of 11 Various 0.8 
Sanders (41) Coffee 2.6* 
Mensink (43) Coffee 6.2 
Ratnayake (44) Oil 5.2 
NSM 3.6 
C + K 4.0 
Oil 2 1 * 
NSM 14* 
C + K 16* 
Beynen (42) Coffee 6.5 
Coffee 6.5* 
MEAN of 10 8.6 
H0stmark (46) Coffee 2.0 
Al-Kanhal (45) Coffee 3.5 
Coffee 3.5* 
Beynen (42) Coffee 1.5 
Coffee 1.5* 
MEAN of 5 2.4 
- 2 - 1 0 1 2 
Change in cholesterol (mmol/L) 
FIGURE 3 . Comparison of the e f fec t of cafestol in man w i t h tha t in various animal species. 
Bars represent the 9 5 % Confidence Intervals of the t rea tment e f fec ts . Treatment periods 
varied f r om 4 t o 2 0 w e e k s ; oil = cof fee o i l ; cof fee = boiled co f fee ; NSM = non-
tr ig lycer ide lipid f ract ion f rom cof fee beans; C + K = purif ied cafesto l and kahweo l . Dose 
is expressed as mg per day of cafestol per kg of body we igh t , and high fa t or high 
cholesterol background diets are indicated by ' * ' . The value for man represents the overall 
mean change in cholesterol in eleven experiments in wh i ch preparations of k n o w n 
diterpene conten t were given (cf Figure 1 ). 
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THE LIVER IS THE TARGET ORGAN FOR COFFEE DITERPENES 
Intake of coffee diterpenes [16,17,26] or unfiltered coffee [1 6,35] raised the 
serum activity of alanine aminotransferase (ALT, formerly SGPT) in volunteers. In 
a pooled analysis of 147 volunteers who received diterpenes in our own trials, each 
10 mg of cafestol or kahweol per day raised alanine aminotransferase by 2 to 3 
U/L, or 8 to 12% (Chapter 9). Aspartate aminotransferase (AST, formerly SGOT) 
usually also rose, but less [16,17,22,26,35]. 
A rise of liver enzyme activity in serum may indicate injury to hepatocytes 
[48]. This is not due to cholestasis, as coffee diterpenes reduce rather than raise 
the serum activity of K_g'utamyltransferase and alkaline phosphatase 
[16,22,26,35]. It is unlikely that a perturbation of liver cell function explains the 
effects of coffee diterpenes on blood lipids, because both cafestol and kahweol 
raise aminotransferases, but kahweol has little effect on blood lipids [22]. 
DlTERPENE LEVELS IN COMMERCIAL ROAST AND GROUND COFFEES 
The main commercial species of coffee are arabica and robusta coffee. 
Robustas contain no kahweol and less cafestol than arabicas [20]; intake levels of 
diterpenes may thus be reduced by increasing the proportion of robustas in coffee 
blends. However, in the US and western Europe consumers prefer the taste of 
arabicas [5]. As a result, diterpene levels in commercial roast and ground coffees 
in these countries are fairly constant at 400 to 500 mg each of cafestol and 
kahweol per 100 g of grounds [23]. Diterpene levels in coffee beans are not 
affected by decaffeination, and are affected little by roasting [23,49]. 
In addition to cafestol, robustas also contain some 16-O-methylcafestol [50]; 
the effects of this diterpene in man are unknown. Its levels are negligible in blends 
with a high proportion of arabicas [23], and five cups of unfiltered coffee brewed 
with pure robusta grounds will provide only 2 to 3 mg of 16-O-methylcafestol. This 
is probably too low to substantially affect blood lipids. 
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DlTERPENE LEVELS IN COFFEE DEPEND ON BREWING TECHNIQUE 
Extraction of diterpenes into coffee brew 
About 10% of the diterpenes present in the grounds used to make unfiltered 
coffee ends up in the brew, either in oil droplets or in small bean particles [26]. In 
volunteers who consumed oily solutions of diterpenes, recovery of coffee 
diterpenes from faeces was about 5%, compared with 25% in subjects who 
consumed coffee grounds [51]. This suggested that most of the diterpenes 
ingested from the grounds are absorbed. Indeed, intake of 8 g dry weight of coffee 
grounds containing 39 to 55 mg of each diterpene per day for three weeks raised 
serum cholesterol by 0.65 mmol/L in volunteers [26]. Diterpene analyses of coffee 
brews should thus include the contribution of grounds floating in the brew. In 
addition, frequent ingestion of coffee beans or of grounds with turbid coffee brews 
should be avoided. 
Brews with low levels of diterpenes 
FILTERED COFFEE. Diterpenes do not pass through a paper filter (table 2), 
which explains why controlled trials have shown no impact of filtered coffee on 
blood lipids [12-14,52]. Fried et al [53] found that 720 mL of filtered coffee per 
day did raise serum cholesterol by 0.25 mmol/L after four weeks, relative to no 
coffee. However, no rise was seen in the groups drinking 360 mL of regular coffee 
per day, or 720 mL of decaffeinated coffee. Therefore, the effect seen might be 
due to chance. 
INSTANT COFFEE. Instant (or soluble) coffee is consumed world-wide [5]. It is 
almost devoid of cafestol and kahweol (table 2). Burr et al [54] found that five 
cups of instant coffee per day raised serum cholesterol by 0.12 mmol/L in 
volunteers. No rise was observed in other trials of instant coffee [55-58], and its 
effect on blood lipids -- if any - should be small. 
PERCOLATED COFFEE. Percolated coffee was popular in the US until a decade 
ago. Although boiled and unfiltered, it is poor in diterpenes (table 2). In the 
percolator pot, the brew is constantly recirculated through a bed of grounds, which 
likely functions as a filter cake retaining the lipids. Whatever the mechanism, 
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predicted effects of percolated coffee on blood lipids are minimal, although this has 
not yet been verif ied in human experiments. 
TABLE 2. Reported levels of coffee diterpenes in various coffee brews, and the estimated 
effect on serum cholesterol of consumption of five cups of coffee per day". 
Coffee type 
Paper-filtered 
Instant 
Percolator 
Mocha 
Espresso 
Cafetière 
Turkish 
Boiled 
Ratnayake 
et al [66] 
C o r Kc 
mg/cup 
0.1 
0.1 
--
--
3.6 
1.6 
3.4 
8.4 
Urgert et 
[23] 
c 
al 
K 
mg/cup 
0.1 
0.2 
0.3 
1.1 
1.5 
3.5 
3.9 
3.0 
0.1 
0.2 
0.3 
1.4 
1.8 
4.4 
3.9 
3.9 
Gross 
C 
m 
<0 .1 
0.2 
--
2.3 
1.0 
--
5.3 
7.2 
et al [24] 
g/cup 
K 
<0 .1 
0.2 
-
2.3 
1.0 
--
5.4 
7.2 
MEAN 
c 
mg/cuf. 
0.1 
0.2 
0.3 
1.7 
2.0 
2.6 
4.2 
6.2 
K 
0.1 
0.2 
0.3 
1.9 
2.1 
3.0 
4.2 
6.5 
Effect on serum 
cholesterol wi th 
five cups/dayb 
mmol/L 
< 0 . 0 1 
0.02 
0.02 
0.13 
0.15 
0.20 
0.32 
0.47 
s
 Cup sizes are 1 50 mL for filtered, instant, cafetière, and boiled coffees, 60 mL for Turkish and mocha 
coffees, and 25 mL for espresso coffees 
b
 Estimations are based on the assumption that each 10 mg/day of cafestol consumed raises cholesterol by 
0.13 mmol/L, and each 10 mg/day of kahweol raises it by 0.02 mmol/L (cf Figure 2) 
c
 Ratnayake et al [66] reported total diterpene content; values are calculated assuming that levels of kahweol 
and cafestol were equal 
Brews with moderate levels of diterpenes 
M O C H A COFFEE. Mocha coffee is common in Italy and Spain [5 ] . Based on 
diterpene contents, each five cups of mocha per day should raise serum cholesterol 
by 0.13 mmol/L (5.4 mg/dL) (table 2, f igure 1). Observational studies in Italy 
[59-61] and Spain [62] are compatible wi th a cholesterol-raising effect of mocha, 
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but experiments [63-65] have failed to conf i rm this. These studies may have 
suffered f rom insufficient power, due to short treatment periods [63] and low 
dosages [64 ,65 ] . However, a major lipid-raising effect of mocha coffee 
consumpt ion appears excluded. 
ESPRESSO COFFEE. The concentration of diterpenes per 100 mL of espresso 
is high [23 ,66 ] . However, in Italy, espresso coffee is served in quantit ies as small 
as 25 mL [67 ] , and absolute levels per cup are moderate (table 2). D'Amicis et al 
[65] found that three cups of espresso per day non-significantly raised total 
cholesterol by 0 .10 mmol/L and LDL cholesterol by 0.15 mmol/L, relative to tea. 
This is consistent w i th a moderate effect of espresso on serum cholesterol. 
Espresso coffees sampled in Italy provided more cafestol per cup than those 
f rom other countries [23 ] . This is partly explained by the ratio of grounds to water, 
which is highest in Italian espresso and is a major determinant of diterpene levels 
in unfi ltered coffee [23] . In v iew of the increasing popularity of espresso wor ld-
wide [10 ] , future studies should address other factors that may affect diterpene 
levels, such as brewing device, contact t ime of steam wi th grounds, and mesh 
width of the filter grid. 
Brews with high levels of diterpenes 
CAFETIÈRE COFFEE. Cafetière coffee - known as French press coffee in the US 
- is fairly uncommon, though its popularity is increasing [10] . Based on its 
diterpene content, f ive cups per day are estimated to raise serum cholesterol by 
0 .13 to 0.27 mmol/L (table 2, figure 1), The cholesterol-raising potential of 
cafetière coffee was confirmed in a controlled tr ial ; 0.9 liter of strong cafetière 
coffee per day raised cholesterol by up to 0 .52 mmol/L [35 ] . 
TURKISH COFFEE. Turkish coffee is consumed in Greece, the former 
Yugoslavia, Turkey, and the Middle-East including Israel ( "mud" coffee), and by 
Muslims in various countries. Five cups provide 21 mg of each diterpene, wh ich 
w i th daily consumption wil l raise serum cholesterol by 0.32 mmol/L (13 mg/dL) 
(table 2, f igure 1). However, diterpene levels f luctuate strongly w i th the amount 
of grounds f loating in the brew, and levels of up to 50 mg of each diterpene per 
f ive cups have been reported [23] . Studies in Israel [68-70] and in Serbia [71] have 
indeed shown an association of cholesterol w i th coffee intake, but the effects of 
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Turkish coffee have not yet been examined experimentally. Its diterpene content 
suggest that it may be as least as effective in raising cholesterol as is boiled 
coffee. 
BOILED COFFEE. Differences in the ratio of coffee grounds used per liter of 
water may explain the large differences in reported diterpene levels of Scandinavian 
boiled coffee (table 2). On average, five cups per day are estimated to raise 
cholesterol levels by 0.47 mmol/L; this is in agreement with results of experimental 
[11-14,25,72] and epidemiologic studies [16,31-34]. 
Decaffeinated coffee brews 
Superko et al [52] found in a large trial that decaffeinated filtered coffee 
raised LDL cholesterol by 0.23 mmol/L compared with regular coffee. Diterpene 
levels of beans are unaffected by decaffeination [23,49]. Therefore, to explain the 
effect of decaffeinated filtered coffee as seen by Superko et al [52], one has to 
assume that besides diterpenes there is a second cholesterol-raising factor in 
coffee beans, which is somehow introduced or activated by decaffeination, and 
which passes through a paper filter. We find this unlikely, especially in view of the 
negative results of other trials of decaffeinated filtered coffee [53,73,74]. For lack 
of a better explanation we ascribe the finding of Superko et al [52] to chance, 
though the large number of subjects argues against that. 
PUBLIC HEALTH CONSIDERATIONS 
Risk of coronary heart disease 
Filtered, instant, and percolated coffee contain negligible levels of diterpenes 
(table 2). The switch from percolated to filtered coffee in the US thus appears not 
to have contributed to the fall in cholesterol levels over the last decades [75]. The 
low intake of brews other than filtered and instant coffee in western Europe also 
excludes a major association with blood lipids in these countries. Little is known 
about effects of coffee or caffeine intake on other risk factors for cardiovascular 
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diseases, such as oxidisability of LDL particles, vascular proliferation, or 
thrombosis. However, prospective cohort studies from the US and western Europe 
mostly failed to find a link between coffee intake and cardiovascular disease 
[76-78], and a major effect of filtered, percolated, and instant coffee seems 
unlikely. 
In the US, about 15% of coffee consumed is decaffeinated [5], and those 
who use decaffeinated coffee often do so because of health concerns [79,80]. In 
a study of 46,000 health professionals in the United States, Grobbee et al [81] 
actually found a 63% higher risk of coronary mortality in consumers of 
decaffeinated coffee compared with coffee abstainers. As this association was not 
seen in a cohort of 86,000 US women studied by Willett et al [82], there is no 
consistent evidence that filtered decaffeinated coffee raises coronary risk. 
However, there is no evidence for a protective effect either; the major proven 
benefit of decaffeinated coffee is that it does not interfere with falling asleep. 
Boiled coffee used to be the dominant type in Scandinavia, but nowadays 
more than three-quarters of Scandinavians use filtered coffee. This switch in 
brewing practices is thought to explain one-third [83] to one-half [2] of the 10% 
fall in serum cholesterol in Scandinavia since 1970, and to have contributed 
significantly to the concurrent fall in coronary mortality [84,85]. This was 
supported by results of the National Health Screening Service in Norway, which 
examined a population largely consisting of boiled-coffee drinkers. Over the period 
from 1980 to 1986, a relative risk for coronary mortality of 3.3 was found in 
heavy coffee drinkers versus abstainers [86]. The risk was reduced to 1.4 after six 
more years of follow-up [87], which may be due to a change in brewing practices. 
Thus, experimental and epidemiologic studies both suggest that a high intake of 
boiled coffee raises the risk of dying from coronary heart disease. 
No prospective studies have examined the effects of other unfiltered brews. 
Because of their moderate amounts of cafestol and kahweol, mocha and espresso 
coffee appear harmless with consumption of a few cups per day. Turkish and 
cafetière coffee are rich in diterpenes, and a recommendation to limit their use in 
favour of filtered or instant coffee seems justified in patients with a high 
cholesterol level or an increased coronary risk. 
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Risk of liver disease 
Could the perturbation of liver cells by diterpene ingestion as suggested by 
rises in serum alanine aminotransferase activity affect hepatic health in consumers 
of unfiltered coffee? Alanine aminotransferase activity remained raised during half 
a year of daily intake of cafetière coffee [35], but it was not raised in life-long 
consumers of boiled [16] or espresso coffee [88]. Mortality rates of liver cirrhosis 
have been typically low in Scandinavian countries and appear to have been 
unaffected by the nation-wide switch to filtered coffee [89]. Also, habitual coffee 
drinkers have lower serum p-glutamyltransferase levels than non-drinkers have 
[88,90-93] - a finding that might have a bearing on the association of coffee use 
with a reduction in the risk of alcoholic liver cirrhosis [94,95]. The negative 
relationship with p-glutamyltransferase was stronger for boiled than for filtered 
coffee [92]. Therefore, clinically relevant damage to liver cells in healthy subjects 
drinking unfiltered coffee appears unlikely. However, subclinical hepatic injury 
cannot be excluded at the present time, and patients with elevated alanine 
aminotransferase levels would do well not to drink more than a few cups of boiled, 
Turkish, or cafetière coffee per day. 
CONCLUSIONS 
Coffee beans and some types of coffee brew -- though not filtered or instant 
coffee - contain the diterpenes cafestol and kahweol. They are not removed by 
decaffeination. Cafestol, and to a lesser extent kahweol, raises serum total and 
LDL cholesterol in humans. Patients at increased risk of heart disease should thus 
be advised to select brews low in diterpenes. Triglycerides also rise with cafestol 
intake, but the effect could be transient with chronic intake. Both cafestol and 
kahweol appear to affect the integrity of liver cells, as suggested by a modest rise 
of alanine aminotransferase activity in serum. All effects are reversible after 
withdrawal of the diterpenes. 
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CHAPTER 9 
In the general introduction (Chapter 1 ), the objective of the studies described 
in the present thesis was subdivided into five research questions. This chapter 
gives the answers to these questions, recommendations for further research, and 
the main conclusions. 
Cafestol and kahweol are available from coffee grounds 
Intake of coffee grounds strongly raised serum levels of lipids and alanine 
aminotransferase (Chapter 2). The rises were similar to those observed with the 
same amount of diterpenes in oils (Chapter 8). Up to 90 percent of diterpenes in 
unfiltered coffee may be carried by floating grounds; these will thus contribute 
substantially to the hyperlipidaemic and hepatocellular effects of unfiltered coffee. 
The brewing method is a main determinant of diterpene content 
Diterpene contents differed strongly between coffee types; boiled, cafetière, 
and Turkish coffee contained 3 to 4 mg, mocha and espresso coffee 1 to 2 mg, 
and filtered, percolated, and instant coffee less than 0.2 mg of cafestol or kahweol 
per cup. Diterpene contents also varied 'within' a particular type of coffee; ten-fold 
differences between samples were found for Turkish, boiled, and espresso coffee. 
Analyses in coffee prepared under laboratory conditions showed that for espresso 
and boiled coffee most of the variation could be ascribed to the amount of grounds 
used per litre of water, whereas amounts in Turkish coffee strongly depended on 
the amount of floating grounds in the brew. Effects of brewing time were minimal. 
Diterpene contents in beans were not affected by roasting or decaffeination. 
Cafestol is more hyperlipidaemic than kahweol, 
but both raise alanine aminotransferase levels 
In a cross-over study with ten volunteers, intake of cafestol alone strongly 
raised serum levels of lipids and of alanine aminotransferase. Addition of kahweol 
to the supplement had little effect on serum lipids, but doubled the responses in 
aminotransferases (Chapter 4). The study involved only men so as to exclude 
possible variation due to gender. However, a meta-analysis of eleven human trials, 
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most of which also included females, confirmed a higher lipid-raising capacity of 
cafestol (Chapter 8). Consequently, our conclusion that cafestol is the prime 
cholesterol-raising factor in unfiltered coffee probably applies to both sexes. Both 
cafestol and kahweol increased serum liver aminotransferases, which indicates that 
lipid metabolism and liver cell integrity may be affected by coffee diterpenes 
through different pathways. 
Prolonged intake of coffee diterpenes persistently raises 
serum levels of alanine aminotransferase 
Volunteers who had consumed five to six cups of strong cafetière coffee per 
day for half a year had higher serum levels of alanine aminotransferase than those 
who had consumed filtered coffee (Chapter 5). Chronic consumers of unfiltered 
coffee did not have elevated levels of alanine aminotransferase [1,2]. We cannot 
exclude that a longer intake is needed to allow alanine aminotransferase levels to 
return to baseline values. Cafetière coffee also raised serum lipids; after half a year 
of intake, levels of total and LDL cholesterol were still raised, but the rise in 
triglycerides had almost disappeared (Chapter 5). The lipidaemic effects agree with 
those observed in epidemiological studies of consumers of boiled versus filtered 
coffee (Chapter 8). 
We prescribed strong coffee; each 150 mL cup of cafetière coffee provided 
6 mg of cafestol. Cafetière coffee sampled from consumers at large provided about 
half this amount per cup (Chapter 2). The linear relation between cafestol and 
changes in lipid levels (Chapter 8) implies that the expected effects with such 
moderately strong brews are about half the effects observed in this study. 
Coffee diterpenes affect levels of lipoprotein(a) 
Norwegians with a chronic high intake of boiled coffee had higher serum 
lipoprotein(a) levels than peers drinking filtered coffee (Chapter 6). However, intake 
of preparations rich in coffee diterpenes reduced Lp(a) levels in four different 
experiments in volunteers who were not accustomed to drinking unfiltered coffee 
(Chapter 7). We could not offer a likely explanation for the divergence between 
short and long term exposure to coffee diterpenes. 
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HETEROGENEITY AND MAGNITUDE OF THE RESPONSES 
Nine human trials wi th preparations rich in coffee diterpenes, including those 
described in this thesis, were done at our department between 1990 and 1996. 
The trials involved 147 subjects who received preparations rich in diterpenes and 
78 control subjects. We pooled their individual responses to obtain more insight 
into the heterogeneity and the magnitude of the effects. 
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FIGURE 1. Individual responses from baseline in serum levels of total cholesterol, 
triglycerides, and alanine aminotransferase in volunteers receiving placebo or no treatment 
(control subjects, n = 78) or volunteers receiving supplements containing 22-85 mg/day of 
cafestol and 0-103 mg/day of kahweol (treatment subjects, n= 147) in any of the nine 
experiments carried out at our department. 
142 
CONCLUDING REMARKS 
Blood lipids and lipoproteins 
Levels of total cholesterol rose in 142 and triglycerides in 141 of the 147 
subjects who received diterpenes in any of the trials (figure 1). Thus, the vast 
majority of subjects were susceptible to the impact of coffee diterpenes on lipid 
metabol ism. We also calculated the responses standardised for the cafestol dose; 
each 10 mg of cafestol ingested per day for four weeks raised total cholesterol by 
0.17 mmol/L and triglycerides by 0.11 mmol/L (figure 2). Gender appeared to 
explain some of the variation in responses; responses of males (n = 85) were higher 
than those of females (n = 62) by 16 percent for total cholesterol, 30 percent for 
LDL cholesterol, and 20 percent for triglycerides (unpublished observations). 
About 75 percent of the rise in total cholesterol is due to a rise in LDL 
cholesterol (figure 2). The effect is substantial; each 10 mg of cafestol per day 
raises LDL cholesterol similar to an increase in intake of about 12 g per day of 
saturated [3] or trans fat ty acids (Peter Zock, personal communicat ion). The effect 
on LDL cholesterol persists wi th chronic intake of cafestol (Chapters 5 and 8), and 
is the principal reason for coffee consumers w i th a high risk of coronary heart 
disease to restrict their intake of unfiltered coffee. 
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FIGURE 2. Effects of each 10 mg per day of cafestol (plus kahweol) ingested from different 
types of coffee for four weeks on serum lipids and lipoproteins, alanine (ALT) and 
aspartate aminotransferase (AST), vglutamyltransferase (GGT), and alkaline phosphatase 
(AP). The estimates are based on diterpene analyses in coffee brews (Chapter 2), and the 
mean responses (95% confidence interval) in 147 volunteers receiving preparations rich 
in diterpenes in any of the nine experiments carried out at our department. The value for 
Lp(a) represents the median change in 63 subjects (Chapter 7). 
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The remainder of the rise in total cholesterol levels is due to a rise in VLDL-
cholesterol, as indicated by the increase in triglyceride levels (figure 2). As most 
of this effect appeared transitory (Chapters 5 and 8), the impact of drinking 
unfiltered coffee on triglyceride levels is of minor importance for atherogenic risk. 
The remarkable impact of cafestol on lipid metabolism is emphasised by their 
effect on serum levels of lipoprotein(a); each 10 mg per day of cafestol reduced 
Lp(a) levels by 0.5 mg/dL or four percent from baseline levels. Due to the 
unfavourable effects of diterpenes on LDL cholesterol and alanine aminotransferase 
levels and the attenuation of the effect on Lp(a) levels in the long run, advising 
individuals with high Lp(a) levels to drink unfiltered coffee is not warranted. 
Blood liver enzymes 
The effects of coffee diterpenes on the liver were evaluated by their effects 
on four enzymes: alanine and aspartate aminotransferase, K-g'utamyltransferase, 
and alkaline phosphatase. Most notable were changes in alanine aminotransferase; 
diterpene treatment raised alanine aminotransferase level in 137 of 147 subjects 
(figure 1 ). Again, there was a striking effect of gender; responses were 64 percent 
higher in males than in females (unpublished observations). 
The rise in alanine aminotransferase persisted during half a year of 
consumption of unfiltered coffee (Chapter 5). However, the changes are not 
dramatic; each 10 mg of cafestol plus kahweol raises alanine aminotransferase 
similarly to an increase in daily alcohol intake of about 3 drinks, or in body mass 
index of about 1 kg/m2 [4]. The changes in other liver enzymes are probably 
negligible (figure 2), and, as was true of alanine aminotransferase, all changes were 
reversible after cessation of diterpene intake. It is therefore most unlikely that 
intake of coffee diterpenes causes chronic damage to liver cells or an impairment 
of liver function. However, the mechanism by which coffee diterpenes raise alanine 
aminotransferase levels is unknown. Subclinical injury to hepatocytes, such as 
small-scale fatty infiltration of the liver or slightly increased breakage of liver cell 
membranes, cannot be excluded; the large differences in individual susceptibility 
suggests that if these processes occur, they may be less innocuous in some 
individuals. Therefore, subjects with raised alanine aminotransferase levels might 
also do well to restrict their intake of unfiltered coffee. 
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gone unrecognised. 
Changes in synthesis or clearance of lipoproteins by the liver are likely 
explanations for the impact of cafestol on lipid metabolism [23]. None of the 
animals tested so far responded to coffee diterpenes, but it may prove worthwhile 
to test animals in which essential genes for cholesterol metabolism have been 
modified. One experiment in humans indicated that serum lathosterol levels which 
are an indicator of cholesterol synthesis, were not markedly raised by boiled coffee 
[24]. Such findings are not definitive, and should be corroborated by turnover 
studies with labelled cholesterol precursors or labelled lipoproteins. 
We recently found that cafestol and kahweol raise the serum activity of 
cholesterylestertransfer protein (unpublished observations). This enzyme catalyses 
the transfer of cholesterylesters from HDL to particles with lower density (LDL and 
VLDL), and increased activity is thus consistent with the changes in lipid levels 
caused by cafestol. However, it is not clear whether a rise in cholesterylester 
transfer protein is a cause or a consequence of rises in LDL and VLDL cholesterol 
[25]. More research is needed to clarify the relevance of these findings. 
Finally, lipidaemic effects caused by treatment with androgenic or other 
steroids partly resemble those caused by cafestol [26]. Steroid treatment also 
reduces Lp(a) levels [27], and may affect liver cells [28]. It is of interest to study 
whether cafestol exerts its action through pathways related to steroid metabolism 
in humans, and whether this could be related to its stronger effects in men than 
in women. 
Epidemiological studies 
Observational studies in heavy consumers of unfiltered coffee might help 
to explain some of the discrepancies in effects of short-term versus chronic intake 
of coffee diterpenes, notably those on alanine aminotransferase and lipoprotein(a). 
In epidemiological studies that address lipidaemic effects of diet in general, the 
method of coffee brewing should be recorded and, if possible, also cup size and 
brewing strength should be taken into account. In the Netherlands, this may 
particularly be meaningful if the study population includes a fair number of 
consumers who drink most of their coffee in retail outlets (where a substantial part 
of the coffee served is a type of espresso), or of Muslim immigrants. 
146 
CONCLUDING REMARKS 
Experimental studies 
Experiments should focus on factors that may explain the heterogeneity of 
responses in lipids and liver enzymes, such as sex or genotype (e.g. for genes 
encoding for apolipoproteins or lipid transfer enzymes). The use of milk in coffee 
is also of interest; cafetière-coffee drinkers (Chapter 5) who used milk had larger 
increases in serum lipids and alanine aminotransferase than those who consumed 
black coffee (unpublished observations). This hypothesis needs to be tested 
specifically in an experiment. 
A biochemical marker for cafestol intake may be useful, both for experiments 
(to monitor compliance) and for epidemiological studies (to measure exposure). 
Measurement of cafestol conjugates in urine proved modestly successful [29], and 
more attempts to measure cafestol in serum should be undertaken. 
Analytical studies 
Due to the large variation in diterpene content in different samples of the 
same type of coffee, more insight is needed into factors that determine intake 
levels of diterpenes with unfiltered brews that are consumed by large populations. 
This recommendation particularly holds for Turkish coffee (e.g. study of the actual 
amount of particles that is consumed with the brew), and espresso coffee (e.g. 
examination of the influence of brewing characteristics, such as steam pressure 
and mesh width of the filter grid). 
CONCLUSIONS AND IMPLICATIONS 
Daily intake of the coffee diterpene cafestol and -- to a lesser extent - of 
kahweol strongly and persistently raises blood levels of total and LDL cholesterol. 
Cafestol occurs in high amounts in boiled, Turkish, and cafetière coffee, and in 
moderate amounts in espresso and mocha coffee; a chronic high intake of these 
types of coffee will increase the risk of coronary heart disease. Amounts of 
cafestol in filtered and instant coffee are too low to affect blood levels of LDL cholesterol. 
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summary 
Consumption of Scandinavian boiled coffee -- prepared by boiling coarsely 
ground coffee beans in water and decanting the fluid without the use of a filter -
increases the blood concentration of low-density lipoprotein cholesterol and 
triglycerides in humans. The disturbance of lipid metabolism is attributable to the 
diterpenes cafestol and kahweol, which are natural constituents of coffee beans. 
Cafestol en kahweol do not pass through a paper filter, which explains why regular 
drip-filtered coffee does not affect blood lipids and lipoproteins. Coffee diterpenes 
also raise the blood concentration of alanine aminotransferase. This enzyme occurs 
in high concentrations in the liver, from where it leaks in small amounts into the 
bloodstream. Elevations of alanine aminotransferase in the bloodstream may thus 
point at a disturbed integrity of liver cells. It is unknown whether the effects of 
cafestol and kahweol on lipid metabolism are related to their effects on liver cell 
metabolism. 
The objective of the present thesis was to further specify the effects of 
drinking unfiltered coffee on health. In our studies, we focused on determinants of 
diterpene concentrations in coffee prepared with various brewing techniques, and 
on effects of cafestol and kahweol on blood concentrations of lipids and liver 
enzymes in humans. 
In unfiltered coffee brews, diterpenes are present in oil droplets and in 
floating bean particles or 'grounds'. The latter may carry up to 90 percent of the 
diterpenes in so-called 'turbid' coffee brews, such as Turkish or Middle-Eastern 
coffee. Coffee diterpenes raise cholesterol concentrations when they are consumed 
dissolved in oil, but their availability from grounds was unknown. We fed coffee 
grounds to volunteers in two separate experiments, and observed marked rises in 
blood concentrations of lipids and alanine aminotransferase. We concluded that 
floating grounds contribute significantly to the effects of unfiltered coffee on blood 
lipid and liver-enzyme concentrations. Therefore, frequent ingestion of floating bean 
particles or of coffee beans should be avoided (CHAPTER 2). 
151 
SUMMARY 
Many studies had shown that life-long consumers of boiled coffee have 
raised blood concentrations of cholesterol. However, one study showed that 
Norwegians who were life-long consumers of boiled coffee did not have higher 
alanine aminotransferase concentrations than matched filter coffee drinkers. A 
possible explanation is that alanine aminotransferase concentrations return to 
baseline concentrations with prolonged intake of cafestol and kahweol. We 
examined this hypothesis in a randomised trial with 46 volunteers drinking 0.9 litre 
of either cafetière or filtered coffee for 24 weeks. Cafetière coffee raised alanine 
aminotransferase by up to 80 percent over baseline relative to filtered coffee. After 
six months of treatment, the rise was still 45 percent. The effect thus did not fully 
subside with prolonged intake of cafetière coffee. In one out of three subjects 
drinking cafetière coffee, alanine aminotransferase concentrations exceeded the 
upper limit of normal, and in one out of seven subjects, concentrations exceeded 
twice the upper limit of normal; high intakes of coffee brews rich in cafestol and 
kahweol may therefore be responsible for unexplained elevations of this enzyme 
in apparently healthy individuals. Patients with (a history of) liver disease or 
patients with otherwise elevated concentrations of alanine aminotransferase might 
do well in limiting their intake of coffee rich in diterpenes. Cafetière coffee also 
strongly raised the blood concentrations of total and low-density lipoprotein 
cholesterol, and those of triglycerides; most of the rises in total and low-density 
lipoprotein cholesterol persisted, but most of the rise in triglycerides was transitory 
within the treatment period of six months (CHAPTER 5). 
We also studied the effects of unfiltered coffee and of supplements rich in 
coffee diterpenes on blood concentrations of lipoprotein(a), which is a risk indicator 
of cardiovascular diseases. The lipoprotein(a) particle consists of a low-density 
lipoprotein particle attached to a large glycoprotein, but despite the structural 
similarity between lipoprotein(a) and low-density lipoprotein, lipoprotein(a) 
concentrations are highly insensitive to dietary influences. We found in an 
observational study that the median concentration of blood lipoprotein(a) in 150 
Norwegians habitually consuming boiled coffee was 65 percent higher than in 1 59 
peers drinking filter coffee (CHAPTER 6). However, in four trials with preparations 
rich in cafestol and kahweol, each 10 mg/day of cafestol ingested for four weeks 
actually reduced lipoprotein(a) concentrations by four percent from baseline values 
(CHAPTER 7). Coffee diterpenes are thus among the few dietary components known 
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to affect blood lipoprotein(a) concentrat ions. We can as yet offer no likely 
explanation for the discrepancy between the effects wi th short-term versus chronic 
intake. The reducing effect on lipoprotein(a) was diminished, but not reversed, 
wi th in half a year of consumption of cafetière coffee. Obviously, short- term 
treatment w i th coffee diterpenes in individuals w i th high lipoprotein(a) 
concentrat ions is not warranted: any potential benefit of a reduction of 
lipoprotein(a) concentrat ions by cafestol and kahweol is overshadowed by their 
effects on total and low-density l ipoprotein cholesterol. 
Persistent effects of coffee diterpenes on lipid metabolism thus appear to be 
confined to increases in total and low-density lipoprotein cholesterol. In a meta-
analysis of eleven human trials wi th supplements rich in coffee diterpenes, we 
found that each 10 mg of cafestol (plus kahweol) per day predicts a rise in blood 
cholesterol concentrat ions of 0.15 mmo l /L Coupled to our analyses of diterpenes 
in coffee brews as described in Chapter 2, this prediction implies that chronic 
intake of f ive cups per day of boiled, Turkish, or cafetière coffee wil l raise blood 
cholesterol 0 .22 to 0.29 mmol/L, and five cups of mocha and espresso wil l raise 
blood cholesterol by 0.08 to 0.11 mmol/L. Effects of f i l tered, instant, and 
percolated coffee on cholesterol concentrations are negligible (CHAPTER 8). 
In conclusion, daily consumption of brews rich in cafestol -- boiled, cafetière, 
and Turkish coffee, and to a lesser extent also espresso and mocha coffee -
increases the risk of coronary heart disease due to a persistent increase in the 
blood concentrat ion of low-density lipoprotein cholesterol. Prolonged intake of large 
amounts of unfiltered coffee also modestly raises alanine aminotransferase 
concentrat ions. Patients w i th an increased risk of heart disease or w i th an elevated 
concentrat ion of alanine aminotransferase should be advised to select brews low 
in cafestol - f i l tered, instant, and percolated coffee. 
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samenvatting 
'Gekookte' koffie wordt gezet door koffiemaalsel op te koken met water en 
het brouwsel af te gieten zonder te filtreren. Deze koffiedrank was tot voor kort 
geliefd in Scandinavische landen. Mensen die gekookte koffie drinken hebben een 
verhoogd bloedgehalte van cholesterol en van triglyceriden. Beide bloedlipiden 
verhogen het risico op het krijgen van hartziekten. De stoffen uit gekookte koffie 
die verantwoordelijk zijn, zijn de diterpenen cafestol en kahweol. Ze zitten van 
nature in koffiebonen, en komen bij het koffiezetten in de drank terecht. Een 
papieren filter houdt de koffiediterpenen tegen, en daarom verhoogt filterkoffie het 
bloedlipidengehalte niet. Hoe cafestol en kahweol de bloedlipiden verhogen is niet 
bekend. Misschien speelt de lever een rol: cafestol en kahweol verhogen het 
gehalte van het enzym alanine aminotransferase in het bloed. Dit kan duiden op^en 
ongunstig effect op levercellen. 
De gezondheidseffecten van cafestol en kahweol staan centraal in dit 
proefschrift. We hebben de hoeveelheid cafestol en kahweol in koffiedranken 
gemeten, en onderzocht hoe de bloedgehaltes van lipiden en leverenzymen 
veranderen bij gezonde proefpersonen die cafestol en kahweol binnenkrijgen. 
Cafestol en kahweol komen alleen voor in ongefilterde koffie. Hierin zijn ze 
verdeeld over oliedruppeltjes en zwevende koffiedeeltjes. We wisten al dat het 
consumeren van olie met koffiediterpenen verhogend werkt op het bloedgehalte 
van lipiden en van alanine aminotransferase. Of ze ook geabsorbeerd worden uit 
koffiedeeltjes was nog niet bekend. Daarom hebben we in twee experimenten 
koffiedrab gegeven aan gezonde vrijwilligers (HOOFDSTUK 2). In beide experimenten 
deed de koffiedrab de bloedgehalten van lipiden en van alanine aminotransferase 
flink stijgen. Diterpenen in zwevende koffiedeeltjes dragen dus bij aan het 
cholesterol-verhogende effect van ongefilterde koffie. 
Vervolgens hebben we de hoeveelheid cafestol en kahweol in koffiedranken 
bepaald (HOOFDSTUK 3). Turkse koffie en cafetière koffie bleken even veel 
diterpenen te bevatten als gekookte koffie: gemiddeld zo'n 3 tot 4 milligram van 
elk diterpeen per kop. Turkse koffie en cafetière koffie zouden dus het cholesterol 
even sterk moeten verhogen als gekookte koffie. Espresso bevatte minder 
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diterpenen, 1 tot 2 milligram per kop, doordat espresso meestal uit kleine kopjes 
gedronken wordt. Gefilterde koffie en oploskoffie bleken vrijwel geen diterpenen 
te bevatten. De manier waarop de koffie wordt bereid is dus van groot belang. 
Hoeveel iedere koffiesoort het cholesterol verhoogt, staat verderop in deze 
samenvatting beschreven. Cafeïne-vrije koffiebonen bleken net zoveel diterpenen 
te bevatten als 'gewone' koffiebonen: ongefilterde koffie die gezet is met 
gedecafeïneerd maalsel zal dus ook het cholesterol verhogen. 
De vraag bleef of het cafestol of kahweol is die het cholesterol verhoogt. 
Deze kennis is nuttig om het werkingsmechanisme te onderzoeken. We wilden 
daarom in een experiment de effecten van cafestol vergelijken met die van 
kahweol. Zuivere cafestol hadden we, maar het lukte ons niet om zuivere kahweol 
te verkrijgen. Daarom hebben we cafestol vergeleken met een mengsel waarin 
naast cafestol ook kahweol zat (HOOFDSTUK 4). We vonden dat cafestol het gehalte 
van cholesterol en van triglyceriden sterk verhoogde. Echter, het mengsel liet 
praktisch dezelfde resultaten zien ^  DIL betekent dat het chpjestero^verhogende^ 
y/ effecLv-agongefilterde koffie voornamejjjk y^roorzaaj^^ordtdoor het gehalte aan 
xafastol. De resultaten van het leverenzym alanine aminotransferase waren heel 
'^ anders: cafestol verhoogdedit enzym, maar het mengsel verhoogde hetjTögj^eeL 
meer. Omdat kahweol dus niet het cholesterolgehalte maar wel het gehalte van 
alanine aminotransferase verhoogt, concluderen we dat koffiediterpenen de 
bloedlipiden en de levercellen op verschillende manieren beïnvloeden. 
Mensen die hun hele leven al gekookte koffie drinken hebben gemiddeld een 
hoger cholesterolgehalte dan mensen die filterkoffie drinken. Het gehalte van het 
leverenzym alanine aminotransferase bleek echterjiieLj/erhoogd jn kookkoffie-
drinkefs^Het effect op dsJevercellen^oiLdus van voorbijgaande aard_kunnen_zjjrL _ 
We hebben een experiment gedaan om te onderzoeken of dit inderdaad zo is 
(HOOFDSTUK 5). Stevige koffiedrinkers werden verdeeld over twee groepen: de ene 
groep-xlr-Of4lc-een half jaarJa_ng^x^s^nQokk£a-steiJce_jiafejtiète koffie pexjdag, de 
andere groep dronk evenveel filterkoffie. In de cafetière drinkers steeg inderdaad 
het gehalte van alanine aminotransferase, maar na een half jaar cafetière koffie was 
het nog steeds verhoogd. Dit geeft aan dat het effect van cafestol en kahweol op 
de levercellen niet binnen een half jaar verdwijnt. Deze kennis is bruikbaar in de 
medische praktijk: als dit enzym verhoogd is bij ogenschijnlijk gezonde mensen, zou 
het kunnen dat ze veel ongefilterde koffie drinken. In dit experiment vonden we ook 
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dat cafetière koffie het hlnarigRhgltg vqn CJT_n|gstpro| en triglyneriden vprhnngrlp Na 
een half jaar bleek de stijging in cholesterol vr i jwel onveranderd, maar was een 
groot deel van de stijging in triglyceriden verdwenen. Een hoger risic_p_ op 
hartziekten met het chronisch drinken—van ongefilterde koffie word t dus 
vnnrnampli jk \/Prnnr7aflkt rinnr hpf pffpr.t np r.hnlpstprn| 
Ook hebben we het effect van koffiediterpenen op het bloedgehalte van 
lipoproteine(a) bestudeerd. Een hoog lipopioteine(a) gehalte is in verband gebracht 
met een hogerejcans op hart- en vaat7ipktpn H P hoeveelheid lipoproteine(a) die in 
helJîlûed^cLrçuleert is echter voor eeaarootdeeLerfel i jk .bepaald, en is ongevoelig 
voor stoffen uit de! voeding. Mensen die doorgaans veel gekookte koffie drinken 
bleken wel hogere waarden van dit l ipoprotéine te hebben dan fi l terkoffie-drinkers 
(HOOFDSTUK 6). Vreemd genoeg bleek uit vier andere studies dat inneming van 
cafestol en kahweol gedurende een korte periode juist het lipoproteine(a) verlaagt^ 
(HOOFDSTUK 7). We hebben hier geen logische verklaring voor. Het is wel duidelijk 
dat het geen zin heeft om mensen die een hoog lipoproteine(a) gehalte hebben te 
behandelen met koff iediterpenen: de^nadejjg^e ejffecjBn-c^J^et-^olostor&lgBhalle.,, 
zouden een eventueei.pos4tief-effect op4ipoproteine(a) teniet doen. 
In HOOFDSTUK 8 hebben we de huidige gegevens over de 
cholesterolverhogende diterpenen gecombineerd, ledere kop Turkse, gekookte, of 
cafetière koffie die per dag gedronken word t , verhoogt het cholesterolgehalte met 
ongeveer één procent. Voor espresso geldt dat ieder kopje per dag het cholesterol 
verhoogt met een derde tot een half procent. Filterkoffie en oploskoff ie verhogen 
het cholesterolgehalte niet. 
Conclusie 
De diterpenen cafestol eg kahwpnl 7 i jn_gar^P7 jg jn j }pknnktp Turkse, en 
cafet|ère_koffift, en in mindere male--ia_esûrfisso. Filter- en oploskoff ie bevatten 
slechts sporen cafestol en kahweol. Cafestol en kahweol verhogen het 
cholesterolgehalte van het bloed zolang ze dagelijks worden geconsumeerd. 
Çp^e jx i i f i j i_^e j t jog f i r i_ze^ h e L . bloedgehalte_„__yjan het levej-er^z^rr^ alanine 
aminotransferase- Stevige koffiedrinkers en mensen met een verhoogd risico op 
hartziekten of een leveraandoening doen er verstandig aan de consumptie van 
diterpeenrijke koffie te beperken. 
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wintervertelling 
Het was guur en bijtend koud. De stadsklokken hadden pas vier uur geslagen, maar 
toch was het al helemaal donker. De oude Urge liep driftig heen en weer in zijn 
kantoor. Hij rangschikte een stapeltje papieren, borg die behoedzaam op in een 
map, en schreef er met grote letters MIJN PROEFSCHRIFT op. 'Af! ' riep hij 
triomfantelijk. Hij had niet gemerkt dat achter hem iemand het kantoor had 
betreden. Het was de zwaargeleerde Zoek, een man met weinig haar maar met een 
hoop publicaties. 'Is het af?' vroeg deze. Urge knikte en glunderde: 'Zeventien 
februari lever ik het in'. 'Mooi,' sprak Zoek, 'dan nu alleen nog een dankwoord!' 
'Een wat?' riep Urge. Zijn voldoening sloeg om in ergernis. 'Een dankwoord? Waar 
is dat in hemelsnaam goed voor? En vertel me eens, beste Zoek,' zei hij smalend, 
'wie zou ik dan wel moeten bedanken?' De zwaargeleerde was even aangeslagen. 
'Nou ja,' stamelde hij, 'iedereen die een steentje heeft bijgedragen aan de 
totstand ko...' 'Humbug!' schreeuwde Urge. 'HUMBUG!' Luid mopperend beende 
hij het kantoor uit. 
Die avond kon Urge de slaap niet vatten. 'Een dankwoord', gromde hij. 'Wat een 
onzin! Zonder mij was er van dat hele onderzoek geen bliksem terechtgekomen.' 
Opeens sloeg de slaapkamerdeur met een klap open. In de deuropening stond een 
doorschijnende gestalte. 'Wat moet dat?' riep Urge. 'Zeg, hoe haal je het in je 
hoofd?' Langzaam kwam de gestalte dichterbij. 'Wel potverdomme!' schreeuwde 
Urge. Plots zag hij dat de ongewenste gast een bordje om zijn nek had hangen. 
'Geest van het verleden,' las Urge hardop. 'Kijk eens aan,' hoonde hij, 'een geest. 
Geesten bestaan niet! Donder op!' De doorschijnende figuur was hem nu tot op een 
halve meter genaderd en strekte zijn armen uit. In een vloeiende beweging pakte 
hij Urge die zwaar tegenstribbelde bij de kraag van zijn nachthemd, en trok hem 
door het vensterraam mee de nacht in. 'Hé!' riep Urge met overslaande stem. 'Zet 
me neer! Waar gaan we naar toe?' 'Zwijg!' sprak de geest. Zijn strenge toon 
bezorgde Urge kippevel. Even later stonden ze in een schaars verlicht vertrek. Aan 
een bureau zat een bebaarde man te puffen en te zweten, terwijl hij met een dikke 
rode stift lange strepen over een bundeltje paperassen trok. 'He, dat is Martijn!', 
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riep Urge verrast, 'maar wat ziet hij er slecht uit...' 'Logisch', sprak de geest, 'hij 
zit net een versie van jouw eerste artikel te lezen.' Urge moest even slikken. 'Jij 
denkt dat je het alleen hebt gedaan,' zei de geest, 'maar zonder Martijn was jij niet 
ver gekomen, mannetje. En wat te denken van professor Hautvast. Zonder zijn 
talenten was de vakgroep er niet eens geweest. Laat staan je proefschrift!' 'Maar 
ze worden daar toch voor betaald?' sputterde Urge tegen. 'Mag ik nu weer naar 
bed?' 'Nee! Het begint pas!' snauwde de geest. 'Want wat te denken van Guido 
en Robert? Truus en Peter? Marga? Waar zou jij zijn zonder hun toewijding en hun 
technische vernuft? Jij kan nog niet eens een pipet en een staafmixer uit elkaar 
houden! En laten we het eens hebben over al de mensen die voor jou koffiedrab en 
pillen en liters koffie hebben weggewerkt? Of over Joanna en Hedwig die de 
medische keuring hebben gedaan? Over Joke en Geke en Jan en Paul van het 
priklab?' Urge was bleek weggetrokken. Hij stopte zijn vingers in zijn oren en riep 
met hese stem: 'Humbug, humbug, humbug!' 'Oh ja?' gilde de geest, 'heb je nog 
wel eens gedacht aan Angela dan, die jou die uitgevallen vriezer heeft doen 
vergeten? En aan Arjan die dozen met poep voor jou vervoerde? Jolieke die koffie 
voor je verzamelde? Susan die je taalfouten moest verbeteren?' De geest wist van 
geen ophouden meer. 'En al je kamergenoten dan? Nicole Z, Gerda, Toine. Daar 
was je toch zo dol op? En zo kan ik nog wel even doorgaan. Menrike, Karin, Paul, 
Trudie. Zonder hen was het een stuk minder gezellig geweest! Oh ja, nu we het 
toch over gezelligheid hebben...' De geest sleurde Urge mee naar een keuken waar 
vijf studenten ontbijtstonden klaarte maken voor deelnemers. 'Hier, kijk dan toch!' 
riep hij woedend. 'Maar geest,' jammerde Urge, 'boterhammen smeren, dat kan 
toch iedereen?' 'Ooooooh, wat ben jij onnozel!'. De geest raakte nu volledig door 
het dolle heen: 'Natasja. Maud. Marjan. Mariska. Henny. Doorzetters zijn het, Urge. 
Cracks! En jij praat over boterhammen smeren? Je mag in je handjes klappen met 
zulke studenten. Jij... j i j .... egocentrische kl. . . ! ' Plotseling stopte de geest. Op 
zachte toon vervolgde hij: 'En dan zwijg ik nog over Saskia. Man, man. Wat die 
allemaal heeft gedaan om die proeven mogelijk te maken....' Hij slaakte een diepe 
zucht. Urge zweeg. In zijn hart begon hij zich af te vragen wat hij eigenlijk wel zelf 
had gedaan. 'Ik wil naar bed,' zei hij schor. Hij had het nog niet gezegd of hij lag 
alweer onder de vertrouwde dekens. 
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Maar niet voor lang. 'Meekomen, Mr Ego!' donderde het plots door de kamer, 'ik 
ben de geest van het heden!' Urge begreep dat ieder verzet zinloos was. Voor hij 
het wist, waren ze bij een drukker in Middelburg. Achter een grote tafel zat een 
jongen op honderden verschillende manieren een koffieboon op een kaft te plakken. 
'Ja', stamelde Urge, 'ik weet het al. Dat is mijn broertje Marcel en die heeft veel 
werk aan de voorkant van mijn proefschrift gehad...'. 'Inderdaad', riep de geestvan 
het heden. 'Weet je nog? Eind januari riep je dat je de kaft gewoon blauw zou 
maken, begin februari had je al twintig ontwerpen van deze arme jongen 
ontvangen! En wat te denken van je maatjes Peter en Annet die je straks ook nog 
eens belangeloos als paranimf terzijde staan? Of wou je soms alléén voor de 
leeuwen? En alle andere mensen die jouw verblijf op de vakgroep zo plezierig 
maken, zoals Baukje en Martine en Robert en Riekie en Marie en Riet? Nou?' En 
weg was hij weer. Even abrupt als hij gekomen was... 
Opnieuw hoefde Urge niet lang te wachten. Daar verscheen de geest van de 
toekomst al in de deuropening. Met een lange en knokige wijsvinger gebaarde hij 
Urge hem te volgen. Met afhangende schouders slofte hij achter de geest aan. 
Plotseling waren ze in een herberg. Aan een tafeltje zaten zijn vrienden van The 
Gang, Marianne, Mark, een groepje toneelspelers, Maarten, Jacco, Francesca. Urge 
ving delen van het gesprek op. 'Pfff, wat is het eigenlijk een verwaande kwast'. 
'Hij heeft zich lelijk in de kaart laten kijken, en dat zal-ie weten ook!' 'Van mij mag-
ie lekker van zichzelf genieten, jongens, ik zal hem daar niet meer bij storen! Kom, 
het leven gaat door, we nemen er nog een!' 'Over wie hebben ze het?', vroeg Urge 
aan de geest. Deze zweeg hardnekkig en gebaarde enkel hem weer te volgen. Ze 
kwamen aan bij een groot huis. Het smalle voortuintje stond vol fietsen. 'He geest', 
riep Urge blij, 'daar woon ik!'. Ze betraden het pand. In de keuken zaten zijn 
huisgenoten en zijn vrouw Caroline uitgeblust rond de tafel. Een hele poos was het 
stil. Toen sprak Caroline bedroefd: 'Het is gewoon een hufter, en dat is het!' Er 
werd instemmend gemompeld. 'Ach ach', zei Urge, 'dat moet wel weer over een 
hele nare man gaan. Hebben ze het over dezelfde persoon?' De geest sloeg geen 
acht op zijn vraag en leidde hem weer naar buiten. Een poos gingen ze zwijgzaam 
voort door de kille nacht, tot ze bij een groot hek kwamen dat toegang gaf tot een 
verlaten park. Bij het openen knarsten de scharnieren als hadden ze in een 
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eeuwigheid niet bewogen. Flarden mist hingen tussen de toppen van de kale 
bomen. Het was doodstil. 'Waar zijn we in vredesnaam?' huiverde Urge. Op een 
bankje zat een oude man, gehuld in een versleten deken. Roerloos staarde hij naar 
een stapel witte boekjes bij zijn voeten. 'Wat een ontzettend zielige en eenzame 
man,' zei Urge. Vertel mij, geest, wie is deze stakker?' Waarom zit hij niet thuis bij 
het haardvuur? Waarom heft hij geen drinkgelag aan met zijn vrienden? Waarom 
zit hij hier moederziel alleen in de kou?' De geest zweeg onverbiddelijk en wees 
naar de boekjes. Urge boog zich voorover om beter te kijken. Op de voorkant van 
ieder boekje prijkte een koffieboon. 'NEE!,' riep Urge ontsteld uit. 'Dat kan niet! Dat 
wil ik niet! Geest, ik verzeker je, ik ben niet meer de man die ik was. Ik weet nu 
wat ik te danken heb aan mijn vrienden, mijn familie, mijn collega's'. Smekend 
wierp hij zich voor de voeten van de geest. 'Beloof me dat ik nog een kans krijg... 
Zeg me dat er nog hoop is, zeg het me! In godsnaam!' Maar toen Urge opkeek, 
was hij alleen. 'Neeee!' kreunde hij. In de verte kraste een kraai. 
Urge ontwaakte door het gekwetter van vogeltjes. Snel keek hij om zich heen. Hij 
zag geen hek. Geen bomen. Alleen een bed. Zijn eigen bed. Hij sprong op en rende 
naar de kalender. Het was de ochtend van de zeventiende februari. 'Het is nog niet 
te laat,' stamelde hij dankbaar. Hij gooide het raam open, stak zijn hoofd naar 
buiten en jubelde luidkeels: 'Het is nog niet te laat!'. Opgelucht zette hij zich achter 
zijn tafel, pakte een vel papier en een pen, en begon te schrijven: Velen hebben een 
steentje bijgedragen aan de totstandkoming van dit proefschrift. Graag wil ik al 
deze mensen hartelijk bedanken... Het papier schitterde in het zonlicht dat naar 
binnen scheen. Het leek wel lente. 
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